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ABSTRACT 
JULIUS ATASHILI: Cervical precancerous lesions in HIV-positive women in 
Cameroon: prevalence, predictors and potential impact of screening   
(Under the direction of William C. Miller, MD, PhD, MPH) 
 
Cervical cancer is the most common cancer in women in low-income countries. 
Although cervical cancer incidence and mortality is higher in HIV-positive women, resource 
limitations restrict the implementation of systematic screening programs in these women. 
The purpose of this dissertation was to explore the potential for targeted screening by 
assessing the prevalence and clinical predictors of cervical squamous intra-epithelial lesions 
(SIL) in HIV-positive women in Cameroon. Furthermore, we sought to explore the potential 
impact of antiretroviral therapy and screening on mortality from cervical cancer.  
We initially conducted a cross-sectional study of HIV-positive women in Cameroon. A 
total of 282 women, aged 19 to 68 years with a median CD4 cell count of 179 
cells/microliter, were enrolled. SIL were detected in 43.5% of the 276 women with 
satisfactory samples: including high-grade SIL (HSIL) in 3.3%. None of the clinical factors 
assessed significantly predicted the presence of any lesion. Among patients with CD4 
counts less than 200 cells/microliter, the prevalence of SIL was higher in patients aged 26-
59 years compared to younger women, while there was essentially no difference amongst 
women with CD4 counts greater than 200 cells/microliter.  
Using a Markov state-transition model of a cohort of HIV-positive women in 
Cameroon, we examined the potential impact of scenarios including: no HAART and no 
screening (NHNS); HAART and no screening (HNS); and HAART and screening once at 
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age 35 (HS35). Compared to NHNS, lifetime cumulative cervical cancer mortality doubled 
with HNS. It will require 202 women being screened at age 35 to prevent one cervical 
cancer death amongst women on HAART.  
The high prevalence of SIL in women initiating antiretroviral therapy in Cameroon 
underscores the need for screening in this population. With neither age nor any other clinical 
factor being a good predictor of SIL, alternative affordable screening options need to be 
explored. Furthermore, the long-term evolution of SIL needs to be assessed in prospective 
studies of these women.  Screening has the potential of reducing cervical cancer mortality in 
HIV-positive women in Africa. The cost of achieving such an effect needs to be assessed. 
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CHAPTER ONE: INTRODUCTION, SPECIFIC AIMS AND HYPOTHESES 
 
 
 
1.1 Introduction 
 
Cervical cancer is the most common cancer in women in low-income countries 
[WHO, 2006] and the second most common cancer in women worldwide [Stewart and 
Kleihues, 2003]. Compared to immuno-competent women, HIV-positive women have a 
higher prevalence, incidence and progression rate of precancerous cervical lesions 
[Palefsky, 2006]. By the end of 2007, women accounted for 50% of the estimated 33 million 
people living with HIV worldwide, and close to 59% of the 22 million in sub-Saharan Africa 
[UNAIDS, 2008]. With the recent increase in access to antiretroviral therapy these women 
are expected to live longer thus potentially allowing sufficient time for cervical cancer to 
develop. In addition to longer life expectancy, antiretroviral therapy is associated with a 
reduction of competing causes of death, such as Kaposi sarcoma and tuberculosis, thus 
potentially increasing the proportion of morbidity and mortality attributable to cervical cancer 
[Franceschi and Jaffe, 2007]. Enhancing early detection and treatment of precancerous 
lesions, through screening could reduce the burden of cervical cancer in these HIV-positive 
women [Goldie et al, 2005; Franceschi and Jaffe, 2007].  
Despite the relatively high association of HIV with precancerous and cancerous cervical 
lesions, unlike other opportunistic affections, the current management of women initiating 
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HAART in most developing countries (including Cameroon) does not include a systematic 
screen for cervical cancer or precancerous lesions. We hypothesize that cervical cancer 
goes undiagnosed and that early diagnosis of precancerous lesions by a screen at HAART-
initiation could be cost-effective in reducing overall morbidity and mortality rates in these 
HIV-positive women. Targeted screening could potentially increase the cost-effectiveness of 
screening in these resource-limited settings. However, for targeted screening to be effective 
the factors associated with a higher prevalence and severity of lesions need to be identified. 
Age has been a common consideration in the targeted screening for precancerous 
lesions in the general population. In effect, current guidelines for screening the general 
population of women in the United States (US) suggest screening commence no later than 
at age 21 years, reducing the frequency of screening at age 30 and stopping screening at 
age 65 (or 70 in some guidelines) [USPSTF, 2008; ACOG 2003, Saslow et al, 2002]. World 
Health Organization (WHO) guidelines aimed primarily at resource-limited settings are less 
stringent, recommending screening begin at age 30, need not be annual and need not be 
done over the age of 65 [WHO, 2006].  These age considerations may not necessarily be 
ideal for HIV-positive women in whom higher human papilloma virus (HPV) prevalence, 
higher HPV persistence, and a faster progression of lesions could mean an earlier 
occurrence and or a longer persistence of precancerous lesions. The optimal age for 
screening in HIV positive individuals could differ substantially from those in the general 
population and needs to be better described.  
This dissertation sought to provide data aimed at improving the detection and 
management of cervical cancer in HIV-positive women. In Cameroon, and other resource-
limited settings, the period of HAART initiation may be a critical time during which HIV-
positive women could be screened as these women already undergo a series of clinical and 
laboratory assessment required for HAART. Age may also be an important consideration to 
further target screening.  
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To assess the need and potential effect of a screening program in a resource-limited 
setting like Cameroon, this dissertation had the following specific aims: 
1.2 Specific Aim 1 
To determine the prevalence, severity and predictors of cervical squamous 
intraepithelial lesions in HIV-positive women initiating antiretroviral therapy in 
Cameroon. 
Rationale: Targeted screening may be a potential cost-effective alternative for the screening 
of HIV-positive women in resource-limited settings. Determining clinical characteristics that 
predict cervical lesions will help identify sub-populations which could be targeted for 
screening and thus potentially increase the ratio of the number of cases detected per 
screening test. We will develop a predictive model for prevalent cervical epithelial lesions in 
women initiating HAART in Cameroon and assess the use of risk-scores to guide screening. 
Hypothesis: We hypothesize that cervical precancerous lesions are prevalent in women 
initiating HAART in Cameroon and that readily available socio-demographic and clinical 
characteristics can be used to predict the presence of lesions. We further hypothesize that 
these characteristics could be used to develop a score that could in turn be used to reliably 
predict which women need to be screen. 
1.3 Specific Aim 2 
To describe the age trends in the prevalence of cervical squamous intraepithelial 
lesions in HIV-positive women on antiretroviral therapy in Cameroon.  
Rationale: The optimal ages to begin and discontinue cervical cancer screening in HIV 
positive women are unknown. By assessing the age-specific prevalence of lesions we would 
estimate the minimum age at which lesions occur, the age with maximum occurrence and 
the latest age at which lesions occur.  This information on age-specific prevalence could be 
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useful in the development of age-targeted screening guidelines in HIV positive women in 
Cameroon.  
Hypothesis: We hypothesize that the prevalence of lesions is dependent on age and that 
age alone could be used as a criterion for targeted screening. 
1.4 Specific Aim 3 
To quantify the potential effect of antiretroviral therapy and screening, on mortality 
from cervical cancer in HIV-positive women in Cameroon 
Rationale: The long term effect of cervical cancer screening in HIV-positive women in 
Cameroon is unknown. Mortality from cervical cancer and mortality from HIV can be 
competing risks in the evolution of each other disease. The increased survival that is 
expected to result from the increased access to HAART in Cameroon may also be 
accompanied by an increase in the incidence and mortality due to cervical cancer. By 
assessing the potential impact of modifiable factors such as antiretroviral therapy and 
screening, we would quantify the potential gains that could be expected from these 
interventions and help policymakers in the allocation of limited resources. 
Hypothesis: We hypothesize that the cumulative mortality due to cervical cancer would 
increase with antiretroviral therapy while screening would substantially reduce this mortality. 
1.5 Overview 
To achieve these aims we conducted two distinct studies: a cross-sectional 
descriptive study of women in HIV clinics in Cameroon who were interviewed on 
demographic and clinical characteristics and then screened for cervical precancerous 
lesions; and a computer-simulated analysis of the potential outcomes in a group of HIV-
positive women in Cameroon. 
  
 
CHAPTER TWO: BACKGROUND AND SIGNIFICANCE 
 
 
 
 
In this section we present the burden of cervical cancer, its pathogenesis and risk 
factors, and the role of screening in reducing cervical cancer mortality in the general 
population. We then summarize the literature on the peculiarities of cervical cancer in HIV-
infected women, the occurrence of precancerous and cancerous lesions by age and end by 
reviewing published studies of the prevalence of precancerous lesions in HIV in developing 
countries, and studies of the impact of age on cervical cancer. 
2.1 Cervical cancer 
2.1.1 Classification and epidemiology 
The term ‘cervical cancer’ is generally used in reference to squamous cell 
carcinoma of the uterine cervix although other histological forms are plausible. The 
cervix is covered by two types of epithelia: a squamous cell epithelium usually limited to the 
ectocervix and a columnar (glandular) epithelium usually limited to endocervix. The 
pathogenesis of squamous cell carcinoma (SCC) involves the exposure and subsequent 
squamous metaplasia of the squamocolumnar (‘transformation’) zone, the intersection of the 
ecto- and endocervix. Other histological forms of cervical neoplasia include 
adenocarcinomas and other non-squamous, non-glandular epithelial tumors such as 
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adenosquamous carcinoma and small cell carcinoma amongst others [Silverberg and Loffe 
2003]. SCC is however by far the most common form of cancer accounting for 80% of 
primary cervical cancers [Waggoner, 2003]. Any unspecified use of ‘cancer of the cervix’ in 
this document will be a reference to SCC.  
Cervical cancer is the second cause of cancer in all-age women worldwide and 
the second cause of cancer death in sub-Saharan Africa.  It is estimated that 500,000 
new cases are diagnosed yearly with 85% of these in the developing world [Waggoner, 
2003; Ferlay et al, 2004]. Cervical cancer is also estimated to cause over 270,000 deaths 
annually with the majority of deaths occurring in developing countries.  Worldwide these 
represent incidence and mortality rates of 16.0 and 8.9 per 100,000 respectively. The 
incidence and mortality rates in Africa (19 and 14.8 per 100,000 respectively) [WHO/ICO 
2007] are higher than those observed in South-East Asia (15.9 and 8.4 per 100,000 
respectively) and substantially higher than those observed in North America (9.0 and 3.6 per 
100,000 respectively) [Ferlay et al, 2004]. These rank cervical cancer the first cause of 
cancer incidence and mortality in women of all ages in Africa. 
In Cameroon, cervical cancer is estimated to be the first cause of cancer and 
cancer mortality in women of all-ages (and the third cause of cancer mortality in women 
aged 15-44 years, after breast cancer and Kaposi sarcoma) [WHO/ICO, 2007]. The 
incidence and mortality rates of 22.6 and 18.2 per 100,000 women in Cameroon more than 
double the rates observed in the US (9.0 and 3.2 per 100,000 women respectively) where 
cervical cancer is the 13th most frequent cancer.  
 
2.1.2 Pathogenesis 
Cervical cancer pathogenesis is characterized by the role of infection with 
oncogenic HPV and the progression over a long time of precancerous lesions prior to 
the development of invasive cancer per se.   
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HPV is increasingly recognized as a necessary, albeit not a sufficient, cause of 
cervical cancer [Castellsague, 2008]. The etiologic role of HPV was first suggested when 
case-control studies worldwide, detected HPV DNA in 90-100% of adequately collected and 
preserved cervical tissue from cases as opposed to 5-20% of cervical samples in controls 
[Bosch et al, 2002]. These findings were confirmed in prospective studies in which women 
with HPV-16 had higher incidence of advanced cervical intraepithelial neoplasia (CIN III) 
[Schiffman and Castle, 2003; Munoz et al, 2006].   
HPV are DNA viruses with more than 100 types identified based on the DNA diversity. 
Anogenital tissues are infected by close to 40 HPV types. Based on epidemiologic data 13 
types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) have been established to have 
high oncogenic risk [Munoz et al, 2003; Munoz et al, 2006]; six other types (types 26, 53, 66, 
68, 73, 82) are considered by some to probably have a high risk[Munoz et al, 2006]. Other 
types are generally considered to be of low oncogenic risk. 
HPV-16 and 18 are estimated to account for 70% of cervical cancers. There is 
however a variability in the frequency and geographic distribution of the different oncogenic 
types. While HPV 16, 31,51 and 53 were the most common types in low-grade lesions 
worldwide, HPV-16 appears more frequent in Europe (2-fold compared to Africa) while HPV-
18 appears more frequent in North America than in Europe and South/Central America 
[Clifford et al, 2005]. Furthermore, a recent meta-analysis reports HPV 16/18 in 74-77% of 
high-grade squamous intra-epithelial/invasive cancer cases in North America, Europe and 
Australia versus a prevalence of 65-70% in Africa, Asia and South/Central America[Smith et 
al, 2007].  
 
The HPV virion has a circular genome enclosed in a capsid shell made of two 
proteins: a major capside protein L1 and a minor protein L2 [Steben and Duarte-Franco, 
2007]. The L refers to ‘Late’ proteins, a reference to when these proteins are synthesized in 
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the virus’ life cycle. The viral genome also codes for six early proteins (E1, E2, E4, E5, E6 
and E7) that interact with host cell genomes and are involved in viral transcription, 
replication and assembly[Munoz et al, 2006].  HPV infects squamous epithelial cells, 
particularly in differentiating cells such as those of the skin or the squamocolumnar junction. 
The complex interaction between viral (particularly E6/E7) proteins and host proteins may 
result in changes the regulation of host cell differentiation and neoplasia. 
HPV infection is not considered sufficient for the development of cervical cancer as 
despite its high prevalence very few infections lead to cancer. The development of 
precancerous and cancerous lesions is a function of persistent infection. In multiple 
studies the relative risk of high grade lesions in women with persistent HPV infection 
compared to HPV negative women ranged from 1.3 (95%CI: 1.1, 1.5) to 813 (95%CI: 168.2, 
3229.2) [Koshiol et al, 2008]. Persistence appears to be multi-factorial depending on viral 
factors (type, viral load), exogenous factors and host factors.  
HPV-persistence may lead to precancerous lesions. Multiple systems have been 
proposed to classify these precancerous lesions. The most frequently used Bethesda 2001 
system classifies lesions based on cervical cytology as unsatisfactory, negative (normal), 
atypical squamous cells of uncertain significance (ASCUS), atypical squamous cells (ASC-
H), low-grade squamous intraepithelial lesions (LSIL), high-grade SIL (HSIL), or invasive 
cervical cancer[Solomon et al, 2002]. The correspondence between this system and other 
classification systems is shown in Table 2.1 below.  
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Table 2.1: Terminologies/classification of cervical precancerous/cancerous lesions 
[source: WHO, 2006] 
Cytological classification 
(screening) 
Histological classification (diagnosis) 
Pap  Bethesda System CIN WHO  
Class I Normal  Normal  Normal  
Class II ASC-US 
ASC-H 
Atypia Atypia 
Class III LSIL CIN 1 including flat 
condyloma 
Koilocytosis  
Class III HSIL CIN2 Moderate dysplasia 
Class III HSIL CIN3 Severe dysplasia 
Class IV HSIL CIN3 Carcinoma in situ  
Class V Invasive carcinoma Invasive carcinoma Invasive carcinoma 
 
2.1.3 Risk factors for cervical cancer 
Other factors, in addition to persistent infection with oncogenic HPV, are associated 
with the development of cervical cancer. With varying magnitudes of association these 
include factors such as the lifetime number of sex partners (more than four), early onset of 
sexual activity (<16 years), high parity, history of genital warts, Chlamydia, or HSV infection, 
immunosuppression, smoking and exposure to environmental tobacco, oral contraceptive 
use (>5 years) [Waggoner, 2003; WHO, 2006]. 
These factors may influence the risk of cervical lesions indirectly with HPV infection 
as an intermediate. Factors such as early onset of sexual activity, lifetime number of 
partners, parity, history of STIs and oral contraceptive use may simply be indicative of a 
higher exposure to HPV. On the other hand factors such as immunosuppresion and oral 
contraceptive use may be indicative of a lower ability to clear HPV infections. 
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Other factors may have a more direct effect on the cell differentiation and 
maturation. Tobacco-specific carcinogens found in the epithelium of smokers can bind and 
damage host DNA and produce neoplastic transformations.  In pooled analysis by the 
International Agency for Research on Cancer (IARC) cancer was twice as likely in women 
who ever smoked compared to those who did not [Bosch and Sanjose, 2007]. 
Epidemiological evidence for the association between oral contraceptive use and 
cervical cancer is not consistent. In IARC’s analysis, though ever use of oral contraceptives 
was associated with an increased risk of cervical cancer OR=1.47 (95%CI: 1.02, 2.12), the 
use of oral contraceptives for less than 5 years was not associated with cervical cancer 
(OR=0.77, 95%CI: 0.46, 1.29). The risk however increased with increased use of oral 
contraceptives: OR=2.72 (95%CI: 1.36, 5.46) for 5-9 years of use, and OR= 4.48(95%CI: 
2.24, 9.36) for 10+ years of use [Bosch and Sanjose, 2007]. Furthermore, the risk also 
seems to return to normal after 5-10 years of cessation of contraceptives. Multiple 
mechanisms have been postulated for the potential role of oral contraceptives in the onset 
of cancer. High hormonal levels may accelerate the progression from premalignant lesions 
to malignant cervical lesions by promoting integration of HPV DNA into the host genome, 
with deregulation of E6 and E7 expression [Castellsague and Munoz, JNCI 2003]. Estradiol 
may also stimulate the transcription of HPV16 E6 and E7 proteins. 
Closely related to oral contraceptive use is the effect of parity which also involves 
higher levels of circulating estrogens. In IARC’s studies HPV positive women with 7+ full 
term pregnancies were four times as likely to have cervical cancer as HPV positive 
nulliparous women and two times as likely to have cancer as women with 1-2 full term 
pregnancies [Munoz et al, Lancet 2002]. Parity may increase cancer risk by maintaining the 
squamocolumnar junction in the ectocervix and thus increasing exposure to HPV. The 
hormonal changes associated with pregnancy are associated with immunosuppression and 
this could possible reduce the ability to clear HPV infection. 
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The independent effect of co-infections with other reproductive tract infections 
(RTIs) is rather difficult to assess because of their colinearity with HPV infection and other 
RTIs. These RTIs may have an independent effect arising from the observation that, among 
HPV positive women, even non-specific inflammatory changes are associated with a modest 
increase in the risk of precancerous cervical lesions [Bosch and Sanjose, 2007]. Large IARC 
multicenter studies found that women with cancer were twice as likely to have antibodies to 
Chlamydia trachomatis as those with no cancer (OR=2.1, 95%CI: 1.1, 4.0) [Smith et al, JID 
2002]. Similarly women with cancer were also twice as likely to have antibodies to HSV-2 
(OR=2.2, 95%CI: 1.4, 3.4) [Smith et al, JNCI 2002]. 
Co-infection with HIV is also a risk factor; see below for a more detailed discussion of 
the role of HIV. 
 
2.1.4 Tests for cervical cancer and role for cytology screening 
Multiple methods can be employed for the diagnosis of cervical cancer and 
precancerous lesions. Screening tests include tests aimed at identifying HPV DNA 
(PCR, DNA Hybridization), to those aimed at identifying precancerous/cancerous 
lesions: cytology (conventional or adapted such as liquid based), Visual methods 
(Visual Inspection with Acetic acid (VIA), Visual Inspection with Lugol’s Iodine (VILI), 
magnified visual inspection with acetic acid (VIAM).  
Conventional cytology (“Pap smear”) has been the most used historically and 
involves collecting cervical samples, making a slide, staining and microscopy. Trained 
personnel are needed both for accurate sample collection, and cytology. There is also a 
need for infrastructure for sample collection and laboratory analysis. In review studies, the 
sensitivity and specificity of conventional cytology for the detection of CIN2-3 ranged from 
47-62% and 60-95% respectively [Sankaranarayanan et al, 2005]. This accuracy was 
maintained in developing countries. The low sensitivity of cytology leaves a potential for 
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high false negative-rates. However this is compensated for by using repeated cytology so 
that cases missed in previous tests can be detected in subsequent tests. This low sensitivity 
(and the recognition of the etiologic role that HPV plays) has been the driving force behind 
the continuous search for alternative testing methods. Nevertheless conventional cytology 
remains the only method that has been proven to be effective in reducing mortality in 
developed countries with high quality screening with high coverage and reliable follow-up of 
women [Sankaranarayanan et al, 2005].   
There is no epidemiologic evidence that conventional cytology is effective in 
reducing cancer morbidity or mortality in developing countries. Major barriers include 
the absence of trained personnel, lack of infrastructure and the need for regular 
follow-up, thus encouraging the search for alternative testing methods.  
Liquid-based cytology is one of the methods that have been proposed to improve 
the sensitivity of conventional cytology at the level of sample collection storage. It involves 
using a liquid conservation medium to preserve the cells collected and allowing for a more 
accurate microscopy. Though sensitivity is increased, it is more expensive and requires 
more infrastructure/instruments to prepare smears, limiting its utility in resource-limited 
settings. 
HPV testing may involve polymerase chain (PCR) amplification of HPV DNA and 
detection or hybridization methods through a second generation Hybrid Capture II (HCII) 
assay that includes RNA probes for high-risk HPV types. Overall the accuracy of these DNA 
detection methods depends on the primers and probes used. In a review of studies in 
developed countries, the sensitivity and specificity of HCII in detecting CIN 2-3 ranged 
respectively from 66-100% and 61-96% [Franco, JNCI 2003]. The sensitivity in developing 
countries has been lower ranging from 50-80% [Sankaranarayanan et al, 2005]. HPV testing 
has been proposed to be used as screening test on its own (so-called primary screening) or 
in conjunction with cytology (“triage”). 
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Visual screening tests, VIA, VILI, VIAM involve visualizing the cervix and using 
chemicals to differentiate neoplastic areas from normal areas. They can be combined with 
immediate care of lesions either by cauterization of excision. They thus have the advantage 
of offering the ability to do ‘one-visit’ screen and care. However they need trained personnel 
and can be very subjective. VIA is the most frequently used and its sensitivity and specificity 
range from 67-79% and 49-86% respectively, which is generally midway between cytology 
and HPV testing [Sankaranarayanan et al, 2005].  
Innovative methods being developed for potential use in cancer detection include 
methods to automate conventional analysis, using markers to enhance cytology and or 
assays that detect markers specific to cancer pathogenesis. These markers include those 
that indicate cell aneuploidy, loss of heterozygosity, telomerase activity or DNA methylation 
[Nijhuis et al, 2006].  
 
2.1.5 Management. 
The primary prevention of cervical cancer lesions rests in the prevention of 
infection with HPV. This involves general methods to prevent STIs (reducing exposure by 
late onset of sexual activity, few partners, safer-sex practices) and a more specific HPV-
targeted intervention: vaccination. Two HPV vaccines have been developed one targeting 
HPV 16 and 18, the other targeting HPV 6,11, 16 and 18. By preventing infection with HPV 
16 and 18 both are expected to prevent the 70% of cancers that are attributed to these two 
types. However the existence of other high-risk HPV types and the fact that not all women 
would have been vaccinated prior to the onset of sexual activity justifies the continuous 
need for screening programs in addition to vaccinations programs. 
Though vaccines have been shown to be efficacious in reducing the frequency of 
HPV infection, HPV persistence, low-grade and high-grade lesions in previously uninfected 
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women aged 15-25 years [Rambout et al, 2007] the extent of long-term prevention offered 
by these vaccines and the best administration regimen remain to be ascertained.  
Secondary prevention is aimed at the early detection of precancerous lesions 
and their treatment. Various guidelines exist depending on the target population and the 
issuing agency. Screening involves the various tests discussed in section 2.1.4 in different 
combinations of onset of screening, frequency of screening and care provided with 
screening. Guidelines for cervical screening in the US are presented in Table 2.2 below.  
WHO guidelines for screening targeted mainly for developing countries recommend at least 
one screen in the 4th and 5th decade or a screen every 3 years where possible [WHO, 2006]. 
Conventional cytology is considered the standard method, though this could be replaced 
with visual methods if possible. 
Screening would result in the detection of precancerous lesions which need to be 
treated. Treatment modalities include outpatient treatments such as cryotherapy, loop 
electrosurgical excision procedure (LEEP), and cold knife conization. 
Tertiary prevention involves the reduction of cancer mortality: treatment options are varied 
and include surgery (hysterectomy), radiology and/or chemotherapy. 
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Table 2.2: Summary of cervical cancer screening guidelines in the US 
[Source CDC, From http://www.cdc.gov/std/hpv/ScreeningTables.pdf] 
 
 American Cancer Society  US Preventive 
Services Task 
Forces 
American College of 
Obstetricians and 
Gynecologists 
 ACS, Nov 2002 USPSTF, Jan 2003 ACOG, Aug 2003 
    
When to start Approximately 3 years after 
onset of vaginal 
intercourse, but no later 
than age 21 
Within 3 years of 
onset of sexual 
activity or age 21, 
whichever comes first 
Approximately 3 years 
after onset of vaginal 
intercourse, but no 
later than age 21 
Intervals     
Conventional 
Pap test  
Annually; every 2-3 years 
for women aged 30+ with 3 
negative cytology tests* 
At least every 3 years Annually; every 2-3 
years for women aged 
30+ with 3 negative 
cytology tests* 
If liquid-based 
cytology 
Every 2 years;  every 2-3 
years for women aged 30+ 
with 3 negative cytology 
tests* 
Insufficient evidence Annually; every 2-3 
years for women aged 
30+ with 3 negative 
cytology tests* 
If HPV testing 
used 
Every 3 years if HPV 
negative, cytology negative 
Insufficient evidence  Every 3 years if HPV 
negative, cytology 
negative 
    
When to stop Women 70+ years with 3+ 
recent, consecutive 
negative tests and no 
abnormal tests in prior 10 
years* 
Women >65 years 
with negative tests 
and not otherwise at 
high risk for cervical 
cancer 
Inconclusive evidence 
to establish upper age 
limit 
    
Post-total 
hysterectomy 
Discontinue if for benign 
reasons and no prior 
history of high-grade CIN* 
Discontinue if for 
benign reasons 
Discontinue if for 
benign reasons and 
no prior history of 
high-grade CIN* 
*some exceptions apply (for example women who are immunocompromised, have a history of prenatal 
exposure to DES etc).  
 
 
2.2 Cervical cancer and precancerous lesions in HIV 
An estimated 33 million people were living with HIV by the end of 2007, about 
half of whom are women and about two-thirds of whom live in sub-Saharan Africa 
[UNAIDS, 2008]. The proportion of women with HIV is much higher in developing countries 
(where the heterosexual route is predominant) compared to most developed countries (with 
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a substantial role for homosexual and intravenous routes).  In Cameroon, which has an 
estimated HIV prevalence of 5.5%, women constitute up to 300,000 of the 490,000 people 
15+ years living with HIV. In the US, with a prevalence of 0.6%, only 230,000 of the 
1,100,000 people 15+ living with HIV are women. 
The early recognition of the frequency of cervical cancer in patients with advanced 
HIV disease led to its definition as an AIDS-defining condition. It is now recognized that HIV-
positive women have: a higher prevalence of HPV and that the risk of infection increases 
with the extent of immunosuppression; a higher prevalence of persistent infection and 
infection with multiple HR-HPV types; a greater risk of precancerous lesions; a higher risk of 
developing cancer, with diagnosis up to 10 years earlier than in the general population and a 
faster progression to advanced disease with poor prognosis [WHO, 2006]. 
HIV positive women have a higher prevalence and incidence of cervical HPV 
infection [Palefsky, 2006]. A recent review of over 30 studies showed that the ratio of HPV 
prevalence in HIV positive to negative women ranged from 1 to 9.3, with most estimates 
being between 1 and 3.6 [De Vuyst et al, 2008]. In an analysis of baseline data from the HIV 
Epidemiology Research Study (HERS) cohort in the US, 64% of 851 HIV positive women 
had HPV infection compared to 28% of 434 HIV negative women [Cu-Uvin 1999].  In a 
longitudinal study of 284 women in the US (186 of whom were HIV positive) with semi-
annual HPV testing, HPV positivity among HIV- women and HIV+ women with CD4+ > or 
=200 and <200 cells/uL was 47.5%, 78.7%, and 92.9% respectively [Ahdieh et al, 2000].   
While about half of these infections may be attributed to the similar sexual transmission 
routes, the other half occurred in women who did not report any recent sexual exposure yet 
had incident HPV-infection, suggesting that there may be a reactivation of previously 
controlled HPV-infection in immunosuppressed HIV positive women [Strickler et al, 2005].  
HIV positive women are less likely to clear HPV infection, ie have a higher HPV 
persistence. Compared with HIV negative women, the relative incidence of HPV clearance 
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was 0.29 and 0.10 among HIV+ women with CD4+ > or =200 and <200 cells/uL [Ahdieh et 
al, 2000]. In another study of 220 HIV positive and 231 HIV negative women in New York, 
HPV was persistent in 24% of HIV positives versus only 4% of HIV  negatives [Sun et al, 
1997]. 
HIV positive women are more likely to have infection with high-risk HPV. HIV-
positive women were 1.8, 2.1, and 2.7 times more likely to have high-, intermediate-, and 
low-risk HPV infections, respectively, compared with HIV-negative women [Ahdieh et al, 
2001]. In a recent meta-analysis of 3230 women with no cytological abnormalities any HPV 
prevalence was 36.3%, multiple HPV type prevalence was 11.9% while the most common 
HPV types were HPV-16, 58, 18, 52, 31 and 33 (respective prevalence of 4.5, 3.6, 3.1, 2.8 
2.0 and 2.0%) [Clifford et al, 2006]. Curiously HIV positive women with HSIL were less likely 
to have HPV-16 compared to other women in the general population with HSIL (OR=0.6; 
95%CI: 0.4, 0.7). Also in studies from Africa and North America, HPV type 58 was more 
prevalent than type 18. Furthermore HIV positive women with HSIL had a higher prevalence 
of low risk –HPV types 11, 53, and 61 suggesting that these supposedly low-risk types 
may have a potential to cause neoplastic changes in immunodepressed women. It is 
also plausible that lower but undetectable levels of high risk types could be leading to 
HSIL. 
Both low grade and high grade precancerous lesions are more prevalent in HIV 
positive women.  In a recent review of published studies the prevalence of LSIL in HIV 
positive women ranged from 9.7% to 19.0% and LSIL was 1.6 to 8.8 times as prevalent in 
HIV positive women as in HIV negative women [De Vuyst et al, 2008]. HSIL was also more 
prevalent in HIV positive women who had prevalence rates ranging from 2.3% to 17.6%, 
representing an occurrence 1.9 to 11.7 times as prevalent in HIV positive women as in HIV 
negative women.  The highest prevalence of lesions was reported in Zambia recently: 76% 
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of HIV positive women had lesions with LSIL in 23%, HSIL in 32% and lesion suspicious of 
ICC in 20% of 150 HIV positive women [Parham et al, 2006].  
HIV positive women have a higher incidence of precancerous lesions. Three 
cohort studies conducted in the US reported four-fold incidence of SIL in HIV positive 
women compared to HIV negative women [Six et al, 1998; Massad et al, 2001; Schuman et 
al, 2003]. In another study conducted in Senegal 71/627 (11%) of women developed HSIL 
after a median 2.2 years of follow-up[Hawes et al, 2006]. HIV-2 positive appeared less likely 
to develop HSIL compared to HIV-1 infected women (HR=0.3, 95%CI: 0.1, 0.9). HIV+ 
women with each of CD4 counts <200 high HIV viral load appeared more likely to develop 
HSIL (HR for CD4<200 versus >200=5.5, 95%CI: 2.0, 15.2; HR for each log increase in viral 
load=1.4, 95%CI: 1.1, 1.7). These factors were however not significantly associated with 
incident HSIL in multivariate adjustments. 
HIV-positive women may have a higher progression and a lower regression of 
precancerous lesions. Few studies have assessed the long-term evolution of lesions in 
HIV positive women. In the US, Six et al [1998] and Massad et al [2001] both reported faster 
progression from LSIL to HSIL in HIV-positive women.  In the former study, 38.1% of LSIL 
had progressed to HSIL over a year in HIV positive women while none had progressed in 
HIV negative women. All the progression occurred in women with CD4 counts less than 
500/uL. In the latter study, the 6-months progression was 13.6 in HIV-positive versus 6.8% 
in HIV negative women. The regression rate was also slower in HIV positive women (43% 
versus 66%). These studies were however not sufficiently powered to assess the role of 
other factors such as CD4 count, HIV viral load on evolution.  
The prevalence and incidence of invasive cervical cancer appear higher in HIV 
positive women.  Though cervical cancer was the most frequent cancer observed in early 
HIV positive women, early comparative studies did not find an increased 
incidence/prevalence of invasive cancer in HIV positive women compared to the general 
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population. A few cohort studies such as the Women Interagency HIV study (WIHS) did not 
find a difference in cervical cancer incidence by HIV status. Initial analysis by IARC in 1996 
did not find any relationship either [De Vuyst, 2008]. However the rarity of cervical cancer 
suggests the best evidence of association could only be gleaned from case-control studies 
or much larger population based cohort studies. The WIHS observed no case of cancer in 
HIV negatives and only one case of confirmed cervical cancer in HIV positives, thus having 
a very low power to detect any difference [Massad et al, 2004]. Furthermore, high HIV-
associated mortality prior to HAART may have prevented the development and subsequent 
detection of cervical cancer in HIV positive women in cancer registries.  In a larger 
population based study, the Sentinel Hospital Surveillance System for HIV infection, the 
prevalence of cancer was slightly higher in HIV positive women (10.4 versus 6.2 cases per 
1000 women) [Chin et al, 1998]. A case-control study in  South Africa found a relative risk 
for cervical cancer of 1.6 (95%CI 1.1, 2.3) [Sitas et al, 2000], while another study in Kenya 
found that among women aged 35 and less women with cervical cancer had a higher HIV 
prevalence (35% versus 17% in women without cancer) [Gichangi, 2002].  Multiple other 
studies have shown an increased risk of cervical cancer in HIV positive women [De Vuyst, 
2008]. 
While HIV related immunosuppression could account for most of the 
aforementioned characteristics of cervical lesions in HIV, other mechanisms, such as 
HIV-HPV interactions, have been postulated to play a role. Multiple studies reported a 
higher prevalence of any HPV, HR-HPV types, persistent HPV, SIL and CD4 count less than 
200/uL (or 500/ul in some studies) [De Vuyst et al, 2008]. In some studies, high HIV viral 
load was independently associated with increased incidence and progression of SIL 
[Massad et al, 2001] suggesting that there may be direct HIV-HPV viral interactions. The 
HIV tat gene may increase the expression of HPV E1 and L1 viral genes as well as HPV-16 
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E7 transcription. Furthermore, it is postulated that the inflammatory responses associated 
with HIV may interfere with the effectiveness of the anti-HPV immune response. 
The effect of antiretroviral therapy on HPV and HPV-associated disease is not 
clearly understood. Highly active anti-retroviral therapy (HAART) does not appear to 
reduce HPV prevalence or incidence. In a French cohort the prevalence of HPV remained at 
81% 5 months after HAART initiation [Heard et al, 2001].  In some studies, highly active 
anti-retroviral therapy (HAART) has been shown to reduce the progression to high-grade 
lesions and increase the regression of lesions to normal [Heard et al, 2004], however this 
has not been consistent. The effect of HAART appears to be best with higher CD4 levels 
[Palefsky, 2003].  
2.3 Need to screen for cervical cancer in HIV in resource poor settings including 
Cameroon 
Cervical cancer could potentially be a major cause of mortality in HIV-positive 
women if their life expectancy is increased with the use of antiretroviral treatment and 
they are never screened.  In developed countries effective screening and early treatment 
of precancerous lesions have been key in preventing cervical cancer [Franceschi and Jaffe, 
2007]. In the US 81% of women on antiretrovirals successfully receive annual Pap smears 
[Stein et al, 2001] and up to 94% of cervical cancers are detected at an early stage of 
carcinoma-in-situ [Frisch et al, 2000]. Furthermore the long interval between precancerous 
lesions and cancers allows for time to screen for cancer. In Italy 50% of HIV positive women 
diagnosed with cervical cancer in 1996-2004 had had their HIV test results at least 10 years 
prior to cancer diagnosis [Franceschi et al, 2006], sufficient time for the women to have 
been screened and received treatment for precancerous lesions. 
Access to antiretrovirals has dramatically increased in developing countries. While 
the increased survival that is expected to accompany this increased access with an 
expected reduction of the burden certain opportunistic affections  such as Kaposi sarcoma, 
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the effect on cervical is expected to be moderate at best, as HAART has a very limited 
effect, if any, on HPV persistence and the progression of lesions [Heard, 2004]. Even while 
on antiretrovirals women would still need to be screened or receive other preventive care for 
cervical cancer.  
One of the reasons why women in resource-limited areas are not regularly screened 
is the limited access to health providers or services. Presumably this could be overcome in 
women on antiretrovirals who because of the need for follow-up of their HIV disease have a 
greater contact with health services. This regular contact could be taken advantage of to 
propose regular screening services.  Once the women can be seen regularly in hospitals the 
next potential barrier would be the cost of screening and the chance that most tests would 
be negative. Screening could be made more cost-effective by targeting. Screening could be 
targeted based on clinical demographic and or behavioral characteristics. HPV DNA tests 
could also be used for screening, however the accuracy of HPV DNA testing in HIV positive 
women is still unclear and it is plausible that HPV types not included in the current tests and 
which are not considered high risk in the general population could well turn out to be 
oncogenic in HIV-positive women. Furthermore the current costs of HPV DNA testing 
remains a barrier for its widespread use in resource-limited settings. Other screening 
methods such as VIA and VILI also have limited assessment in HIV positive women. 
Recently developed HPV vaccines could potentially be useful, however so far their 
efficacy has only been demonstrated in immunocompetent women. Screening with cervical 
cytology thus offers better prospects for effectiveness in reducing cervical morbidity and 
mortality in HIV positive women. Knowing the risk factors for cervical lesions could help in 
reducing the cost of screening resource-limited settings. 
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2.4 Age and cervical cancer 
The occurrence of cervical cancer and precancerous appears to be age 
dependent and may reflect the interaction of multiple physiological and pathological 
factors. 
Physiological changes in the size and anatomical position of the cervical 
squamocolumnar junction (SCJ) may play a role in the age at which lesions occur.  
Prior to puberty the SCJ is located at the external cervical os, at the intersection between 
the endocervix (covered by a single-layered and thus relatively fragile columnar epithelium) 
and the ectocervix (covered by a stratified squamous epithelium). At puberty, under the 
influence of higher estrogen levels, the uterus and cervix grow in size, a growth that results 
in the original SCJ being pushed externally such that a substantial proportion of columnar 
epithelium is exposed to the vaginal atmosphere and its consequent acidity. Under the 
influence of this acidity and increased estrogen levels, this area of columnar epithelium 
begins undergoing a process called squamous metaplasia (which is considered normal) with 
a gradual change of the columnar epithelium into a squamous epithelium. This occurs until 
women are in their thirties and both the original and a new SCJ become visible on 
colposcopy. The area between the new and the original SCJ is known as the transformation 
zone and is the site where most precancerous lesions are detected. As women age into 
menopause the influence of estrogen decreases, with a resultant decrease in the size of the 
cervix that leads to the transformation zone retracting to the endocervical canal. In the 
postmenopausal women both the new SCJ and the transformation zone have completely 
retracted into the cervical canal and only the original SCJ is visible on colposcopy [WHO, 
2006]. 
It can be inferred from these physiological changes that squamous lesions would be 
very rare in prepubescent girls as there is no transformation zone. Lesions occur after 
 23 
 
puberty and incidence could increase until reaching a peak in the premenopausal ages and 
then decrease after menopause with a reduction in the amount of transformation zone 
exposed to the ectocervix. Although the retraction of the transformation zone in the canal 
after menopause may imply a reduction in the occurrence of new lesions, it may also imply 
that, particularly in settings with little or no systematic screening, lesions that occurred prior 
to menopause may be retracted into the endocervical canal rendering detection by cytology 
smears more difficult and thus resulting in the detection of cancers at a relatively advanced 
stage in older women. It may also be inferred that, in countries with repeated regular 
screening, in the absence of any lesions in the early post-menopausal period, it will be 
unlikely to detect new lesions at older ages (as the transformation zone is less exposed). 
The age at which lesions occur may also be related to the age-specific 
incidence, prevalence and persistence of HPV infection. Potentially reflecting higher 
exposure to HPV and increased susceptibility to HPV-infection, multiple studies have shown 
that the incidence of HPV peaks amongst adolescents and women aged less than 25 years 
then decreased in women in their third to fifth decades (35 to 55 years) only to have a 
second peak after age 55 [Baseman and Koutsky, 2005; Herrero et al, 2000]. The latter 
increase is thought to be reflective of the lesser ability to clear HPV infections, a reactivation 
of latent HPV infection or a cohort effect at older ages.  A recent review of age-specific HPV 
prevalence, confirmed these trends to be consistent across geographical regions, with peak 
ages varying to reflect sexual activity at different ages [Smith et al, 2008]. 
The age-specific occurrence of cervical lesions appears to reflect that of HPV 
infection albeit with a delay. Numerous studies report peak prevalence of lesions in 
women under 40[Chang et al, 1991; Sadeghi et al, 1989; Gupta et al, 2008]. The median or 
mean age of occurrence however increases with severity of lesion [Chung et al, 1982; 
Gupta et al, 2008]. There is no evidence that the progression or regression rates of lesions 
are a function of age: Winn and Jones [2005], Giannopoulos et al [2005] and Wright et al. 
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[2005] found no age differences in regression or progression. However in one study of HSIL 
cases in India, lesions in older women (as well as women with high parity) were more likely 
to progress than those in younger women [Misra et al, 2006].  
Unlike HPV-infection and precancerous lesions, the incidence of and the 
mortality due to cervical cancer increases with age as shown in figure 2.1 below. While 
the increase is gradual in countries with a well established screening system, it is very 
marked in less developed countries peaking after the fourth decade of life.  
The relationship between age and the occurrence of precancerous or 
cancerous lesions led to the consideration of age as targeting factor in screening the 
general population of women.  As described in Table 2.2 all the major screening 
guidelines consider the age at which to begin screening, the age at which to modify the 
interval between screening tests and the age to discontinue screening. Such is not the case 
for guidelines in HIV positive women at least not explicitly. Differences in the pathogenesis 
of cervical SIL and age specific mortality may imply different age considerations in HIV 
positive women. The age of occurrence of lesions in HIV-positive women, as well as the 
progression of lesions by age and the cost-effectiveness of age-targeted screening needs to 
be better described.  
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Figure 2.1: Age-specific incidence and mortality of cervical cancer (Source: Globocan 
2002, [Ferlay et al, 2004]) 
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2.5 Review of previous studies 
2.5.1 Studies of the prevalence and predictors of cervical lesions in HIV-positive 
women developing countries 
Though numerous studies have documented the epidemiology of cervical squamous 
intraepithelial lesions in HIV positive women in developed countries few do so for developing 
countries. Table 2.3 summarizes the main studies conducted in the latter. The prevalence of 
SIL was quite varied ranging from 1.2% [Mbakop et al, 1996] to 76% [Parham et al, 2006]. 
Because most studies were conducted to establish the association between HIV infection 
and the presence of SIL, very few assessed the risk factors specific to HIV positive women. 
Amongst these, immunosuppression (low CD4 count), high HIV viral load and or infection 
with high-risk HPV types tended to be associated with the presence of SIL. Only one 
prospective study in sub-Saharan Africa was identified in the literature and this study 
indicated a SIL incidence rate of 11% over a mean of 2.2 years of follow-up [Hawes et al, 
2006]. 
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Table 2.3: Summary epidemiology of HPV, cervical precancerous and cancerous lesions in HIV positive women in 
developing countries  
Author(s), year, study 
population, site, subject 
Aim and methods Results  
SUB-SAHARAN AFRICA   
Adam et al, 2008.  
South Africa. 
Predictors and 
progression of lesions  
To assess predictors of lesions following LEEP 
in patients with HSIL or worse. Follow-up Pap 
smears were conducted in 575 of these 
patients. 
The median time between LEEP and follow-up Pap was 
122 days. 49% of patients still had abnormal lesions: 6.3 
ASCUS, 47.6% LSIL, 1.8% ASC-H, 0.4% AGUS, 43.2% 
HSIL, 0.7 ICC. The odds of persistence in HIV positive 
women was 8 fold that in women self reporting as HIV-
negative. Predictors of persistence in HIV positive women 
included the low CD4 count and the presence of disease 
at excision margins. 
Mbu et al, 2008. 
Cameroon. 
Prevalence of lesions 
Prevalence of lesions in 198 HIV positive 
pregnant women. 
HIV positive women were more likely to have LSIL 
(18.2% vs 4.4%) and HSIL (12.1% vs 1.5%). 
Yamada et al, 2008. 
Kenya.  
Prevalence of HPV and 
lesions 
HPV prevalence and cervical lesions studied in 
488 women visiting a clinic in Kenya. HPV 
diagnosed by PCR.  
32% (155/488) of women were HIV positive, 23% of 
whom were on antiretrovirals. Cervical HPV was more 
prevalent in HIV positives (49% vs 17%).  LSIL and HSIL 
were also more frequent in HIV positive: 21% vs 6.9% 
and 5.8% vs 0.6% respectively. Infection with HR-HPV 
and low CD4 counts were risk factors for cervical lesions 
Ng’andwe et al 2007. 
Zambia. 
Prevalence of HPV 
Cross-sectional study to describe HPV 
prevalence, genotype and risk factors in a 
cohort of patients in Lusaka, Zambia. Cross 
sectional study. HPV diagnosed by PCR 
Overall HPV 16 and 18 each had a prevalence of 21.6%  
HIV positive patients were two times as likely to have HR-
HPV as HIV-negatives. Meanwhile the prevalence of LR-
HPV was similar in HIV positive and negatives. 
Sahasrabuddhe et al, 
2007. 
Zambia 
Prevalence of HPV and 
lesions 
In a cross-sectional study 145 HIV positive 
women were screened using LBC and HPV 
genotyped. 
HR-HPV were more frequent in women with CD4<200 
(OR: 4.9, 95%CI: 1.4, 16.7) and in women with HSIL or 
squamous cell carcinoma (OR: 8.0, 95%CI: 1.7, 37.4). In 
women with HSIL or squamous cell carcinoma HPV HR 
type proportion was as follows: HPV-52=37.2%, 
58=24.1%, 53=20.7%, 16=17.2%, 18=13.1%. High 
prevalence of non-16/18 HR types suggest probable 
inadequacy of HPV 16/18 vaccines. 
Gaym et al, 2007. 
South Africa. 
Prevalence of lesions. 
Cross-sectional study to assess the 
association between HIV and cervical 
dysplasia and a cross sectional study was 
24.5% of patients were HIV positive. The overall 
prevalence of ASCUS=6.4%, LSIL=9.2%, HSIL=1.3%.  
Among the 114 HIV positive patients the prevalence of 
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conducted in 466 women at a primary health 
care clinic in KwaZulu-Natal. 
ASCUS=10.5%, LSIL=21.0%, HSIL=4.4%.   
Parham et al, 2006. 
Zambia. 
Prevalence of lesions. 
Cross-sectional study to evaluate the 
prevalence and predictors of SIL in 150 HIV-
infected women in Zambia (age 23-49). 
Screening was done using LBC and HPV 
typing by Roche linear array PCR 
CD4 ranged from 7 – 942 (median 165)/uL. 
76% had SIL: of which LSIL=23.3%, HSIL=32.6% and 
20% had lesions suspicious of SCC. 
85.3% had HR-HPV. 
Overall very high prevalence of SIL and HR-HPV. The 
highest in any study population. 
The HR-HPV type independently predicted the presence 
of HSIL/SCC (adjusted OR: 12.4, 95%CI: 2.62, 58.1). 
Didelot-Rousseae et al, 
2006. 
Burkina Faso. 
Prevaence of HPV and 
lesions 
Cross-sectional study of HPV and cervical SIL 
in 379 high-risk women.  
HIV-1 seroprevalence=36.0%. 
Overall HPV prevalence=66.1% of 360 validly tested. 
HPV prevalence was higher in HIV (87% vs 54%; 
PR=1.61, 95%CI: 1.4, 1.8). Similarly HR-HPV types and 
multiple HPV infections were more frequent in HIV 
positive women. 
Prevalence of SIL in 126 HIV+ women= 48.4%; 
LSIL=38%, HSIL= 10% 
Hawes et al, 2006. 
Senegal. 
Incidence of lesions 
627 women were assessed for the persistence 
of HPV and incidence of HSIL over a mean 
follow-up time of 2.2 years. 
71/627 (11%) of women developed HSIL. 
HIV-2 positive appeared less likely to develop HSIL 
compared to HIV-1 infected (HR=0.3, 95%CI: 0.1, 0.9). 
HIV+ women with each of CD4 counts <200 high HIV 
viral load appeared more likely to develop HSIL (HR for 
CD4<200 vs>200=5.5, 95%CI: 2.0, 15.2; HR for each log 
increase in viral load=1.4, 95%CI: 1.1, 1.7). 
These factors were however not significantly associated 
with incident HSIL in multivariate adjustments. 
Moodley and Garib, 2004. 
South Africa. 
Prevalence of lesions 
To determine the prevalence of SIL in 160 
HPV positive women in South Africa. 
HIV prevalence=41.9%; SIL prevalence=36.9%. 
Biopsy confirmation of SIL in HIV positive=49.3% vs 28% 
in HIV negative. But no difference by grade. Authors 
suggest similar management of HPV positive women 
whether they are HIV-positive or not. 
Hawes et al, 2003. 
Senegal. 
Prevalence of HPV and 
lesions  
Cross-sectional study of prevalence and 
predictors of HSIL/ICC in 4114 outpatient 
women in Senegal. 
HIV prevalence =10.5%, 433 women. HIV-1 only=8.1%, 
HIV-2=1.7%, HIV1 and 2= 0.7%.  
Prevalence of HR-HPV in HIV-1 only (N=330), -2only 
(N=68), -1 and -2 (N=28) was respectively 53%, 41%, 
and 60%. 
In all 3 groups about 1/3rd did not have HPV. 
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Prevalence of LSIL or worse was 17.2%, 19.5% and 
34.5% respectively (vs 4% in HIV negative).  
Prevalence of HSIL or worse was 4.5%, 10.5% and 
13.8% respectively (vs 1.4% in HIV negative).  
The association between HIV and HSIL/ICC was 
restricted only to women with HR-HPV infection. 
Among HIV positive women factors associated with 
HSIL/ICC and HR-HPV included high HIV viral load and 
low CD4 count 
Chirenje et al, 2002. 
Zimbabwe. 
Prevalence of lesions 
Cross-sectional study in 554 women in Harare. HIV prevalence = 36.8%.  
Prevalence of lesions in HIV+ = 25.6% (vs 6.7% in HIV 
negative): with ASCUS=12.6%, LSIL=9.7%, HSIL=3.4%. 
Mayaud et al, 2001. 
Tanzania. 
Prevalence of lesions 
To determine the prevalence and interrelation 
of HPV genotypes, SIL and other reproductive 
tract infections in 660 urban ANC attendees in 
Mwanza. 
HIV prevalence was 15%. HPV prevalence was 34%. 
86% of HPV-typable samples had HR-HPV. 
No association between HIV and HR-HPV (OR=1.02, 
95%CI: 0.6, 1.6). 
Higher prevalence of HPV in HIV women at older age.  
Prevalence of SIL overall was 7% with HSIL in 3%.  
Prevalence of SIL in HIV positive= 9/90 = 10%. 
Kapiga et al, 1999. 
Tanzania 
Prevalence of lesions 
To determine the prevalence and risk factors 
for SIL in 691 HIV positive women in Dar es 
Salam (1996-1997). 
Prevalence of SIL = 2.9% (20/686). LSIL=1.6%, 
HSIL=1.3%. 
Presence of SIL was associated with CD4<200 (adjusted 
OR=6.15, 95%CI: 1.19, 41.37) and a decrease in mid-
upper arm circumference (adjusted OR=0.32, 95%CI: 
0.10, 0.93 per 5cm increase in circumference). 
The number of lifetime sexual partners and parity were 
marginally and non-significantly associated with SIL. 
Womack et al, 2000. 
Zimbabwe 
Prevalence of HPV and 
lesions 
To determine the utility of the HCII test in 
primary screening of 466 women at risk of HIV 
in Zimbabwe 
HIV positive proportion=53.5% 
Prevalence of HPV in HIV = 64.3% (vs 27.6% in HIV 
negative). 
Prevalence of HSIL in HIV= 17.3% (vs 5.9%) 
Strong association between HSIL and HPV in both HIV-
negative and positive. 
Sensitivity and specificity of HCII for detecting HSIL in 
HIV = 90.7% and 41.3% (vs 61.5% and 74.5%). 
Utility of HCII test depends on prevalence and availability 
of resources. 
Leroy et al, 1999.  To assess the prevalence of SIL and their Prevalence of SIL in HIV =24.3% (vs 6.5%) 
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Rwanda 
Prevalence of lesions 
association with HIV in pregnant women in 
Kigali. (1992-1993). 103 were HIV positive 
while 107 were HIV negative. 
Women with SIL tended to have a lower CD4 count. 
Temmerman et al, 1999. 
Kenya 
Prevalence of HPV and 
lesions 
To identify risk factors for HPV and SIL and 
determine the role of HIV in 513 family 
planning clinic attendees in Nairobi. 
An analysis stratified by HIV-1 showed a stronger 
association between HPV and HSIL in HIV-1 negative 
women (OR: 17.0, 95%CI: 6.4, 46.3) than in HIV-1 
positive women (OR:4.5, 95%CI: 0.8, 27.4). 
La Ruche et al, 1998. 
Cote d’Ivoire 
Prevalence of lesions 
To assess the prevalence and factors 
associated with SIL and ICC in 2170 women in 
Abidjan. 
HIV prevalence= 21.7%. 
In HIV-1 positive women, the prevalence of LSIL 
increased slightly with the clinical stage of HIV-related 
disease, from 14.4% in Stage I to 19.8% in Stage III, 
without reaching statistical significance (very few women 
(5) were in stage IV). HSIL prevalence increased from 
10.3 to 13.8%.  
Prevalence of LSIL increased markedly and significantly 
with a decrease in CD4 cell count, from 14.1% in women 
with CD4 count >500/mL to 41.9% in women with CD4 
count<200/mL. The prevalence of HSIL also increased 
with a decrease in CD4 count. 
Langley et al, 1996. 
Senegal. 
Prevalence of HPV and 
Lesions 
To determine the effect of HIV 1 and 2 on the 
prevalence of HPV and SIL a cross sectional 
study was conducted in 759 female 
commercial sex workers in Dakar 
68 women had HIV-1 only, 58 HIV-2 only, 14 HIV- and -2.  
Among with HIV, women with HPV had lower CD4/CD8 
ratio.  
Motti et al, 1996. 
Malawi 
Prevalence of HPV and 
lesions. 
To assess cervical abnormalities, HPV and 
HIV infection in women in Malawi.  
Of 132 HIV positive women SIL prevalence=15%. 
60% of HIV women with CD4<300 had HPV DNA. 
Mbakop et al, 1996. 
Cameroon. 
Prevalence of lesions 
To present the cytological aspects of smears 
in HIV positive versus HIV negative women in 
Cameroon. 
Only 1 of 65 (1.5% HIV positive women had SIL and it 
was LSIL.  
Unexpectedly lower than 4% of 50 HIV negative who had 
SIL. But note small sample sizes. 
OTHER DEVELOPING 
COUNTRIES 
  
Mangclaviraj et al, 2008. 
Thailand. 
Predictors of lesions 
Cross sectional study of 385 HIV positive 
women in Bangkok. Pap smears were done in 
these women. 
Prevalence of LSIL=11.2%. HSIL=4.7% and invasive cell 
carcinoma=0.5%. 
Only nadir CD4 count and income were significantly 
associated with the presence of cervical anomalies 
(women with nadir CD4<200 and income <$125 each 
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had twice the odds of having anomalies) 
Gheit et al, 2006. 
Brazil. 
HPV type 
A comparison of HPV-16 variants in 19 HIV 
positive women to 22 HIV negative women.  
Non-European variants of HPV-16 were approximately 3 
times as frequent in HIV positive women (36.8% vs 
13.6%) as in HIV negative women.  Association of 
European variants with HSIL in HIV negatives but no 
association of non-European variants with HSIL in both 
populations.  Very small numbers though.  
Chalermchockcharoenkit 
et al, 2006. 
Thailand. 
Prevalence lesions 
To assess the prevalence of lesions iat post-
partum visit of 636 women in a PMTCT 
program n Siriraj(1996-2004).  
Prevalence of SIL=13.3%, 90% of these were LSIL. 
Women with CD4<200 had a higher prevalence of 
lesions (21.2% vs 12.2%). 
Sirivongrangson et al, 
2007. 
Thailand. 
Prevalent lesions and 
prevalent HPV 
Cross-sectional study (2003-2004) with Pap 
smear and HC2 testing for HR-HPV in 210 
HIV-infected women 
Prevalence of HR-HPV=38.6%. 
Prevalence of abnormal cytology=20.4% 
Estimated prevalence of cervical cancer was 1.9% (4 of 
210) however this was  based only on 23 women having 
a pathology result. 
Levi et al, 2004. 
Brazil. 
Prevalence of HPV 
To determine the prevalence of HPV 
genotypes in cervical samples from 255 HIV 
infected women and compare to a control of 
36 HIV negative women. 
Prevalence of abnormal lesions in HIV+=18% 
HPV-DNA prevalence = 87% 
Multiple HPV types in 45%. 
All HIV negative had HPV but only 3/36 had multiple 
types. Thus an increased rate of multiple HPV infection in 
HIV. But no association between the presence of multiple 
HPV and SIL. The authors however do not distinguish 
between multiple infection with HR-HPV and multiple 
infection with any HPV. 
Goncalves et al, 2003. 
Brazil. 
Predictors of lesions 
 
Cross-sectional study of 141 HIV-positive 
women. Outcome was anogenital lesions (not 
just cervical lesions)  
Not clear how many had abnormal lesions. However 
biopsy conducted in 35, 10 had low grade lesions while 8 
had high grade lesions.  
Both undetermined HPV and HR-HPV type were 
associated with the presence of lesions 
Volkow et al, 2001. 
Mexico. 
Prevalence of HPV 
To determine the prevalence of HPV and SIL 
in 85 HIV positive in Mexico. 
Prevalence of HPV 69%, of HR-HPV = 33%. 
Prevalence of LSIL=17.8%, HSIL=8.2% 
No association with CD4 counts and antiretroviral 
therapy. 
Goncalves et al, 1999. 
Brazil. 
Prevalence of HPV 
To characterize HPV prevalence and types in 
141 HIV positive women 
Prevalence of HPV=80.8% 
Prevalence of multiple (2+) HPV types = 45%. 
Prevalence of HPV 16, 18 = 30.5%; HPV 61, 53 = 24.4%, 
unidentified types = 18.7%. 
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2.5.2 Studies of the relationship between age and cervical lesions 
While the age of onset and occurrence of precancerous and cancerous lesions in 
HIV women is not well described, the literature is crammed with studies exploring these 
characteristics in the general population. These studies are summarized in Table 2.4. As 
soon as the 1980’s, studies were published documenting the prevalence of lesions in young 
women. Subsequent studies showed that the peak of occurrence of precancerous lesions 
was in the third to fourth decade while malignant lesions tended to occur later in the fourth 
or fifth decade. Lesions also appeared to be less frequent in women far past menopause. 
The implementation of successful frequent screening resulted in a decrease of the mean 
ages at which patients have dysplasias, though this may simply reflect detection bias. Most 
studies also noted similar progression rates irrespective of age. More recent studies have 
confirmed the higher prevalence of HPV in younger sexually active women. 
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Table 2.4: Summary of studies of that addressed the impact of age on the prevalence of lesions, the progression of 
lesions, the prevalence of HPV or diagnostic work-up. 
 
Author(s), year, study 
population, site, subject 
Aim and methods Results  
PREVALENCE OF LESIONS 
Gupta et al, 2008. 
India. 
Prevalence of lesions 
To identify target age groups were screening 
efforts could be concentrated a retrospective 
analysis of hospital-based cytology screening 
data from 29 475 women in India (2001-2004) 
was conducted. 
The prevalence of abnormal lesions was 5.6%. the 
highest incidence of SIL was observed in the age group 
30-39, while that of malignancies was in the age group 
>60. the mean ages for LSIL, HSIL and cancer were 
34.7, 37.7 and 51.8 respectively. Screening in both the 
fourth and fifth decades of life could detect 2/3rd of SIL. 
Tanaka et al, 2001. 
Japan.  
Prevalence of lesions.  
To assess the prevalence of premalignant or 
malignant lesions in patients HPV 16 positive. 
207 women referred for colposcopy during a 
20-month period between 10/1994 – 05/1996.  
Amongst HPV 16 positive women, premalignant or 
malignant cervical diseases were approximately 8 times 
as frequent in women 44 years or younger (n=111) as in 
women 45 year or more. HPV testing thus recommended 
in younger women. 
Sujathan et al, 1995. 
India. 
Prevalence of lesions 
Assess the prevalence of cervical cytology 
abnormalities and risk factors at early stages 
of a screening program in South India. 
Only low-grade lesions were found in women aged less 
than 40 years.  
Vishnevskii et al, 1994.  
Russia. 
Prevalence of lesions 
Prevalence of HPV associated lesions Females of reproductive age revealed a significantly 
higher frequency of HPV-associated dysplasia and 
preinvasive carcinoma (4.2%) than in 
pre- and postmenopausal women (2.8%). 
Carson and DeMay, 
1993. 
USA. 
Prevalence of lesions 
 
To describe the age distribution of 1947 cases 
with dysplasia or carcinoma at a pathology unit 
in the US.  
Only the age of women with carcinoma was normally 
distributed. The ages of women with dysplasia are not 
distributed normally, but are asymmetrically skewed to 
younger women; authors suggest that the mode better 
describes the central tendency for ages of women with 
dysplasia. 
Das et al, 1992. 
India. 
Prevalence of lesions 
To assess the efficacy of hospital based 
cytology in six hospitals in India. From 1976 to 
1986 117471 women were screened with 
cytology 
Dysplasia was present in 1.6% of patients while 0.2% 
had malignant lesions (confirmed by histology in 90.1% of 
these). 
The median age of detection of mild/moderate, severe 
dysplasia, carcinoma in situ and invasive cancers was 
34, 37.9, 38.6 and 47.8 years respectively. 
Estimated 15 years between onset of precursor lesions 
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and occurrence of invasive disease. 
 
Chang, 1991. 
New Zealand. 
Prevalence of lesions. 
Analysis of histology samples from 1371 
women on colposcopy in New Zealand. 1982-
1988 
Women <29 years accounted for 58.3% of CIN3 lesions.  
Mitchell and Medley, 
1990. 
Australia 
Prevalence of lesions 
Assessed the trends in prevalence of 
neoplasia un a Victorian Cytology service 
between 1970 and 1988.  
The age group having the highest prevalence of “definite” 
CIN decreased from 40-49 in the years 1970-1973 to 25-
29 in the years 1982-1988.  
Kaminski et al, 1989. 
USA. 
Prevalence of lesions 
To evaluate the influence of age on 
colposcopy following the detection of 
squamous dysplasia on cytology in 1074 
women 
Abnormal biopsy findings were detected in 19.6% of 787 
women aged <41 had versus only 6.3% of 287 women 
aged >40 
The New Zealand 
Contraception and Health 
Study group, 1989. 
Prevalence of lesions 
Study of cytology smears from 9430 women 
seen between 1980 and 1986 in New Zealand 
4.3% of women had abnormal lesions. 
The prevalence of dysplasia decreased slightly with 
increasing age (over ages 20-39), but the prevalence of 
carcinoma in situ/invasive cancer increased from 0.18% 
at ages 20-24 to 0.74% at ages 35-39. 
Sadeghi et al, 1989. 
USA. 
Prevalence of lesions. 
Study of prevalence and risk factors for 
cervical neoplasia in a population of 1,672,847 
women screened over a 3-year period in the 
US. 
Mild-to-moderate dysplasias were most frequent between 
ages 25-29, while severe dysplasia and carcinoma in situ 
were most frequent between ages 35 to 39.  
Wheat et al, 1988. 
USA. 
Prevalence of lesions 
To assess the need to screen women aged 
65+. Pap smear results of women in two San 
Francisco hospitals were reviewed.  
Only 5 of 140 (3.5%) women aged 65+ had class II 
atypia. None had dysplasia or carcinoma in situ. Thus 
suggesting screening in this age group may not be 
indispensable particularly in women who have had 
multiple previous screens. 
Benmoura et al, 1986. 
France. 
Prevalence of lesions 
To describe the epidemiology of cervical 
lesions in a sample of 870 adolescents (<21 
years) screened by cytology. 
11% had mild or moderate dysplasias. 
With such a high prevalence the authors recommend 
early screening. 
Chung et al, 1982. 
USA. 
Prevalence of lesions 
To describe the prevalence and incidence 
rates of cervical dysplasia and invasive 
carcinoma in 58,053 patients in Maryland 
Medical Center.  
The mean age for mild to moderate dysplasia was 25.7 
years, for moderate to severe dysplasia, 29.29 years and 
for Carcinoma in situ, 33.25 years. Lesions were present 
at young age. 
Macgregor and Teper, 
1978. 
USA. 
Prevalence of lesions 
9000 women aged <=20 years in 1967-1976 
period.  
1.6% (145) of women had abnormal smears. On follow-
up for up-to 10 years, 50% of abnormalities regressed to 
normal while 19/145 had smears suggestive of 
malignancy. No carcinoma-in –situ or invasive carcinoma 
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was found in women <21.  
PROGRESSION OF LESIONS 
Misra et al, 2006. 
India. 
Progression  
To assess factors associated with the 
progression of lesions 
571 HSIL cases out of 33,658 smears over 35 years. 
High age and parity each played significant role in 
progression of SIL 
Winn and Jones 2005. 
UK. 
Regression  
To identify the proportion of 1484 women 
(between 1996 -1998) with first abnormal 
smear who returned to normal in later cytology. 
And also to see if this was influenced by age 
or HPV status. 
50.9% of women returned to normal without colposcopy. 
This was not influenced by age (<36 vs >35) or HPV 
status. 
Giannopoulos et al, 2005  
UK.  
Progression 
To estimate the incidence of CINII and III in 
510 women with mildy dyskaryotic smears and 
verify if this was a function of age. 
Overall incidence of CINII and CINIII in women with mild 
dyskaryosis was 28.7% and was similar in all 3 age 
groups (<20, 20-25 and >25 years). Age would thus not 
be a suggested criterion for targeting referral. Also 5-
yearly screen may result in young women carrying CIN 
for 5 years before they are first screened. 
Wright et al, 2005. 
USA. 
Regression, Progression 
and Persistence 
Adolescents (<=18 years) seen between 1997-
2003 with a diagnosis of LSIL or HSIL.  
477 LSIL and 55 HSIL cases had follow-up results.  At 
follow-up of girls with LSIL 47% were normal, 47% had 
ASCUS/LSIL/CINI while 18% had HSIL/CINII/III. After 36 
months 62% had regressed while 21.8% progressed. At 
follow-up of girls with HSIL, 21.8% were negative, 27% 
had ASCUS/LSIL/CINI while 50.9% had HSIL/CINII/III. 
After 36 months 31% had progressed to CINIII. 
Progression rates in adolescents similar to that in adults. 
Knudsen et al, 2003. 
Denmark. 
Progression 
To assess compliance to screening, 
progression, treatment and follow-up after 
treatment in a 993 women in a hospital 
database, between 1990-1991. 
Age was not significantly associated with progression of 
lesions. 
Konno et al, 1998. 
Japan. 
Progression 
To assess the significance of HPV infection, 
grade of CIN and age on CIN progression. 
Study of follow-up data from 194 patients.  
Age did not impact progression rate (while HPV status 
and CIN grade were independent predictors of 
progression). 
HPV PREVALENCE    
Gonzalez-Bosquet et al 
2006.  
Spain. 
HPV prevalence 
To assess the prevalence of HPV in 215 
women with abnormal cytology results. 
Women aged ≤ 35 years had a higher HPV prevalence 
(85.6%) compared to women over 35 years (54%) 
De Villiers et al, 1992. 
Germany. 
To determine the prevalence of HPV 6, 11, 16, 
and 18 in a population of 11,667 women 
8.8% of women with normal cytology were positive for 
HPV.  HPV prevalence was much lower in women aged 
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HPV prevalence. without abnormalities attending 3 clinics in 
Germany.  
>=55 (98/3062 = 3.2%) than in women <55 (852/7716 = 
11%). 
Tideman et al, 2003. 
Australia. 
HPV prevalence 
Cross-sectional study to assess risk factors 
and prevalence of HPV and Pap smear 
abnormalities in 288 commercial sex workers 
and 266 controls 
HPV prevalence of 31.6% in CSWs and 24.4% in 
controls. Age less than 36 was associated with higher 
HPV prevalence. 
Hankins et al, 1999. 
Canada. 
HPV prevalence in HIV 
To assess risk factors for HPV infection in a 
group of 375 HIV positive women. 
HPV was prevalent in 67.2% of women; intermediate or 
HR-HPV in 49.1%. HPV infection was associated with 
CD4 count less than 200/uL, non-white race, inconsistent 
condom use in the 6 months preceding study and lower 
age (<30 years), with women aged 30-39 years having 
an adjusted OR 0.51 [95% Cl 0.30-0.87] and women 
aged 40 years or older having an adjusted OR 
0.52 [95% Cl 0.26-1.01] compared to women aged <30 
years.  
Gjooen et al, 1996. 
Norway. 
HPV prevalence 
To assess HPV prevalence in 231 women with 
no lesions ad 103 women with histologically 
confirmed CINII-III. 
In both groups HPV prevalence was higher in patients 
aged less than 30 years. 
DIAGNOSIS    
Crowther et al 2008. 
Ireland. 
Colposcopy  
To assess the ratio of HSIL to LSIL by age 
strata. To determine if colposcopy 
recommendations following the detection of 
cytology could be a function of age.  
34,180 Pap smears conducted between 07/2004 and 
06/2005, 2326 had abnormalities, 67% low grade and 
33% high grade. The ratio of low grade to high grade 
remained 2:1 across age strata suggesting that age 
targeted colposcopy may not be useful. 
Cibas et al,  2005. 
USA 
Cytology 
To assess the role of ’PM’ cells ie cells with 
band nuclear enlargement, smooth nuclear 
membranes and fine chromatin (common in 
perimenopausal women) in the interpretation 
of cytology as ASCUS. Cytology results from 
100 women aged 40-55 with ASCUS as result 
were re-assessed 
15% of ‘ASCUS’ actually had PM cells and should have 
been classified as negative. PM cells were identified as a 
significant cause of ASCUS overdiagnosis in women 40 
to 55 years old. 
Melnikow et al, 1997. 
USA. 
Cytology 
To estimate age-specific positive predictive 
values and likelihood ratios for the diagnosis of 
High grade lesions using Pap smears. 
Women under age 25 were less likely to have high-grade 
biopsies (positive predictive value, 7.3%; likelihood ratio 
0.7). Repeat Pap smears for ASCUS and LSIL showing 
only HPV in women under age 30 would have reduced 
the immediate colposcopy rate by 60% and delayed 
diagnosis of high-grade lesions by 23%. Age could be 
factor in determining extent of follow-up care.  
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2.5.3 Cost effectiveness studies: in HIV positive women, targeting age, and in 
developing versus developed countries. 
Practical and ethical difficulties limit the use of randomized studies to identify optimal 
screening strategies. In addition to the very long observation period that would be needed to 
implement a clinical trial with cancer mortality as outcome, a multitude of other parameters 
(such as age of onset, type of screening test used, screening frequency, age of screening 
discontinuation) would need to be randomized for such an endeavor. Cost-effectiveness 
analysis (CEA) and other simulation methods thus have a prominent role in directing cancer 
prevention policy. CEA have been used with varying purposes over the past decade, 
reflecting the changes in tests available and then the availability of HPV vaccines. Initial 
CEA focused on the impact of improving the sensitivity of conventional Pap smears with 
methods such as repeat testing or liquid based cytology. Later CEA assessed the impact of 
HPV DNA testing either as a primary test, alone or in conjunction with conventional cytology. 
Most recent CEA have sought to assess the need for screening in populations exposed to 
HPV vaccinations.  
A summary review of each of the published CEA is shown in Table 2.5 (below). The exact 
costs and cost-savings were quite varied reflecting the diversity in the target study 
populations (HIV positive, populations in less-developed countries and populations in 
developed countries),  and the strategies assessed. We summarize the major trends that 
could be noted below. 
Very few CEA focused on screening in HIV-positive women [Goldie et al 1999; and 
Goldie et al 2001]. In comparing six strategies for screening in HIV-positive women in the 
US ( no screening, annual Pap smears, annual Pap smears after two negative 6-monthly 
smears, semi-annual Pap smears, annual colposcopy and semi-annual colposcopy), Goldie 
et al[1999] recommended annual smears after two negative semi-annual screens as the 
most cost-effective strategy. This strategy (compared to annual screening) cost $14,800 per 
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QALY saved and is the currently recommended strategy for screening in HIV positive 
women. A later analysis to assess the impact of adding HPV-testing in HIV positive women 
in the US showed that compared to no screening, a targeted screen (with cytology every 6 
months in high-risk HPV positive women and annual cytology in HR-HPV-negative women) 
cost between $10,000-14,000 per QALY gained [Goldie et al, 2001]. We could not find any 
CEA of screening in HIV positive women in less-developed settings, care in these women 
being extrapolated from studies in developed countries. 
Age has been a frequent consideration of CEA (albeit in HIV negative populations). 
In developed countries with existing effective screening programs, screening women as 
from age 21-25[Goldie et al, Vaccine 2006b] followed with frequent screening was found CE 
as well as was reducing the screen  frequency to 2-yearly or 3-yearly once the age of 30 
was reached. Screening women aged 65 or more who had consistently had previous 
negative screens was not CE while screening those who had not previously had screen was 
CE. In less developed settings one-time lifetime screening targeting women aged 35 or 
more, or two- or three-times in the lifetime screening of women between 30-50 years with 5-
yearly screening tended to be CE.  
Other trends in CEA of screening in developed settings include that: CE reduces as 
screening becomes more frequent than every 2-3 years; increasing the sensitivity of pap 
smear/screening tests would be CE if screening interval was increased to 3-4 years; 
strategies that use HPV testing and reduce screening frequency can be CE [Goldie et al 
2006]. Adding HPV vaccination to current screening procedures was still CE [Kulasingam et 
al, 2007; Szucs et al, 2008], however the screening frequency may need to be reduced 
[Myers et al, 2008]. 
In less developed settings CE was influenced by the choice of test: HPV testing 
(effective), visual screening methods (inexpensive) or cytology (sensitive); and the need to 
have fewer visits that offer screen and treat. Increasing sensitivity could be more CE when 
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there was infrequent testing, while specificity only had an impact when there was frequent 
screening [Goldie et al 2006]. The combination of vaccination and screening three-times in 
the lifetime appeared CE [Diaz et al, 2008]. 
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Table 2.5: Summary of cost-effectiveness studies of the cervical cancer screening. 
 
Author(s), year,  study 
population, site 
Aim and methods Results  
HIV POSITIVE   
Goldie et al, 2001 
HIV positive women, 
USA. 
To assess the cost effectiveness of adding 
high-risk HPV-testing in screening for cervical 
cancer in HIV positive women. Used a Markov 
model to assess two strategies: 1)targeted 
screening in which HPV testing is added to the 
two initial cytology results to determine 
subsequent follow-up.  2)Universal screening 
involving no HPV testing. 
Compared to no screening a targeted screen (with 
cytology every 6 months in high-risk HPV positive women 
and annual cytology in HR-HPV-negative women) cost 
between $10,000-14,000 per QALY gained.  
Annual cytology regardless of HPV results was 15% less 
effective than targeted screening. 
A screening strategy based on initial HPV results to 
determine whether subsequent cytology will be annual or 
every 6 months appeared to be cost-effective.  
Goldie et al, 1999. 
HIV positive women. 
USA 
To assess the cost-effectiveness of various 
screening strategies, used a Markov model to 
simulate a clinical practice in the US. 
Assessed six strategies: no screening, annual 
Pap smears, annual Pap smears after two 
negative 6-monthly smears, semi-annual Pap 
smears, annual colposcopy and semi-annual 
colposcopy 
Compared to no screen, annual Pap smear gained 2.1 
months in QALY’s, at a of cost $12,800 per QALY saved. 
Annual Pap smears after 2 negative semi-annual smears 
cost 14,800 per QALY saved (with an average gain of 
0.04 QALY) compared to annual screen. 
Semi-annual smears cost $ 27,600 per QALY saved (with 
an average gain of 0.17 QALYs) compared to annual 
screening after 2 negative semi-annual screen.   
Colposcopy-based strategies were much more costly.   
This study recommended annual smears after two 
negative semi-annual smears as the most cost effective 
and as having a cost similar to other clinical preventive 
interventions such as mammogram etc.  
HIV NEGATIVE   
Diaz et al, 2008 
General population, 
India 
To assess the potential impact of HPV-16/18 
vaccination and cervical screening in India 
(where 25% of worldwide cases of cervical 
cancer occur).  Strategies assessed: 
vaccination of girls before age 12, screening of 
women aged >30, combined vaccination and 
screening.  Screening strategies were differed 
by test (cytology, visual 
inspection, HPV DNA testing), number of clinic 
With a 70% coverage vaccine alone resulted in a 44% 
(range 28-57%) reduction in lifetime risk of cancer while 
screening by conventional cytology 3x per lifetime 
resulted in 21-33% reduction in lifetime risk; a 
combination of vaccination plus 3-visit cytology resulted 
in 56% reduction and a combination of vaccination plus 
2-visit HPV DNA testing resulted in 63% reduction in risk. 
A combination of vaccination (cost per vaccinated girl of 
$10) and screening 3x in the lifetime was considered 
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visits (1, 2 or 3), frequency (1 
x , 2 x , 3 x per lifetime), and age range (35-
45). 
cost-effective as costing less than the countries per 
capita GDP.  
Szucs et al, 2008 
General population 
Switzerland 
To assess the cost-effectiveness of adding a 
quadrivalent HPV vaccine to the cervical 
screening program in Switzerland. Used a 
Markov model of a simulated cohort of 41,200 
girls aged 11 years for their lifetime. Compared 
conventional cytology only and HPV 
vaccination plus conventional cytology. 
Assuming an 80% coverage rate and lifetime protection 
from vaccine, adding vaccine to screening could prevent 
62% of cervical cancer and related deaths. The 
incremental cost-effectiveness ratio was CHF 26,005 per 
QALY gained. The ICER was sensitive to the need for 
boosters and discount rates.  
Authors conclude that adding quadrivalent HPV is likely 
to be cost-effectiveness in Switzerland.  
Kulasingam et al, 2007 
General population 
Australia 
To assess the cost-effectiveness of adding a 
HPV vaccine to the Australian National 
Cervical Cancer Screening Program. A Markov 
model of a cohort of girls. Strategies 
compared:  vaccination at age 12, assuming 
80% coverage and lifetime efficacy in 
conjunction with screening  versus screening 
only 
Compared to screening only, vaccination (with cost per 
dose of $115) plus screening had an ICER of $18 735 
per QALY. Accounting for herd immunity this ICER 
reduced to $13 316 per QALY.  
Vaccinating both boys and girls resulted in an ICER of 
$33 644. 
A vaccination with catch-up dose for 14-year-olds had an 
ICER of $16 727 per QALY. 
A vaccination with catch-up dose for 26-year-olds had an 
ICER of $34 536 per QALY. 
Adding vaccination to current screening was thus cost-
effective compared to screening only.  
Kulasingam et al, 2006 
Women with prior normal 
tests, 
USA 
To assess the cost-effectiveness of screening 
women with 3 or more prior normal test 
compared to screening those with no prior 
tests.  Cost-effectiveness model and data from 
the CDC National Breast and Cervical Cancer 
Early Detection Program.  
As the number of prior normal tests increased, the cost 
per life year saved increased substantially. For example 
for women aged 30-44 years; with no prior test the ICER 
for screening annually and triennially were respectively 
$331,837 and $20,533 per life year saved (compared to 
no screening). Meanwhile in same aged women with 3 
prior normal tests the costs for annual and triennial 
screening were respectively $709,067 and $60,028 per 
life year saved. 
Goldie et al, 2005 
India, Kenya, South 
Africa, Peru, Thailand. 
To assess the cost-effectiveness of screening 
strategies in developing countries (in which 
conventional cytology is judged to be 
impractical).  Strategies assessed included 
single-visit, two-visit and three-visit strategies.  
VIA or HPV DNA testing in one or two-visits are cost-
effective alternatives to conventional cytology with three-
visits in resource-limited settings.  
One-time screening of women at age 35, with one-visit or 
two-visit VIA or HPV testing reduced lifetime risk by 25 to 
36% and cost <$500 per year of life saved. Two lifetime 
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screens at age 35 and 40 years, further reduced lifetime 
risk by 40% and was very cost-effective. 
Kim et al, 2005 
UK, Netherlands, France, 
Italy 
To assess cost-effectiveness of adding HPV 
DNA testing in countries with established 
cytology –based screening programs.  
Strategies assessed 1. Each countries 
ongoing strategy versus 2. HPV as triage for 
equivocal cytology results in a lifetime cytology 
program; 3. Cytology until age 30, then HPV 
combined with cytology in women aged 
>30years. 
Both strategies with HPV testing as triage or in 
combination with cytology were more effective than 
ongoing strategies with respective ICER of $13,000 and 
$9800-75,900 (depending n screening interval) per year 
of life saved.  
Sherlaw-Johnson and 
Philips, 2004. 
UK. 
Assess liquid-based cytology (LBC) versus 
HPV testing (either as triage for borderline 
cases or as a primary test) in the UK cervical 
cancer screening program.  
Unless the marginal cost of LBC is higher than that of 
conventional cytology, then LBC is as cost-effective as 
conventional cytology. Five-yearly combined LBC and 
HPV testing has similar cost-effectiveness to 3-yearly pap 
smear or HPV testing alone. Combined testing and HPV 
testing alone reduced false positive cases. 
Goldie et al, 2004 
USA 
To assess the CE of HPV testing in 
combination with cytology in women aged 30 
years or m ore. Markov model simulating a 
cohort of US women. Strategies compared: no 
screening, screening at different frequencies 
with conventional cytology, LBC with HPV for 
triage of equivocal results and HPV testing 
plus cytology in women after age 30. 
For women aged >30 years, 2 or 3-yearly screening with 
a combination of cytology and HPV testing (either primary 
or as triage) is more CE than annual conventional 
cytology. With ICER of $95,300 and $228700 per year of 
life gained, all age 3-yearly LBC and 3-yearly HPV testing 
plus cytology in women aged >30 years had equal or 
greater benefits when compared to annual conventional 
cytology.  Annual cytology plus HPV testing was not very 
beneficial with a ICER of $2,000,000 per year of life 
gained.  
Mandelblatt et al, 2002 
Thailand 
To assess the costs and benefits of different 
screening strategies in less-developed 
countries. A population based model 
assessment of  7 strategies in Thailand: 1) 1-
visit VIA; 2) 2-visit VIA; 3) HPV DNA testing; 4) 
Pap smear screening; 5) Pap smear screening 
with HPV DNA testing, followed by evaluation 
of women with an abnormal result from either 
test; 6) VIA followed by HPV DNA testing, with 
women who are found to have VIA-detected 
lesions that are not appropriate for immediate 
Costs ranged from $121 to $6720 per life year saved. 5-
yearly ‘screen and treat’ VIA in women aged 35-55 was 
the most CE strategy with a cost of $517 per life year 
saved. HPV testing had similar CE if the HPV test cost $5 
and if 90% of patients returned for follow-up.  
Cytology would result in similar results if the sensitivity 
was >80% and 90% of women underwent follow-up. 
A combination of 5-yearly HPV and Pap in women aged 
20-70 years could reduce mortality by 90% at a cost of 
$1683 per life year saved; while VIA could reduce 
mortality by 83% at a cost of $524 per life year saved.  
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treatment being referred for appropriate care 
(work-up of lesion), regardless of HPV test 
result; and 7) no screening (but treatment of 
symptomatic disease). 
Maxwell et al, 2002. 
Military beneficiaries in 
the US.  
To assess the costs and CE of new screening 
methods for cervical cancer in the military. 
Used a Markow model on a simulated cohort 
of 100000 military beneficiaries aged 18-85.  
Strategies compared include: conventional 
cytology, LBC, LBC plus HPV triage with 1-, 2-, 
and 3-year screening intervals.  
Cancer incidence and mortality reduced with increased 
sensitivity of screening method.  
Both LBC and LBC plus HPV triage are CE (with 
<$50,000 per life year saved) when conducted 3-yearly 
but not CE when conducted more frequently than 3-
yearly. 
A more sensitive test performed less frequently may be 
more CE than annual conventional cytology. 
Kim et al, 2002 
US 
To determine the most CE management 
strategy for women with ASCUS in the US. 
Strategies assessed: 1. immediate 
colposcopy; HPV triage (1-visit or 2-visit) with 
colposcopy if HR-HPV detected; repeat 
cytology involving follow-up cytology at 6 and 
12 months and then colposcopy if repeat 
abnormal result detected; reclassifying ASCUS 
as normal and ignore.  
Reclassifying ASCUS as normal was least costly, 
reducing the lifetime cancer incidence by 75% when 
conventional cytology is used.  
HPV testing and immediate colposcopy each respectively 
reduced cancer incidence by 86% and 87%. 
Biennial (versus triennial) LBC with reflex HPV testing 
costs $174200 per years of life saved. Similarly triennial 
(vs 5-yearly) LBC cost $59600 per YLS and was more 
CE compared to biennial conventional cytology with 
repeat cytology or immediate colposcopy. 
Reflex HPV is more CE than other management 
strategies. 
Mandelblatt et al, 2002  
USA  
To compare the CE of HPV testing, Pap 
smears and their combination. 18 strategies 
assessed distinguished by 3 possible tests 
(Pap plus HPV testing, Pap testing alone, and 
HPV testing alone); 2 possible frequencies 
(every 2 or every 3 years); all beginning at age 
20 years but distinguished by the age at 
discontinuation (65 years, 75 years, or at 
death).  
Compared to biennial Pap smears alone, biennial HPV 
testing plus Pap smears (both until death) had an ICER 
of $76183 per QALY. Stopping HPV and Pap testing at 
age 75 and 65 years respectively captured 97.8% and 
86.6% of the benefits of lifetime screening.  
HPV testing alone was equally as effective as Pap testing 
alone, (irrespective of age and frequency) but was more 
costly.  HPV testing would be more CE than Pap testing if 
it cost $5 or less per HPV test. 
Costs can be reduced by using HPV plus Pap test 
biennially (compared with Pap smear alone); Applying 
age limits maintain benefits while reducing costs. 
Van den Akker-van Marle 
et al, 2002 
To compare the CE of various cancer 
screening strategies in high-income countries. 
15 efficient screening policies (with no alternative less 
costly policy) were identified. For these policies the 
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High-income countries. Used a microsimulation screening analysis to 
model approximately 500 potential strategies 
that differed with respect to the recommended 
number of screenings, screening 
intervals, and targeted age ranges.  
screening age ranged from 40-52 to 20-80 years, and the 
screening interval decreased from 12 to 1.5 years. The 
average ICER ranged from $6700 to $23900 per life year 
gained. CE could generally be improved by reducing the 
frequency of screening or starting screening at a later 
age. 
Philips and Whynes, 
2001. 
UK 
To assess the CE of early withdrawal from 
screening. 
Median cost savings were always less than £1000 per 
life-year lost. The estimates were sensitive to the age at 
which cancer occurred and the rate of cancer 
progression. The authors did not think the cost-savings 
were worth the life lost with early withdrawal. 
Goldie et al, 2001 
South African women 
To assess the CE of several screening 
strategies a hypothetical cohort of previously 
unscreened 30-year –old South African 
women. Strategies assessed include; direct 
visualization of cervix (DVI), cytology and HPV 
testing. These strategies also differed by the 
number of visits, screening frequency and 
response to a positive test result.  
Amongst one time screening strategies, HPV testing with 
treatment of screen-positive women at a second visit was 
the most CE, reducing cancer incidence by 27% and 
costing $39 per life-year saved; DVI with immediate 
treatment of positive cases reduced cancer incidence by 
26% and cost less than cytology. Cytology with treatment 
of positives at a second visit was least effective reducing 
cancer incidence by 19% only at a cost of $81 per life-
year saved.  
In general HPV testing was more effective but more 
costly than DVI, and also more effective and less costly 
than cytology.  
Montz et al, 2001. To assess the impact of increasing Pap smear 
sensitivity and compliance using a Markov 
model of a cohort of women followed from age 
20 to 80 years. Pap smear was compared to 
LBC using 3 different compliance rates. 
Analyses were conducted for all women then 
limited to each of white and black women 
Increasing compliance from the Healthy People 2000 
rates (5% never compliant, 85% fully compliant, and 10% 
partially compliant) to the Healthy People 2010 target 
compliance rates (3% never compliant, 90% fully 
compliant, and 7% partially compliant) resulted in cancer 
incidence reductions of 23%, 21.7% and 17% in all 
women, Whites and Blacks respectively. Using LBC 
instead of conventional cytology resulted in reductions in 
cancer incidence of 32-33%.  The ICER for LBC 
(compared to conventional cytology) in black women was 
$10,335 while it was $17,967 per life-year save in white 
women.  
Suba et al 2001; 
Vietnam 
To assess the CE of cytology screening in 
developing country, Vietnam 
A total annual cost of $148,400 was needed to establish 
a nationally cytology screening program with 5-yearly 
testing. A 70% program coverage resulted in a reduction 
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of cancer incidence from 26 to 14.8 per 100,000 
inhabitants, costing $725 per life year saved. Pap smear 
cytology in developing countries could be cost-effective 
and relatively inexpensive, despite perceptions of it being 
otherwise.  
Myers et al, 2000 
 
To assess the potential effects of sensitivity, 
specificity and screening frequency on the 
cost-effectiveness. The baseline sensitivity 
and specificity of Pap smear was estimated to 
be 51% and 97% respectively. 
Increasing sensitivity, while holding specificity constant 
increased life expectancy and cost. Decreasing specificity 
increased cost.  Costs were further increased with higher 
screening frequencies. Most caused were attributed to 
the diagnosis and care of low-grade lesions. Authors 
recommend tests that can detect lesions highly predictive 
of invasive cancer. 
Sherlaw-Johnson and 
Gallivan, 2000. 
Eastern Europe. 
To compare HPV testing to conventional Pap 
smears in Eastern Europe. Various strategies 
varying test used, age of onset, frequency and 
coverage were assessed. However costs were 
based on estimates from the UK. 
Cost reduced with increased coverage. This is partly 
because cost of increasing coverage was assumed to be 
negligible compared to the cost of tests and care. 
The ICER increased as screening frequency decreased 
from 10-yearly to 5 yearly and as HPV testing was used 
in lieu of Pap smears. 
Hutchinson et al, 2000 
USA 
To assess the impact of test sensitivity on the 
cost-effectiveness of cancer screening.  Used 
a model of women who were screened 
between ages 20 to 65 years. New 
technologies assessed included the ThinPrep 
Pap Test which addresses problems in 
specimen preparation by providing a 
standardized fluid for collection and automates 
the process 
of transferring the specimen to a microscope 
slide; the AutoPap Primary Screening System 
that automatically screens the slides before 
human screening and selects the 75% most 
likely to contain abnormalities for subsequent 
screening by a cytotechnologist. The AutoPap 
QC 300 rescreening device which rescreens 
all slides found negative by the human 
screeners and flags those most likely to 
contain abnormalities for review by a 
cytotechnologist. 
Increasing test sensitivity by 50% had the potential of 
reducing cancer incidence by 45-60% depending on the 
screening frequency. With this increased sensitivity, the 
cost effectiveness ratio was below $50,000 when the 
screening interval was 2 years or more.  
Increasing sensitivity may be realistic and cost-effective 
in screening for cervical cancer. 
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Brown and Garber, 1999. 
 
To estimate the cost-effectiveness of 3 
enhancements (with improved sensitivity) to 
the conventional Pap smear test (ThinPrep, 
AutoPap, and Papnet). Modeled a cohort of 
US women from age 20 to age 65.  
All 3 technologies increased both cost and life 
expectancy. In general Autopap was the most CE, 
costing $7777 with quadrennial screening and $166000 
with annual screening. CE increased with increased 
sensitivity of new method, increased disease prevalence 
and lower frequency of screening.  
Sherlaw-Johnson et al 
1997.  
Resource-limited settings 
To evaluate the CE of screening programs in 
resource-scarce settings. HPV testing 
compared to cytology as one-time lifetime 
screen with varied coverage. 
One-time screening of women age 30-59 reduced cancer 
incidence by 30%. Inconclusive/speculative on the CE of 
HPV testing; would be a function of the prevalence of 
HPV infection, and the cost of the HPV test. 
Gustafsson and Adami, 
1992 
To investigate how a screening program 
interacts with the natural history of cervical 
neoplasia. 
Effect of screening is sensitive to age at first screen and 
age at last screen (though to a lesser extent). 
Mandelblatt and Fahs, 
1988. 
Low-income elderly 
women. US 
To assess the CE of cervical screening in 
infrequently seen elderly women in an urban 
municipal clinic.  
 11 of 816 women had an abnormal Pap smear. This 
resulted in savings of $5907 and 3.7 years of life per 100 
pap smears.  Further including medical cost per year of 
life extended, the program cost $2874 per year of life 
saved. 
The program appeared cost-effective (with benefits of 
screening offsetting the cost).  
REVIEWS    
Stanley, 2008 
 
Review study to compare  HPV vaccination to 
screening  
HPV vaccination considered most effective in developing 
countries with unavailable or ineffective screening 
programs. 
In countries with well developed screening programs 
these screening programs would still be needed since 
only two of 15 oncogenic types are included in vaccines 
and for at least 3 decades unvaccinated women will still 
need to be screened. A combination of vaccination and 
screening is thus recommended in such settings 
Myers et al 2008, Review on the role of screening in the era of 
HPV vaccination. 
Screening will still be needed to further reduce cancer 
incidence. However screening guidelines may need to be 
modified and cost-effectiveness of different screening 
scenario may depend on the age and effectiveness of 
vaccination. 
Bosch et al, 2008 Review of the role of screening versus 
vaccination in the prevention of cervical 
cancer. HPV and cervical cancer: screening or 
Both but not a straightforward answer.  
Screening will be needed because of the 25-30% of 
cancers due to types other than HPV 16 and 18. 
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vaccination? Argues that vaccination and screening will be needed in 
scenarios in which an effective screening program 
already exists. There might be a role for vaccination only 
(if affordable) in developing settings were screening is 
ineffective and poorly implemented. Otherwise in these 
settings other efficient screening strategies such as use 
of low-cost HPV tests, and ‘screen and treat’ approaches 
will be needed. Finally, a potential polyvalent vaccine that 
could prevent 90% HR-HPV could be the answer for both 
settings.  
Schiffman 2007,  Review  HPV 16 and 18 vaccines could prevent 70% of cancers. 
Universal vaccination of adolescents may affect cytology 
and HPV testing. 
HPV infections are common particularly at a young age. 
90% of infections are cleared within 2 years 
Infection with oncogenic HPV is more predictive of cancer 
than are grade1/2 precancerous lesions. Controlling for 
HR-HPV infection the risk of CIN3 is equal for ASCUS 
and LSIL. 
Vaccination would reduce the positive predictive values 
of cytology and HPV tests.  
Goldie, 2006 Review considering screening versus 
vaccination strategies to cervical cancer 
control as well as the methodologic issues 
involved in decision analyses. 
Cervical cancer is still a substantial cause of cancer and 
death in developing countries. 
Conventional cytology remains difficult to implement 
successfully in developing countries. 
Alternative non-cytologic approaches for HPV detection, 
visualization of lesions and vaccination are needed. 
Wright et al, 2006 A summary of a workshop to review the role of 
HPV vaccines and screening in the prevention 
of cervical cancer and how HPV vaccines and 
new diagnostic methods can be integrated to 
provide maximum benefit to women. 
Next step issues age of vaccination, vaccinating boys, 
introduction in developing countries 
Holmes et al 2005 
Review 
Review of modeling studies of the cost-
effectiveness of HPV screening for cervical 
cancer.  
Most models assumed screening starts at 18 
or 20 years; HPV prevalence of 10% in those 
aged 18 years to 20% in those aged 20-25 
Cost per QALY varied in the range $ 12400-16600.  The 
highest cost was observed with a strategy that involved 
annual screening with liquid cytology and HPV testing.  
Cost of triennial HPV testing is less than that of biennial 
pap smear cytology. 
Screening using HPV testing in women after age 30 is 
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years, then drops after age 30.  Costs for 
diagnosis and treatment vary considerably. 
recommended. 
Fahs et al, 1996. 
 
Review of cost-effectiveness studies. CE programs have the following characteristics: 
Centrally organized, having guidelines allowing for 
spontaneous discretionary screening, begin at age 25 to 
35 and end at age 65 to 70 years, older women need to 
get 3 negative screens before discontinuation, screening 
interval between 3 and 5 years, better to screen more 
women less frequently than screen fewer women more 
frequently; screening previously unscreened women very 
cost-effective.  
 
 
 
 
  
 
CHAPTER THREE: RESEARCH DESIGN AND METHODS 
 
 
 
 
3.1 Methods to determine the prevalence, severity and predictors of cervical 
squamous intraepithelial lesions in HIV-positive women on antiretroviral therapy in 
Cameroon. 
3.1.a Study design and population 
Study design: Descriptive cross-sectional study. 
Study setting: Participants were enrolled in HIV care clinics in Cameroon. These clinics were 
chosen such that on average 20 women on HAART will be recruited per week and achieve 
the required sample size in a reasonably short time. Cytological slide analysis, cervical swab 
storage and data entry were conducted in the Center for the Study and Control of 
Communicable Disease (CSCCD) of the Faculty of Medicine and Biomedical Sciences, 
Yaoundé, Cameroon.  
Study population: Women initiating HAART in Cameroon.  
Eligibility criteria: Women aged 18 years or more, initiating HAART and consenting to study 
procedures.
Sample size considerations: Our primary aim was to determine the prevalence of cervical 
epithelial lesions in women initiating HAART. Valid cytology results were obtained for 276 
women. Figure 3.1 shows the precision (measured as the w
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interval) of the prevalence estimates that would be obtained with a sample size of 276 
women. This was estimated using the formula 
. Where d= precision (width of 95%CI), p=prevalence estimate and 
n=sample size. 
For example with 276 women we will be able to detect a prevalence of 10% with a 95%CI 
width of 0.5% and a prevalence of 50% with a 95%CI width of 1.4%. Overall, irrespective of 
the prevalence obtained in our sample the width of the 95%CI around the prevalence 
estimate will be less than 1.5%. 
 
Figure 3.1: Precision of prevalence estimates based on a sample size of 276 women 
 
3.1.b Study procedures 
After obtaining administrative and IRB approval we trained three interviewers (with a 
previous medical training) to ensure that study procedures and cervical sampling in 
particular are being implemented correctly. This was necessary for an optimal quality of 
cervical smears. 
Participant recruitment: At each site clinicians, after providing usual care referred the 
patients to our study interviewers who then explained the study to each eligible patient.  
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Interview: After obtaining written informed consent, the interviewers questioned and 
collected data on demographic and clinical characteristics with the aid of a standardized 
questionnaire (see appendix). 
Sample collection: The interviewers collected cervical smear samples using conventional 
methods. For each participant, two slides were labeled with a unique identification number.  
Cervical smear samples were collected by placing the sharp tip of a spatula in the 
endocervical canal while the blunt tip of the spatula was on the squamocolumnar junction. 
The spatula was then rotated for 360 degrees and the sample collected immediately 
smeared on pre-labeled slides. The slides were immediately fixed using a 95% ethanol 
solution. The slides were stored at room temperatures while the swabs in STM media were 
stored in refrigerators (at 2-8 degrees Celsius) for the duration of patient enrollment (1 
month). These samples (swab and slides) were sent for analysis and storage in the 
laboratory of the CSCCD which has experience in the staining and reading of cervical 
smears.  
Laboratory analysis: Cervical samples will be stained using the conventional Papanicolau 
method. Briefly, this method involves staining the nuclei with hematoxylin and then using 
Orange G and Eosin and Light Green SF yellowish as counterstains. The stained slides 
were observed under the microscope (at 400X) and then scored according to the Bethesda 
2001 system, as unsatisfactory, negative, atypical squamous cells of uncertain significance, 
low-grade squamous intraepithelial lesions (LSIL), high-grade SIL (HSIL), or invasive 
cervical cancer[Solomon et al, 2002].  
Cytology results were returned to the clinicians who transmitted them to participants. 
Patients with LSIL or less were advised to repeat screen within a year. Participants with 
HSIL or more severe precancerous lesions are being invited back to the clinic for 
specialized care of the lesions involving a colposcopy with biopsy and cryotherapy/LEEP. 
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Participants with cancer in situ or invasive cancer were referred to gynecologists for 
specialized care. 
 
3.1.c Data analysis 
Data collected were entered into MS Access interface on Epi-info. Statistical analysis 
were conducted using SAS version 9.2 (SAS institute inc, Cary NC) and STATA version 10 
(STATA corps, Texas USA). 
Outcomes: Two outcomes were considered for this analysis: 1) Prevalent cervical lesions 
(defined as the proportion of women who had any cervical epithelial lesions); 2) Prevalent 
severe cervical lesions (defined as the proportion of women who had ASC-H/HSIL or worse 
cervical lesions, requiring coloscopy and biopsy). 
We assessed the univariate distribution of both predictors and outcomes. From this 
analysis we discerned the prevalence and severity of precancerous lesions in this 
population.  
Predictors: marital status, parity, number of lifetime sex partners, age, history of hormonal 
contraception, smoking history, CD4 count, AIDS clinical stage. These predictors were 
chosen based on the ease with which they can be elicited and recorded in a clinical setting 
and previous literature describing their association with the presence of cervical lesions or a 
plausible etiological role. The maximum number of predictors that could be included in a 
multivariate logistic regression was determined using the formula 3*N1*N0/10(N1+N0) where 
N1 is the number of participants with the outcome being analyzed and N0 is the number of 
participants without the outcome [Harrell, 2001].   
We described the univariate distribution of predictors. To determine predictors of 
lesions we conducted bivariable and multivariable (adjusted) analyses of the association of 
each predictor with each outcome. For bivariable analysis, proportions were compared using 
chi-square statistics while continuous variables were compared using t-test (when 
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comparing the means of two-groups) or ANOVA test (when comparing the means of more 
than two groups). Prevalence odds ratios and their 95% confidence intervals, comparing the 
odds of each outcome between predictor groups were also estimated.   
Assessment of linearity: The linearity of the odds of the outcomes for each continuous 
variable (such as age and CD4 count) were assessed prior to their being included in 
regression models that assume the linearity of the outcome. The assessment was done 
graphically and statistically. In graphical analysis we plotted the log of the odds of cervical 
lesions (on the y-axis) by the continuous variable (on the x-axis). The plots were smoothed 
using Lowess estimation methods that are locally weighted moving averages of the odds 
within small categories of continuous variables. The statistical significance of improving the 
model fit by including non-linear (quadratic terms) for the continuous variable was assessed. 
A model with the continuous variable and a non-linear (quadratic) term and one with only the 
continuous variable were compared using a likelihood ratio test.  When there was evidence 
against linearity, continuous variables were coded as categorical variables using clinically 
meaningful cut-offs such as 200 cells/uL for CD4 counts or based on the lowess trend 
estimates (example 26-59 versus other women for age).  
Predictive models:  All models were unconditional logistic regression models. For each 
outcome we created an initial (full) model that included all the predictors described above. A 
parsimonious subset of clinically or statistically significant variables were then determined 
based on a backward elimination strategy in which we removed one variable at a time from 
the initial model, based on the largest p-value [Harell, 2001]. The predictive value of each 
variable was assessed by a likelihood ratio test (LRT) comparing two successive models 
with or without the variable being assessed, and a comparison of the area under the curve 
(AUC) of the ROC plot (a plot of the sensitivity, on the y-axis, by 1-specificity, on the x-axis, 
at potential cut-off point) of two successive models with or without the variable. Variables 
were dropped from the model if the LRT of their removal had a p-value >0.2 and the AUC 
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changed by <10%. A final reduced model was thus obtained retaining only predictors that 
when dropped resulted in a LRT <0.2 or a 10% changed in the AUC.  
For each outcome, the models developed were based on the full sample. However 
the internal validity of the model performance was ascertained by repeating the analysis 
within data subsets corresponding to each study site.  
Development of risk scores: For each outcome we attempted to develop two sets of risk 
scores (one each from the full model and the reduced model). The numeric score assigned 
to each predictor was based on the model slope coefficients. To allow for a simple and 
feasible application in clinical settings, each predictor score was obtained by multiplying the 
model slope coefficients by a constant (for example 10 or 100) and then rounding to the 
nearest integer. The aggregate risk score was based on the sum total of each predictor 
score. The overall accuracy of the score was assessed using the area under an ROC curve 
(ie a plot of the sensitivity, on the y-axis, by 1-specificity, on the x-axis, at potential cut-off 
point). The best cut-off values for each risk score model was assessed by calculating the 
number of false positives and false negatives that would result from using each cut-off point.  
Sensitivity analyses: We conducted sensitivity analyses of the error in estimating prevalence 
based on the sensitivity and specificity of conventional cytology.  
We used the following formula: 
Observed prevalence = (true positive rate + false positive rate) 
If P’ designates the observed prevalence and P designates the “true”, unobserved 
prevalence then  
1
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  The above formula was applied on a spreadsheet for different combinations of 
sensitivity (range 0.5 -1) and specificity (0.7-1). 
Limitations and strengths: Though we sampled in three different clinics, the sample may not 
be representative of all HIV women in Cameroon as the clinics were conveniently selected 
and not randomly chosen. There may be measurement errors for the outcomes as the 
limited Pap smear has a low sensitivity and we did not perform confirmatory histology on the 
lesions detected. While the sample size was adequate for estimating prevalence, only a 
limited number of covariates could be considered as potential predictors. The study was 
however strengthened by the fact that sample size was adequate for prevalence estimation, 
multiple sites were used to reflect some of the diversity of women in Cameroon, interviewers 
were trained to insure adequate sample collection, the primary data collection insured that 
questions pertaining to this study were directly ascertained, two slides were collected per 
patient to increase the sensitivity of the pap smear which were read by a trained cytologist. 
The statistical analysis using only clinically feasible predictors would allow for results that 
could be easily implemented by clinicians.  
3.2 Methods to describe the age trends in the prevalence of cervical squamous 
intraepithelial lesions in HIV-positive women on antiretroviral therapy in Cameroon. 
This objective focused on modeling the prevalence of cervical lesions by age and 
determining the optimal model relating age to prevalent cervical epithelial lesions. We also 
attempted to estimate the minimum and maximum age at which cervical lesions are present 
as well as the age (or age group) with the maximum prevalence of lesions.  We refer to 
these three as critical ages. 
3.2.a Study design and population 
These were identical to those for aim1 and described in section 3.1.a above. 
3.2.b Study procedures 
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These were identical to those for aim1 and described in section 3.1.b above. 
3.2.c Data analysis 
Data collected were entered into MS Access interface on Epi-info. Statistical analysis 
were conducted using SAS version 9.2 (SAS institute inc, Cary NC) and STATA version 10 
(STATA corps, Texas USA). 
Outcomes: 1) Prevalent cervical lesions (defined as the proportion of women who had any 
cervical epithelial lesions); 2) Prevalent severe cervical lesions (defined as the proportion of 
women who had ASC-H/HSIL, requiring coloscopy and biopsy). 
Predictors: Age.  Age was analyzed in following forms: 
- age as a binary variable (<30 versus ≥30, based on current recommendations for 
cervical cancer screening),  
- age as a continuous linear variable (assuming that the prevalence of cervical lesions 
increase linearly and monotonically with age),  
- age as a continuous quadratic variable (assuming that the prevalence of cervical 
lesions has a quadratic shape ie initially increasing with age, reaches a maximum 
and then decreases).  
- Age coded as (<26, 26-59, 60+) based on the lowess plot 
- Age coded as binary (26-59 versus <26 and 60+) as age <25 and 60+ had similar 
characteristics and we had few women aged 60+. 
Potential modifiers of the prevalence ratio: marital status, parity, number of lifetime sex 
partners, history of hormonal contraception, smoking, CD4 count, and AIDS clinical stage. 
Potential confounders: None. As shown in the Directed Acyclic Graph (DAG) below, in the 
absence of any covariate that affects age, there is no unblocked backdoor path between 
age and prevalent cervical lesions, thus no confounding of the effect of age. 
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Figure 3.2: Directed acyclic graph (DAG) of the relationship between age, prevalent 
cervical lesions and other covariates. 
 
Bivariable model estimation 
We initially assessed the univariate distribution of predictors, outcomes and 
covariates.  
Age Prevalent cervical 
lesion 
Marital status 
AIDS clinical stage 
CD4 counts 
Sex partners 
Condom use 
 
Smoking  
Unmeasured 
Parity 
Hormonal contraception 
? 
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In bivariable analysis, we used a linear risk binomial model (ie a form of generalized linear 
model that assumes a binomial distribution for the outcome, and an identity link between 
predictors and outcome) to model the prevalence of cervical lesions by age. Using the 3 
types representations of the age variable, these models can be summarized mathematically 
viz. 
 
A binary age model: Pr (Y) = α1 + β1 age30 …………………………………Equation 3.2.1 
 
A linear age model: Pr (Y) = α2 + β2 agec ……………………………………Equation 3.2.2 
 
A quadratic age model: Pr(Y) = α3 + β3 agec + β4 agec2 ………………… Equation 3.2.3 
 
Where  
Y is a variable indicating prevalent cervical lesion (Yes/No) 
age30 is a variable that takes a value of 1 when age ≥30 and a value of 0 when 
age<30 
agec is a variable with participant’s age centralized (ie age – mean age) 
α1 is the prevalence of cervical lesions in participants aged <30 
β1 is the prevalence difference (PD) comparing the prevalence of cervical lesions in 
participants aged≥30 to those aged <30. 
α2 is the prevalence of cervical lesions in participants with mean age 
β2 is the increase in prevalence of cervical lesions for every one year increase in age 
(ie the annual change in prevalence) 
α3 is the prevalence of cervical lesions in participants with mean age 
β3 and β4 do not have any meaningful epidemiologic interpretation. 
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All α and β parameters for each model were estimated using maximum likelihood 
estimation (MLE). The relative fit of these models to our data (and thus the best of the 
models) were assessed using Likelihood ratio tests comparing pairs of nested models and 
Akaike information criteria (AIC) for non-nested models.  
Estimation of critical ages 
The minimum and maximum ages at which cervical lesions are present as well as 
the age with the maximum prevalence of lesions were estimated primarily from the quadratic 
age model. The minimum/maximum age at which cervical lesions are present could also be 
estimated from the linear age model while the binary age models is not suitable for 
estimating any of these parameters.  
To estimate minimum and maximum ages at which lesions are prevalent using the quadratic 
model, we equated the right hand side of Equation 3 to 0 (after substituting the parameters 
obtained by MLE) and then solved for agec. 
We thus obtained the quadratic equation: 
α3 + β3 agec + β4 agec2 =0 ………………………………………………… Equation 3.2.4 
 
Just as the solution of a general quadratic equation ax2 + bx + c=0 is given by  
( ) aacbbx 242 −±−= , the solution to Equation 3.2.4 will be given by 
434
2
33 24 βαβββ 


 −±−=agec   
 
The age of maximum prevalence will be the age at which the first differential of 
Equation 3.2.4, with respect to agec, takes a value of 0 ie when β3 + 2* β4 agec =0. 
The centralized age of maximum prevalence will thus be solved as agec = - β3/(2* 
β4).  
 60 
 
 
The minimum/maximum age at which lesions are prevalent can also be estimated 
using the linear age model. After substituting the parameters obtained by MLE, we equated 
the right hand side of equation 3.2.2 to 0 and then solved for agec. 
We thus obtained the equation: 
 α2 + β2 agec =0 ………………………….……………………………………… Equation 3.2.5 
 
The solution was given by agec= - α2 / β2. 
 
The 95% confidence intervals for each of these estimates of the minimum and 
maximum ages at which cervical lesions are present as well as the age with the maximum 
prevalence of lesions  were obtained using post-model estimation commands in Stata.  
Multivariable analysis 
In multivariate analysis, modifiers of the prevalence difference were assessed by 
comparing each of the models in equations 1- 3 with similar models that include product 
interaction terms between the age variable(s) and the potential modifier.  All potential 
modifiers were made binary (and coded 0/1) to allow for an understandable analysis.  As an 
example, for a potential modifier, Z, the models in equations 3.2.1- 3.2.3 will become:  
 
A binary age model: Pr (Y) = α1 + β1 age30 + γ1 Z + δ1age*Z …….………Equation 3.2.6 
 
A linear age model: Pr (Y) = α2 + β2 agec + γ2Z + δ2age*Z ……………… Equation 3.2.7 
 
A quadratic age model: Pr (Y) = α3 + β3 agec + β4agec2 + γ3Z + δ4age*Z + δ5 Z*age2 
……Equation 3.2.8 
Where  
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α1 is the prevalence of cervical lesions in participants aged <30 in whom Z is coded 
0. 
β1 is the prevalence difference comparing the prevalence of cervical lesions in 
participants aged≥30 to those aged <30, when Z is coded as 0. 
γ1 is the increase in the prevalence of cervical lesions for a unit increase in the 
coding of Z, when age takes its mean value 
δ1 is the difference in the prevalence difference comparing the prevalence of cervical 
lesions in participants aged≥30 to those aged <30, when Z is coded 1, to the same 
prevalence difference when Z is coded 0. 
α2 is the prevalence of cervical lesions in participants with mean age and Z coded 0. 
β2 is the increase in the prevalence of cervical lesions for every one year increase in 
age (or the annual change in prevalence), when Z is coded as 0. 
γ2 is the increase in the prevalence of cervical lesions for a unit increase in the 
coding of Z, when age takes its mean value 
δ2 is the difference between the annual change in prevalence  when Z is coded 1, 
and the annual change in prevalence when Z is coded 0. 
α3 is the prevalence of cervical lesions in participants with mean age and Z coded 0 
γ3 is the increase in prevalence of cervical lesions for a unit increase in the coding of 
Z, when age takes its mean value 
β3 , β4 , δ4 , and δ5  do not have direct epidemiologic interpretations (because of the 
quadratic terms involved). 
 
Modification of the prevalence difference was assessed statistically by a likelihood 
ratio test comparing a model with the age variable, the potential modifier and a product 
interaction term to a similar nested model without the product interaction term. A p-value of 
<0.1 was considered statistically significant and evidence of heterogeneous prevalence 
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differences. The detection of any significant prevalence difference modifier led to a repeat of 
the bivariable analysis but this time stratified by categories of the modifier. 
 Sensitivity analysis: We conducted sensitivity analysis of non-differential misclassification of 
prevalent lesions in estimating the prevalence difference between age-categories. 
Assumptions  
- Pi indicates true unobserved prevalence in ‘exposure’ group i. 
- Pi’ denotes the observed prevalence in ‘exposure’ group i. 
- Non-differential misclassification implies sensitivity and specificity are equal within 
‘exposure’ groups, ie sensi = sens and speci = spec, where sens and spec represent 
the sensitivity and specificity of detecting the outcome in each ‘exposure’ group. 
Based on formula above 
1
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And the prevalence difference:   
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Because of the non-differential nature of misclassification the above formula simplifies to: 
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Limitations and strengths: Though we sampled in three different clinics, the sample may not 
be representative of all HIV women in Cameroon as the clinics were conveniently selected 
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and not randomly chosen. Furthermore, because of the cross-sectional design of the study, 
the age-specific prevalence described here reflects the age of detection of lesions and not 
necessarily the age of incidence or the age-specific prevalence in the population. Age 
differences in access to clinics may result in artificially increased prevalence in older women 
who are more likely to be in the health care system. The latter detection bias is however 
expected to be minimal in a study population of HIV positive women in whom access to care 
is largely driven by worsening HIV disease rather an age. There may also be measurement 
errors for the outcomes as the limited Pap smear has a low sensitivity and we did not 
perform confirmatory histology on the lesions detected. Because all models are inherently 
smoothed mathematical summaries of real life data, the mathematical estimates of the 
critical ages will simply be approximate estimates. 
The study was however strengthened by the fact that multiple sites were used to 
reflect some of the diversity of women in Cameroon, interviewers were trained to insure 
adequate sample collection, the primary data collection insured that questions pertaining to 
this study were directly ascertained, two slides were collected per patient to increase the 
sensitivity of the pap smear which were read by a trained cytologist. The statistical analysis 
using models that permit flexible non-linear shapes of age-trends allowed for the detection 
of a more accurate description of the trends and permitted us to propose a better method for 
analyzing age in subsequent models of the age at which lesions are detected in HIV positive 
women.  
 
3.3 Methods to quantify the potential effect of antiretroviral therapy and screening, on 
mortality from cervical cancer in HIV-positive women in Cameroon 
3.3.a Study design and population 
Study design: A mathematical simulation. 
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Study setting: We simulated a clinical practice in Cameroon.  
Study population: HIV-infected women in Cameroon. 
Model type: We used a state-transition Markov model. This type of simulation model allows 
analysts to model transitions of a cohort of patients among a number of health states over a 
long period of time subdivided into a series of short intervals [Nainmark et al, 1997].  We 
developed a computer model of cervical neoplasia in HIV similar to that previously 
developed, validated and published by Goldie et al [1999]. The form of the model is shown 
below.  
 
 
Figure 3.3: Summary of states in the Markov model (Adapted from an original 
depiction by Goldie et al, [1999]) 
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The model summarizes the progression of cervical neoplasia in HIV in five states: 
Normal with no lesion, LSIL, HSIL, cervical cancer and death. Each of the four (non-death) 
states is stratified by CD4 cell count.  The cancer stage is further stratified by stage of 
cervical cancer and whether this has been diagnosed (and thus being treated) or not. During 
their lifetime women’s disease state can progress from normal to LSIL to HSIL to cervical 
cancer. Women in the HSIL and LSIL states can regress to lower states. Death can occur to 
women in any of the four states and can result from cervical cancer, HIV related-causes or 
other causes of death. 
The plausible transitions between states are depicted in Table 3.1 below.  
Assumptions: As with every simulation assumptions were made in order to have a model 
that is analytically manageable and easier to summarize. We adopted the following 
assumptions included in Goldie et al’s model: 1)The natural history of cervical cancer 
involves progress from normal to LSIL to HSIL to local cancer to regional/distant cancer to 
death from cancer, without skipping. 2) The regression of neoplasia can only be from HSIL 
to normal or LSIL, of from LSIL to normal. A patient cannot regress from cancer. Cancer 
stages also cannot regress. 3) HIV diseases progression is only from CD4 500+ to 200-500 
to <200. This is a historic parameter, indicating the advance in HIV disease. Once a patient 
has CD4 <200 she will always be classified in the CD4 <200 category, even if her actual 
CD4 count improved with treatment. In other words worsening HIV-disease cannot regress. 
The latter assumption is consistent with data that show that improvements in antiretroviral 
therapy do not appear to reduce the progression of precancerous lesions even amongst 
women with improved CD4 counts. 
In addition to these assumptions, unlike in Goldie et al’s [1999] original paper, we assumed 
that the progression/regression rate of cervical precancerous lesions is not dependent on a 
previous history of precancerous lesions. This is because even though Goldie et al originally 
assumed a higher transition probability from a precancerous lesion to cancer in those with a 
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previous history of treated lesions Goldie and Kuntz [2003] later showed this could be 
erroneous: the source of the error being the fact that the parameters used in the model are 
from heterogeneous populations (that include patients with and without a previous history of 
lesions). 
3.3.b Study procedures 
In the absence of prospective data on HIV-progression, cervical precancerous 
disease progression and regression for Cameroonian women, we developed a Markov chain 
model using parameters published in Goldie et al’s validated model for cervical cancer in 
HIV. We recognize that the parameters were primarily based on US cohorts at the initiation 
of HAART. However the model was calibrated to reflect the shape of age-specific cancer 
incidence and mortality in the Cameroon, as estimated by the WHO.  
3.3.c Data analysis 
The model was constructed and analyzed using the Healthcare module of Treeage 
Pro 2008, a software meant primarily for decision analysis including those based on Markov 
models.  
Model parameters: Parameters used in the model were abstracted from the published 
literature and reflected data for Cameroon as much as possible. The values used in the 
baseline model are shown in Table 3 2. The baseline model was designed to simulate the 
progression over time of a cohort of HIV-positive women aged 25 with CD4 count >500, 
30% of whom had precancerous lesions (one-third of which were high grade lesions). All 
cause age-specific mortality rates were estimated based on abridged life tables for women 
in Cameroon [WHO, 2008]. HIV mortality rates were estimated based on WHO data 
[UNAIDS, 2007]. The proportion of HIV-mortality that occurs in each CD4 category was 
estimated based on data by Goldie et al [1999]. Cervical cancer mortality rates were also 
abstracted from WHO estimates of annual cervical cancer incidence and deaths in 
Cameroon [Ferlay et al., 2004]. Age-specific mortality rates from other causes were 
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estimated by adjusting (using another Markov analysis) all-cause age-specific mortality rates 
to deduct mortality from cervical cancer and mortality from HIV. 
In the absence of published data on long-term progression or regression rates of 
precancerous lesions in HIV positive women in Cameroon, we used published estimates 
from women in the pre-HAART era from Goldie et al [1999].  
 
Scenarios and outcomes assessed: We assessed the projected lifetime cumulative mortality 
due to cervical cancer in four plausible scenarios of HIV and cervical cancer care in 
Cameroon: no HAART and no screening (NHNS), HAART when indicated and no screening 
(HNS), HAART when indicated and screening once at age 35 (HS35), and HAART when 
indicated and screening on HAART initiation (HSHI).  
 
Sensitivity analyses: The sensitivity of cumulative cervical cancer mortality to parameter 
estimates was analyzed in one-way sensitivity analyses. We were particularly interested in 
the sensitivity of HAART effectiveness in lowering HIV-mortality and SIL progression rates 
since the baseline values used were all external to the study and these values are likely to 
vary substantially depending on the study population. 
 
Limitations and strengths: As with every model, this model will be limited by the veracity of 
the model assumptions and parameters.  
The analysis is strengthened by the use of a previously validated model of cervical 
cancer screening in HIV positive women. The use of a Markov model allows for time 
changes such as the progression and or regression of lesions in individuals in the cohort.   
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Table 3.1: Plausible transitions (blank cells) between stages in the Markov model.  
State normal normal normal LSIL LSIL LSIL HSIL HSIL HSIL cx ca cx ca cx ca cx ca cx ca cx ca cx ca cx ca cx ca Death Death Death
CD4 count 500+ 200-500 0-200 500+ 200-500 0-200 500+ 200-500 0-200 500+ 500+ 500+ 200-500 200-500 200-500 0-200 0-200 0-200 NA NA NA
cancer stage NA NA NA NA NA NA NA NA NA local regional distant local regional distant local regional distant NA NA NA
cause of death NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA other HIV Cx Cancer
State CD4 countcancer stagecause of death
normal 500+ NA NA
normal 200-500 NA NA
normal 0-200 NA NA
LSIL 500+ NA NA
LSIL 200-500 NA NA
LSIL 0-200 NA NA
HSIL 500+ NA NA
HSIL 200-500 NA NA
HSIL 0-200 NA NA
cx ca 500+ local NA
cx ca 500+ regional NA
cx ca 500+ distant NA
cx ca 200-500 local NA
cx ca 200-500 regional NA
cx ca 200-500 distant NA
cx ca 0-200 local NA
cx ca 0-200 regional NA
cx ca 0-200 distant NA
Death NA NA other
Death NA NA HIV
Death NA NA Cx Cancer
 
Rows and columns respectively represent initial and final stages at each transition time. (cx ca: Cervical Cancer, NA: Not applicable). 
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Table 3.2 Baseline values  
Variable CD4 
>500  
CD4  
200-500  
CD4  
<200  
Source  
Initial prevalence of lesions, % 30 NA NA Mbu et al, 2008 
Initial proportion of lesions that were 
HSIL (%) 
33 NA NA Mbu et al, 2008 
 
    
HIV infection 
    
HIV mortality rate (per 1000 per year)* 0.05 6.06 48.6 UNAIDS, 2007 
Effect of HAART in reducing HIV 
mortality 
NA NA 4-fold Murphy et al, 2001; 
Mermin et al, 2008 
HIV progression rate (per 100 per 
year)** 
18.1 27.5 NA Goldie et al, 1999 
 
    
Cervical Cancer 
    
Cancer mortality rate (per 1000 per 
year)* 
   [Ferlay et al., 2004 
Local invasive cancer  41.1 41.1 41.1  
Regional invasive cancer 222.1 222.1 222.1  
Distant invasive cancer 543.5 543.5 543.5  
 
    
Progression rate (per 100 per year) 
   Goldie et al, 1999 
Normal to LSIL 0.016  0.67  0.67   
LSIL to HSIL 0.73  2.93  2.93   
HSIL to local invasive cancer 2.0  2.42 2.42  
Local to regional invasive cancer 4.03  4.03  4.03   
Regional  to distant invasive cancer 4.03  4.03  4.03   
 
    
Regression rate (per 100 per year) 
   Goldie et al, 1999 
LSIL to normal 2.99  2.99  2.99   
HSIL to normal 0.30  0.30  0.30   
 
    
Screening test 
   Goldie et al, 1999 
Sensitivity, % 70  70  70   
Specificity, % 90  90  90   
* Mortality in each CD4 category or cervical cancer stage were determined by weighting crude estimates by the proportions 
due to each category or stage from Goldie et al[1999]. ** estimated from mean duration at each stage  
 
  
 
CHAPTER FOUR: CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS IN WOMEN 
INITIATING ANTIRETROVIRAL THERAPY IN CAMEROON: PREVALENCE AND 
PREDICTORS 
 
 
 
 
4.1 ABSTRACT 
Background: Cervical cancer is the most common cancer in women in low-income 
countries. Although cervical cancer incidence and mortality is higher in HIV-positive women, 
resource limitations restrict the implementation of systematic screening programs in these 
women. 
Objectives: We explored the potential for targeted screening by assessing the prevalence, 
severity and predictors of cervical squamous intra-epithelial lesions (SIL) in HIV-positive 
women in Cameroon. 
Methods: We conducted a cross-sectional study of women initiating antiretroviral therapy 
between August and September of 2008 in three clinics in Cameroon. Socio-demographic, 
behavioral, and clinical information was obtained from eligible women by trained 
interviewers. Cervical exfoliated cells were then collected, a conventional cytology 
performed and epithelial lesions classified according to the Bethesda 2001 system. 
Results: A total of 282 women, aged 19 to 68 years, were enrolled in this study. The 
median CD4 count was 179 cells/microliter (interquartile range: 100 to 271). SIL were 
detected in 43.5% of the 276 women with satisfactory samples: including atypical squamous 
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cells of unknown significance (ASCUS) 0.7%, low-grade SIL (LSIL) 25.0%, atypical 
squamous cells, cannot exclude high grade lesions (ASC-H) 14.5%, and high-grade SIL 
(HSIL) 3.3%. None of the demographic or clinical characteristics considered significantly 
predicted the presence of any SIL or the presence of severe lesions requiring colposcopy. 
However, compared to women from urban areas, SIL were more frequent in women from 
rural areas (adjusted OR: 1.68; 95%CI: 0.88, 3.18). SIL were also slightly more frequent in 
women aged 26-59 (aOR: 1.57; 0.65, 3.81).   
Conclusion: The prevalence of SIL in women initiating antiretroviral therapy in Cameroon 
was high underscoring the need for screening in this population. In the absence of any 
accurate demographic or clinical predictor of SIL, alternative affordable screening options 
need to be explored. 
 
4.2  INTRODUCTION 
Cervical cancer is the most common cancer in women in low-income countries 
[WHO, 2006]. Compared to immuno-competent women, HIV-positive women have a higher 
prevalence, incidence and progression rate of precancerous cervical lesions [Palefsky, 
2006; De Vuyst et al, 2008]. By the end of 2007, women accounted for 50% of the estimated 
33 million people living with HIV worldwide, and close to 59% of the 22 million in sub-
Saharan Africa [UNAIDS, 2008]. With the recent increase in access to highly-active 
antiretroviral therapy (HAART), these women are expected to live longer thus potentially 
allowing sufficient time for cervical cancer to develop and progress to be a clinical burden. In 
addition to a longer life expectancy, HAART is associated with a reduction of competing 
causes of death, such as Kaposi sarcoma and tuberculosis, while appearing to have little or 
no impact on the prevalence and progression of cervical precancerous lesions [Franceschi 
and Jaffe, 2007].  The proportion of morbidity and mortality attributable to cervical cancer in 
women on HAART is thus expected to increase. Enhancing early detection and treatment of 
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precancerous lesions through screening could reduce the burden of cervical cancer in these 
HIV-positive women [Goldie et al, 2005; Franceschi and Jaffe, 2007].  
Despite the relatively high risk of precancerous and cancerous cervical lesions in 
HIV-positive women, unlike many other opportunistic infections, the current management of 
women initiating HAART in most low-income countries does not include a systematic screen 
for cervical cancer or precancerous lesions. We hypothesize that cervical cancer goes 
undiagnosed and that early diagnosis of precancerous lesions by a screen at HAART-
initiation could be cost-effective in reducing overall morbidity and mortality rates in these 
HIV-positive women. Targeted screening among HIV-positive women could potentially 
increase the cost-effectiveness of screening in these resource-limited settings by increasing 
the ratio of the number of cases detected per screening test. However, for targeted 
screening to be effective socio-demographic and clinical factors associated with a higher 
prevalence and severity of lesions need to be identified. 
In this paper, we describe the prevalence and severity of cervical epithelial lesions in 
women initiating HAART in Cameroon and assess the clinical predictors of lesions in these 
women.  Clinical risk scores are also developed based on the aforementioned predictors 
and their potential performance assessed.  
 
4.3 METHODS 
Study design and study population 
We conducted a cross-sectional study of HIV-positive women recruited from three 
HIV-care clinics in Cameroon: the Bamenda Provincial Hospital AIDS Treatment Center 
(ATC), the Limbe Provincial Hospital ATC and the Nylon District Hospital ATC in Douala. 
The clinics are all located in urban areas in Cameroon but provide regular care to patients 
from surrounding urban and peripheral rural areas. Consecutive HIV-positive women 
receiving care in these clinics, between August and September 2008, were invited to 
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participate in the study. Women aged 18 years or more, who initiated HAART within a year 
of study enrollment and consented to study procedures, were eligible. Women who were 
either pregnant, having menses or had a previous total hysterectomy were excluded. Study 
procedures were approved by the relevant ethical review boards in Cameroon and the 
University of North Carolina, USA.  
Study procedures  
Three research assistants with previous medical training were trained on study 
procedures and cervical sampling to optimize the quality of cervical smears. After providing 
usual care clinicians at each site referred the patients to our research assistants who then 
explained the study to each eligible patient. After obtaining written informed consent, data 
on demographic and clinical characteristics was collected with the aid of a standardized 
questionnaire. The assistants then collected cervical smear samples using conventional 
methods. Two slides were made for each participant. The slides were immediately fixed 
using a 95% ethanol solution and stored at room temperature for the duration of patient 
enrollment. These slides were sent for analysis and storage in the laboratory of the Center 
for the Study and Control of Communicable Disease (CSCCD) of the Faculty of Medicine 
and Biomedical Sciences, Yaoundé, Cameroon.  
Slides were stained by the Papanicolau’s method and examined under the 
microscope by a trained cytologist. Each slide was scored according to the Bethesda 2001 
system as unsatisfactory, negative, atypical squamous cells of uncertain significance 
(ASCUS), low-grade squamous intraepithelial lesions (LSIL), atypical squamous cells, 
cannot exclude high grade lesions (ASC-H), high-grade SIL (HSIL), or invasive cervical 
cancer[Solomon et al, 2002]. Cytology readings were conducted blinded of clinical 
characteristics. For quality control purposes, both research assistants and cytologists 
received specific training related to the study, two slides were made and analyzed for each 
patient (the most severe result was considered the final result, in case of differences 
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between both slides), and slides with lesions were double-checked by a cytologist external 
to the study (differences were resolved by consensus). Furthermore, a subset of 25 slides 
were reviewed by an experienced cytologist at the University of North Carolina at Chapel Hill 
– the percentage agreement on the presence of lesions was 76%, (kappa=0.49) while the 
percentage agreement on lesions being ASC-H/HSIL was 60%(kappa=0.26). The potential 
impact of these limitations with conventional cytology was assessed in sensitivity (bias) 
analyses [Rothman et al, 2008]. 
Statistical analysis 
Data collected were entered into MS Access interface on Epi-info 2000. Statistical 
analyses were conducted using SAS version 9.2 (SAS institute inc, Cary NC) and STATA 
version 10 (STATA corps, Texas USA). Two outcomes, based on cervical cytology, were 
considered: 1) Prevalent cervical lesions (defined as the presence of any cervical epithelial 
lesions); 2) Prevalent  ASC-H/HSIL (lesions requiring colposcopy). Participant’s age, marital 
status, parity, number of lifetime sex partners, age at first sexual intercourse, history of 
hormonal contraception, history of exposure to cigarette smoke, CD4 count, and AIDS 
clinical stage were considered as potential clinical predictors of lesions. These 
characteristics were chosen based on the ease with which they can be elicited and recorded 
in a clinical setting and previous literature describing their association with the presence of 
cervical lesions or a plausible etiological role. 
We assessed the univariate distribution of predictors and outcomes. We conducted 
bivariable and multivariable (adjusted) analyses to assess the association of each predictor 
with the outcomes. Prevalence odds ratios (OR) and their 95% confidence intervals(CI), 
comparing the odds of each outcome between predictor levels were estimated using 
unconditional logistic regression models. Continuous variables, such as age and CD4 count, 
were assessed graphically and statistically for the linearity of the logit. Graphically, we 
plotted the log-odds of cervical lesions by the continuous variable. The plots were smoothed 
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using locally weighted estimation methods with a smoothing parameter of 0.5[Rothman et al, 
2008]. We also used a likelihood ratio test of the improved model fit with non-linear 
(quadratic terms) for the continuous variable. In the presence of evidence against linearity, 
continuous variables were coded as categorical variables using clinically meaningful cut-offs 
(for example 200 cells/uL for CD4 counts) or as a function of the shape of the graph of the 
log-odds of the outcome (for example 25-60 years versus others for age). 
All predictors considered were included in multivariable analyses. For each outcome, 
an initial (full) model that includes all the predictors was created. We then attempted to 
determine a reduced model based on a parsimonious subset of clinically and statistically 
significant predictors identified by a stepwise backward elimination strategy [Harell, 2001]. A 
final reduced model was thus obtained retaining only predictors that when dropped resulted 
in a likelihood ratio test p-value<0.2 or a more than 10% change in the area under the curve 
of the ROC plot (c-statistic). A reduced model was possible only for the prediction of 
prevalent SIL (and not for the prediction of ASC-H/HSIL).  
The models developed were based on the full sample. However the internal validity of the 
models’ performance was ascertained by implementing the models to three subsets of the 
sample corresponding to each study site. The c-statistics for the models were all within 20% 
of the model implemented on the full sample. 
One objective of this analysis was to identify if any clinical predictor(s) could be used 
in a resource-limited settings to develop a targeted screening approach. We thus developed 
and assessed potential risk scores for targeting screening only to patients more likely to 
have lesions. Risk scores were developed from each of the three final models: the two 
models for predicting the presence of any lesion (the full model and the reduced model) and 
the full model for predicting the presence of ASC-H/HSIL. The numeric score assigned to 
each predictor was based on the model slope coefficients. To allow for a simple and feasible 
application in clinical settings, each predictor score was obtained by multiplying the model 
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slope coefficients by 10 and then rounding to the lower integer. The aggregate risk score 
was based on the sum total of each predictor score. We assessed the performance 
(sensitivity, specificity, positive and negative predictive values) of each risk score for 
targeting 25%, 50% and 75% of women. We also evaluated the total errors that would result 
from implementing either targeted screening based on the risk scores versus universal or no 
screening. Total unweighted errors were estimated as the sum of ‘false negative’ and ‘false 
positive’ errors, respectively defined as the number of patients with no lesion being 
screened and the number of patients with lesions not being screened. Total weighted errors 
were also estimated taking into account the relative cost (both monetary and non-monetary) 
associated with having a ‘false negative’ versus a ‘false positive’ error. 
4.4 RESULTS 
Study population 
Altogether 282 women were enrolled in this study. Participants’ age ranged from 19 
to 68 years, with a mean of 36 years (Table 4.1). Most participants (73.4%) were from urban 
areas. As many as 26.9% were widowed, while 21.3% had never been married. The median 
parity was 2 (range 0-11). Active tobacco exposure (2.5%) and oral contraceptive pill usage 
(23.8%) was relatively infrequent. The number of lifetime partners exceeded 5 in 25.2% of 
participants. A history of genital warts was reported by 7.1% of participants while 43.3% 
could not say if they previously had genital warts or not.  
HIV diagnosis had preceded study enrolment by 18.5 months on average (range 0-
136 months). The median CD4 count was 179 cells/microliter (interquartile range: 100 to 
271). The vast majority of patients (80.9%) had advanced HIV disease (WHO HIV clinical 
stages III/IV). Only 2.1% were certain they had previously had a Pap smear. 
Prevalence and severity of lesions 
The prevalence of SIL was 43.5% (95%CI: 37.5, 49.6%) in the 276 women with 
satisfactory samples. The prevalence of specific abnormalities was ASCUS 0.7% (95%CI: 
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0.09, 2.3%), LSIL 25.0% (95%CI: 20.0, 30.5%), ASC-H 14.5% (95%CI: 10.6, 19.2%), and 
HSIL 3.3% (95%CI: 1.5, 6.1%). The overall prevalence of ASC-H/HSIL was 17.8% (95% CI: 
13.4, 22.8%).  
Association of clinical predictors and prevalent SIL 
Most of the clinical factors assessed were either weakly associated with prevalent 
SIL or had a poor precision (Table 4.2). Compared to women from urban areas, SIL were 
more frequent in women from rural areas (adjusted OR: 1.68; 95%CI: 0.88, 3.18). SIL were 
also slightly more frequent in women aged 26-59 (aOR: 1.57; 0.65, 3.81). Although 
estimates were relatively imprecise, the odds of SIL were lower in women with HIV stage 
III/IV compared to women in stage I/II (aOR: 0.63; 95%CI: 032, 1.23). The odds of SIL did 
not differ substantially by marital status, educational status, previous exposure to tobacco 
smoke, previous pill usage, parity, age at first sex, time since HIV diagnosis or CD4 count 
(all aORs were more than 0.8 and less than 1.25).  
The overall predictive value of the model with all these variables was relatively low 
with a c-statistic of 0.60. A reduced model included only two predictors: participants’ 
residence (rural vs. urban aOR 1.58 (95% CI: 0.87, 2.87) and HIV clinical stage (HIV stage 
III/IV vs. I/II aOR 0.61 (95% CI: 0.31, 1.19)), with a c-statistic of 0.58.  
Association of clinical predictors and lesions requiring colposcopy/biopsy 
Bivariable and multivariable associations with ASC-H/HSIL were relatively weak 
(Table 4.2). However, ASC-H/HSIL were somewhat more frequent in women who reported 
age at first sexual intercourse less than 16 years (aOR: 1.27; 95%CI: 0.64, 2.53) as well as 
in patients with CD4 counts below 200 (aOR: 1.49; 95%CI: 0.72, 3.07). ASC-H/HSIL were 
less frequent in women self-reporting exposure to tobacco smoke (aOR: 0.66, 95%CI: 0.33, 
1.34). The odds of ASC-H/HSIL did not differ substantially by age, marital status, education, 
residence, age, previous pill usage, parity, HIV clinical stage, or time since HIV diagnosis (all 
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aORs were more than 0.8 and less than 1.25). With a c-statistic of 0.59, the overall 
predictive value of the model with all these variables was also low.  
Assessment of clinical risk scores for targeted screening 
The clinical risk scores developed are defined and assessed in Tables 4.3(A and B). 
Overall the classification accuracy based on these scores were all less than 70%.  If the risk 
score based on the full model for any SIL was used to target the screening of 25% of 
women, then only 35.7% of women with lesions would have been screened while 23% of 
women with no lesions would be screened as well. If the target was to screen 25% of 
women with ASC-H/HSIL, then using the score based on the full model predicting ASC-
H/HSIL would result in 38.1% of women with ASC-H/HSIL lesions being screened while 
26.7% of women with no ASC-H/HSIL would also be screened.  
It is worth noting that despite the relatively poor performance of these scores, their 
value compared to universal screening or no screening was a function of the relative weight 
given to ‘false negative’ errors compared to ‘false positive’ errors. In screening for any 
lesion, when ‘false negative’ errors were considered equal to ‘false positive’ errors, then the 
total error rates associated with targeting 50% (406 errors per 1000 women) or 25% (410 
errors per 1000 women) of women was lower than each of universal screening (565 errors 
per 1000 women) or no screening (435 errors per 1000 women). However, as the relative 
cost of ‘false negative’ errors (compared to ‘false positive’ errors) increased, universal 
screening tended towards having the least total errors while the total errors associated with 
screening fewer proportions of patients increased (Figure 4.1).  Similar trends were 
observed in assessing potential screening for ASC-H/HSIL only (Figure 4.2). While no 
screening was associated with the least errors when ‘false negative’ errors were considered 
equal to ‘false positive’ errors, increasing the proportion of women screened was a 
preferable option when the former errors were at least five times the latter. 
Bias analyses 
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We conducted bias analyses assessing what the true population prevalence of 
lesions could be considering the inaccuracies in conventional cytology. Our analysis showed 
that a lower sensitivity of cytology would mean that the study tended to underestimate the 
true prevalence while a lower specificity would have resulted in the study overestimating the 
true prevalence. Our data were compatible with a true population prevalence of lesions 
ranging from 19.3% (when the sensitivity was 100% and the specificity 70%) to 87.0% 
(when the sensitivity was 50% and specificity 100%). Meanwhile the prevalence of ASC-
H/HSIL could be as low as 0% (if the specificity was 80% or less) and as high as 35.6% 
(when sensitivity was 50% and specificity 100%). 
 
4.5 DISCUSSION  
To appraise the need and potential for targeted screening for cervical cancer in HIV-
positive women in resource-limited settings, we assessed the prevalence, severity and 
predictors of SIL in women initiating antiretroviral therapy in Cameroon. We document that 
the prevalence of precancerous lesions is high in these women. Approximately twenty 
percent of these women have lesions severe enough to warrant colposcopy. In this study 
population, readily available demographic and clinical factors, both individually and as a 
group, did not accurately distinguish women with lesions from those without. 
While the overall prevalence of any cervical lesion in this population appears high 
(43%), it is within the range described in women in similar conditions. Among HIV-positive 
pregnant women in Yaounde, Cameroon, lesions were detected in 40%, including 12% with 
high grade lesions [Mbu et al, 2008]. The prevalence of SIL in HIV-seropositive women 
living in sub-Saharan Africa has ranged from 15 to 48% in Burkina Faso[Didelot-Rousseau 
et al, 2006], Kenya [Yamada et al, 2008], South Africa[Moodley and Garib, 2004; Gaym et 
al, 2007], Zimbabwe [Chirenje et al, 2002], Rwanda [Leroy et al, 1999], Malawi [Motti et al 
1996] and Cote d’Ivoire [LaRuche et al]. The highest prevalence of SIL (76%) so far was 
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detected in a study of 150 HIV-positive women in Zambia who had a median CD4 count of 
165/uL. Although an unusually low prevalence of 7% was reported in a study of 691 women 
in Tanzania, the vast majority (86%) of these women were in WHO clinical stage I and only 
12% had CD4 count less than 200[Kapiga et al, 1999]. 
The prevalence in our study could be influenced by study population characteristics 
or the accuracy of cytology results. Though we sampled in three different clinics, the sample 
may not have been exactly representative of all HIV-positive women in Cameroon as the 
clinics were conveniently selected and not randomly chosen. We do not however expect the 
difference to be substantial as the clinics sampled offer care to a very high number of 
patients in regions with the highest HIV-prevalences and our participant characteristics were 
similar to those reported nationwide [Mosoko et al, 2009]. Potential errors due to the Pap 
smear’s low sensitivity could actually mean that our prevalence is an underestimate. 
Nevertheless, the sensitivity of cytology in this study was assured by research assistants 
being trained to insure adequate sample collection, collecting two slides per patient to 
reduce sampling error and having the interpretations validated by an experienced cytologist. 
The latter review suggested a tendency of the initial cytologist to overclassify participants as 
having lesions. Our bias analyses however shows that the lowest true population prevalence 
of lesions compatible with our data was in the order of 19% which is still relatively high. 
The high prevalence of cervical lesions in this population reiterates the current need 
to offer screening and care for cervical precancerous lesions in HIV-positive women. Despite 
being at increased risk for cervical cancer, less than 5% of participants in our study had 
previously been screened. Access to antiretrovirals has dramatically increased in developing 
countries. While the increased survival that is expected to accompany this increased access 
the effect on cervical precancerous lesions is expected to be moderate at best, as HAART 
has a very limited effect, if any, on HPV persistence and the progression of lesions [Heard, 
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2004]. Even while on antiretrovirals women will still need to be screened or receive other 
preventive care for cervical cancer.  
We are not aware of any other study that assessed the potential for clinical risk 
scores for targeted cervical cancer screening in HIV-positive women. Because most studies 
were conducted to establish the association between HIV infection and the presence of SIL, 
very few assessed the risk factors specific to HIV-positive women. Amongst the few that did, 
immunosuppression (low CD4 count), high HIV viral load and or infection with high-risk HPV 
types tended to be associated with the presence of SIL[Kapiga et al, 1999; Yamada et al, 
2008; LaRuche et al, 1998; Leroy et al, 1999].  While our sample size was adequate for 
estimating prevalence, only a limited number of covariates could be considered as potential 
predictors. Predictors were thus judiciously chosen taking into account the established 
literature and the ease of clinical assessment.  Women with lower CD4 counts and younger 
age at first sex thus appeared more likely to have severe lesions. We did not consider HIV 
viral load as resource limitations render it difficult to ascertain in most patients, making it of 
little clinical use in this setting. Unexpectedly, women who self-reported exposure to 
cigarette smoke or a history of taking contraceptive pills tended to be less likely to have 
lesions. We attribute these apparent lower odds to these factors being indicators of higher 
socio-economic status in these settings. It is not clear why women with more advanced 
clinical HIV disease appeared less likely to have lesions. Nevertheless this association was 
relatively imprecise. 
Considered as a group, the clinical predictors only slightly performed better than 
chance in differentiating women who had lesions (or women with severe lesions) from those 
without. For comparison the commonly used Framingham cardiovascular risk score had a c-
statistic in the order of 0.65 -0.70 in a population of diabetics in the UK [Guzder et al, 2005]. 
Nonetheless, the choice between universal screening, targeted screening or no screening 
would depend on how much policy makers value the cost of ‘false negative’ errors relative to 
 82 
 
the cost of ‘false positive’ errors. We expect that most would attribute a higher long-term 
cost to ‘false negative’ errors than to ‘false positive’ errors as cancer can develop in the 
former, while the latter would only result in an unnecessary pap smear. With this being the 
case, strategies advocating for more screening (thus with higher sensitivity and lower ‘false 
negatives’) will tend to be better options. Formal cost-effectiveness analyses may aid in 
further clarifying which option is best in each setting.  
In addition to prevalence, the need to screen would also depend on the progression 
of lesions towards self-resolution or cancer. It was not possible to assess the progression or 
regression of lesions, given the cross-sectional nature of our study. Further studies would 
need to assess the long-term progression of lesions in HIV-positive women in this setting. 
In conclusion, the prevalence of SIL in women initiating antiretroviral therapy in 
Cameroon was high. This high prevalence, in light of the potential to treat precancerous 
lesions when detected early and the limited role of HAART on the progression of lesions, 
underscores the need for screening in this population. In the absence of any accurate 
demographic or clinical predictor of SIL, alternative affordable screening options need to be 
explored. A prospective study of the long-term evolution of these lesions and their 
determinants is needed to further guide policy decisions. 
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Table 4.1: Socio-demographic and clinical characteristics in 282 women initiating 
HAART in Cameroon  
Characteristic  Level  N  % or Mean 
(SD)* 
Median* Range 
* 
 
     
Marital status Never married 60 21.3   
 Married 
monogamous 
56  19.9   
 Married polygamous  13  4.6   
 Living with a partner  30  10.6    
 Separated 31  11.0   
 Divorce  16  5.7    
 Widow  76  26.9    
 
     
Education None 14 5.0   
 Primary  135 47.9    
 Secondary  121 42.9    
 Tertiary  12 4.3   
 
     
Residence  Urban  207 73.4   
 Rural  75 26.6   
 
     
Previous use of hormonal 
pills 
Yes  67 23.8   
 No  215 76.2   
 
     
Exposure to tobacco 
smoke 
No 141 50.0   
 Active 7 2.5    
 Passive  133 47.2    
 Missing  1 0.3   
 
     
WHO HIV clinical stage  I 8 2.8    
 II 46  16.3    
 III 168  59.6    
 IV 60 21.3   
 
     
Previous Pap smear No 269  95.4   
 Yes 6 2.1   
 Don’t know/missing 7 2.5   
 
     
Lifetime sex partners 1 9 3.2    
 2 29 10.3   
 3 56 19.9   
 4 34 12.1   
 5 35 12.4   
 6+ 71  25.2   
 Missing  48 17.0   
 
     
Sex partners since HIV 
diagnosis 
0 127 45.0   
 1 136 48.2   
 2+ 19 6.8    
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Characteristic  Level  N  % or Mean 
(SD)* 
Median* Range 
* 
 
     
Lifetime condom use Never  102 36.2   
 Less than 50% of the 
time 
138 48.9   
 More than 50% of the 
time 
39 13.8   
 Always  3 1.1    
 
     
Condom use since HIV 
diagnosis 
Never  29 10.3   
 Less than 50% of the 
time 
37 13.1   
 More than 50% of the 
time 
19 6.7   
 Always  69 24.5    
 No new 
partner/missing 
128 45.4   
 
     
History of genital warts  No 140 49.6   
 Yes 20 7.1   
 Don’t Know/missing  122 43.3   
 
     
Age (years) 281 36.3 (9.6) 34 19 - 68 
Age at first sex (years)  272 16.9 (2.4) 17 12 – 27 
Parity  282 3.1 (2.6) 2 0 - 11 
Time since HIV diagnosis (months) 282 18.5 (19.0) 12 0 – 136 
CD4 count (per uL) 267 206 (170) 179 1 - 1759 
* Mean (standard deviation), median and range for continuous characteristics. 
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Table 4.2: Association of clinical predictors with prevalent cervical precancerous lesions in 282 women initiating HAART 
in Cameroon 
Characteristic N   ANY CERVICAL PRECANCEROUS LESION    ASC-H/HSIL 
    Prev 
(%) 
 OR* 95% CI  aOR**  95% CI    Prev 
(%) 
 OR* 95% CI  aOR**  95% CI 
                     
Marital status                     
Single, never married 59   42.4  1. -  1. -    18.6  1. -  1. - 
Married/in partnership 98   43.9  1.06 0.55, 
2.04 
 0.99 0.47, 
2.11 
   17.4  0.92 0.40, 
2.12 
 0.95 0.37, 
2.49 
Separated/divorced/widowed 119   43.7  1.05 0.56, 
1.98 
 0.95 0.45, 
2.01 
   17.7  0.94 0.42, 
2.10 
 0.89 0.34, 
2.34 
                     
Education                     
None/primary 144   43.1  1. -  1. -    17.4  1. -  1. - 
Secondary/tertiary 132   43.9  1.04 0.64, 
1.67 
 1.24 0.71, 
2.16 
   18.2  1.06 0.57, 
1.96 
 1.05 0.51, 
2.18 
                     
Residence                     
Urban 204   39.7  1. -  1. -    16.7  1. -  1. - 
Rural  72   54.2  1.79 1.04, 
3.09 
 1.68 0.88, 
3.18 
   20.8  1.32 0.67, 
2.59 
 1.20 0.52, 
2.74 
                     
Age (years)                     
25 and  less or  60+ 32   37.5  1. -  1. -    21.9  1. -  1. - 
26-59 243   44.0  1.31 0.61, 
2.80 
 1.57 0.65, 
3.81 
   16.9  0.72 0.29, 
1.79 
 1.07 0.35, 
3.24 
                     
Previous use  of pills                     
No 210   43.8  1. -  1. -    18.6  1. -  1. - 
Yes  66   42.4  0.95 0.54, 
1.65 
 0.95 0.50, 
1.83 
   15.2  0.78 0.37, 
1.67 
 0.83 0.34, 
2.01 
                     
Exposure to tobacco smoke                     
No 137   46.0  1. -  1. -    19.7  1. -  1. - 
Yes  139   41.0  0.82 0.51,  0.86 0.51,    15.8  0.77 0.41,  0.66 0.33, 
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1.32 1.46 1.42 1.34 
                     
Age at first sex (years)      
  
             
16 or less 126   45.2  1.18 0.71, 
1.98 
 1.17 0.69, 
2.01 
   19.1  1.27 0.64, 
2.53 
 1.31 0.65, 
2.63 
More than 16 141   41.1  1. -  1. -    15.6  1. -  1. - 
                     
Parity                     
2 or less 152   42.1  1. -  1. -    17.8  1. -  1. - 
More than 2 124   45.2  1.13 0.70, 
1.83 
 1.04 0.59, 
1.83 
   17.7  1.00 0.54, 
1.86 
 0.95 0.45, 
2.00 
                     
Time since HIV diagnosis                      
1 year or less 165   44.2  1. -  1. -    18.2  1. -  1. - 
More than 1 year 111   42.3  0.93 0.57, 
1.50 
 0.83 0.49, 
1.42 
   17.1  0.93 0.49, 
1.75 
 0.97 0.48, 
1.97 
                     
WHO HIV stage                     
I/II 51   54.9  1. -  1. -    19.6  1. -  1. - 
III/IV 225   40.9  0.57 0.31, 
1.05 
 0.63 0.32, 
1.23 
   17.3  0.86 0.40, 
1.86 
 0.95 0.39, 
2.27 
                     
CD4 count (/µL)      
  
             
Less than 200 155   42.6  1.04 0.61, 
1.78 
 1.10 0.64, 
1.88 
   19.4  1.46 0.71, 
3.09 
 1.49 0.72, 
3.07 
200 or more 106   41.5  1. -  1. -    14.2  1. -  1. - 
*OR: unadjusted odds ratio; **aOR: adjusted for all other covariates in table; OR: Prev: Prevalence; Odds ratio; CI: confidence interval. 
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Table 4.3A: Definition of clinical risk scores developed and assessed for predicting 
the prevalence of cervical precancerous lesions in women initiating HAART in 
Cameroon 
 
Characteristic Score 
Full model for predicting prevalent SIL  
HIV diagnosed within 1 year 2 
Age at first sex less than or equal 16 years 2 
Not exposed to tobacco 2 
Secondary/tertiary education 2 
Rural residence 5 
WHO HIV Stage I/II 5 
Age  26-59 years  5 
TOTAL 23 
  
Full model for predicting  prevalent ASC-H/HSIL  
Neither  separated/widowed/divorced  1 
Aged 26-59 1 
Rural residence 2 
No previous use of pills 2 
Age at first sex less than or equal 16 years 3 
Not-exposed to tobacco 4 
CD4 count less than 200 4 
TOTAL 17 
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Table 4.3B: Performance of potential clinical risk scores for targeting cervical screening in 282 women initiating HAART 
in Cameroon 
 
Targeted proportion to screen Cut-off 
predictive 
probability 
Cut-off 
score 
 SENS 
(%) 
SPEC 
(%) 
PPV 
(%) 
NPV 
(%) 
Total unweighted** 
errors 
 (per 1000 women) 
Detection of any SIL         
Risk score for any SIL 
        
Screen 25% > 0.500 > 14  35.7 77.0 54.0 61.3 410 
Screen 50% > 0.434 > 11  45.2 70.4 53.6 62.9 406 
Screen 75% > 0.381 > 8  81.7 30.9 47.2 69.1 470 
Universal screening (100%)* None  None   100.0 0.0 43.5 NA 565 
No screening (0%)* None  None   0.0 100.0 NA 56.5 435 
 
        
Detection of ASC-H/HSIL         
Risk score for ASC-H/HSIL 
        
Screen 25% > 0.201 > 12  38.1 73.3 22.2 85.6 330 
Screen 50% > 0.171 > 10  61.9 51.4 20.3 87.1 467 
Screen 75% > 0.134 > 7  76.2 32.9 18.5 87.3 594 
Universal screening (100%)* None  None   100.0 0.0 17.8 NA 822 
No screening (0%)* None  None   0.0 100.0 NA 82.2 178 
SENS: Sensitivity; SPEC: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; SIL: Squamous intra-epithelial lesion; NA: Not applicable 
because using cut-off resulted in every woman being targeted for screening. 
*included for comparative purposes; ** total unweighted errors = sum of ‘false positives’ and ‘false negatives’ 
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Figures 
 
 
 
Figure 4.1: Total weighted errors associated with  screening for any precancerous 
lesion by the relative ‘cost’ of ‘false negative’ errors compared to ‘false positive’ 
errors. (A-C: Screening based on risk score with a cut-off targeting 25%, 50% and 75% 
of women for A,B and C respectively; D: Universal screening; E: No screening).  Note 
that ‘cost’ is used as a generic term, not just limited to monetary value, while ‘false 
positive’ and ‘false negative’ respectively refer to screening a patient with no lesion 
and not screening a patient with lesions. 
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Figure 4.2: Total weighted errors associated with  screening for ASC-H/HSIL by the 
relative ‘cost’ of ‘false negative’ errors compared to ‘false positive’ errors. (A-C: 
Screening based on risk score with a cut-off targeting 25%, 50% and 75% of women 
for A,B and C respectively; D: Universal screening; E: No screening).  Note that ‘cost’ 
is used as a generic term, not just limited to monetary value, while ‘false positive’ and 
‘false negative’ respectively refer to screening a patient with no severe lesion and not 
screening a patient with severe lesions. 
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CHAPTER FIVE: AGE AND THE PREVALENCE OF CERVICAL SQUAMOUS 
INTRAEPITHELIAL LESIONS AMONG HIV-POSITIVE WOMEN IN CAMEROON 
 
 
 
5.1 ABSTRACT 
 
Background: Cervical squamous intra-epithelial lesions (SIL) are more frequent in HIV-
positive women overall. However the appropriate age at which to begin and end cervical 
cancer screening for early detection of lesions in HIV-positive women is not clear. We 
assessed the age-specific prevalence of any SIL and SIL requiring colposcopy in HIV-
positive women in Cameroon. 
Methods:  We enrolled, interviewed and conducted conventional cervical cytology in 282 
women, aged 19-68 years, initiating antiretroviral therapy in three clinics in Cameroon.  
Results: SIL were detected in 43.5% of the 276 women with satisfactory samples, 17.8% of 
whom had ASC-H/HSIL. On average, women aged 26 to 59 tended to have a slightly higher 
prevalence of any SIL than other women (Prevalence difference PD: 6.5%; 95%CI: -11.4, 
24.4%). This PD was a function of CD4 count (heterogeneity test p-value =0.09): amongst 
patients with CD4 counts less than 200cells/uL, the prevalence was higher in patients aged 
26-59, while there was essentially no difference amongst women with CD4 counts greater 
than 200 cells/uL. ASC-H/HSIL were present in women as young as 19 and as old as 62. 
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Overall the prevalence of ASC-H/HSIL increased by 0.7% (95%CI: -3.8%, 5.1%) per decade 
increase in age.  
Conclusion: Both severe and less severe lesions were prevalent at all ages suggesting little 
utility of age-targeted screening among HIV-positive women. Nevertheless, the long-term 
evolution of these lesions needs to be assessed in prospective studies.   
 
 
5.2 INTRODUCTION 
 
Cervical cancer is the second most common cancer in women worldwide [Stewart 
and Kleihues, 2003]. Although cervical cancer incidence and mortality is higher in HIV-
positive women, resource limitations restrict the implementation of systematic screening 
programs in these women in developing countries. With the recent increase in access to 
antiretroviral therapy HIV-positive women are expected to live longer, potentially allowing 
sufficient time for cervical cancer to develop. Targeted screening could potentially alleviate 
the strain on resources needed to screen these women. 
Age has been a common consideration in the targeted screening for precancerous 
lesions in the general population.  Current guidelines for screening the general population of 
women in the United States (US) suggest screening commence no later than age 21 years, 
reducing the frequency of screening at age 30 among women with previously negative 
cytology results and stopping screening at age 65 (or 70 in some guidelines) [Saslow et al, 
2002; ACOG 2003; USPSTF, 2008]. World Health Organization (WHO) guidelines aimed 
primarily at resource-limited settings are less stringent, recommending screening begin at 
age 30, need not be annual and need not be done over the age of 65 [WHO, 2006].  These 
age considerations may not necessarily be ideal for HIV-positive women among whom 
higher human papilloma virus (HPV) prevalence, higher HPV persistence, and a faster 
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progression of lesions [Sun et al, 1997; Six et al, 1998; Cu-Uvin et al, 1999; Ahdieh et al, 
2000; Massad et al, 2001; Palefsky, 2006; De Vuyst et al, 2008;] could mean an earlier 
occurrence and or a longer persistence of precancerous lesions. The optimal age for 
screening in HIV-positive individuals could thus be younger than for women in the general 
population.  
We describe here the age-specific prevalence of lesions in HIV-positive women 
initiating antiretroviral therapy in Cameroon, with the aim of estimating the minimum age at 
which lesions occur, the age with maximum occurrence and the latest age at which lesions 
occur.   
5.3 METHODS 
Study design and population 
In this cross-sectional study, HIV-positive women were recruited from three HIV-care 
clinics in Cameroon: the Bamenda Provincial Hospital AIDS Treatment Center (ATC), the 
Limbe Provincial Hospital ATC and the Nylon District Hospital ATC in Douala. These are all 
located in urban areas in Cameroon and provide regular care to patients from surrounding 
urban areas and peripheral rural areas. Consecutive HIV-positive women receiving care in 
these clinics, between August and September 2008, were invited to participate in the study. 
Women aged 18 years or more, who initiated HAART within a year of study enrollment and 
consenting to study procedures were eligible. Women who were either pregnant, bleeding 
due to menses or had a previous total hysterectomy were excluded. After obtaining written 
consent from each participant, socio-demographic and clinical data were collected using a 
structured interview, a clinical examination and a review of medical records. Cervical cell 
samples were then collected using Ayre’s spatula, and smeared into two pre-labeled slides.  
.  
Conventional cytology slides collected were transported to the laboratory of the 
Center for the Study and Control of Communicable Diseases (CSCCD) in Yaounde, 
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Cameroon where they were stained by the Papanicolau’s method and examined under the 
microscope by a trained cytologist. The stained slides were observed under the microscope 
(at 400X) and then scored according to the Bethesda 2001 system, as unsatisfactory; 
negative; atypical squamous cells of uncertain significance (ASCUS); low-grade squamous 
intraepithelial lesions (LSIL); atypical squamous cells, cannot exclude high grade lesions 
(ASC-H); high-grade SIL (HSIL); or invasive cervical cancer [Solomon et al, 2002].  For 
quality control purposes, both research assistants and cytologist received specific training 
related to the study, two slides were made and analyzed for each patient (the most severe 
result was considered the final result, in case of differences between both slides), and slides 
with lesions were double-checked by a cytologist external to the study (differences were 
resolved by consensus). Furthermore, a subset of 10% slides were reviewed by an 
experienced cytologist at the University of North Carolina at Chapel Hill – the percentage 
agreement was on the presence of lesions was 76%, (kappa=0.49) while the percentage 
agreement on lesions being ASC-H/HSIL was 60%(kappa=0.26). The potential impact of 
these limitations with conventional cytology were assessed in sensitivity (bias) analyses 
[Rothman et al, 2008]. The study was approved by relevant ethical committees in Cameroon 
and the University of North Carolina, Chapel Hill (USA). 
 
Data analysis 
Data collected were entered into MS Access interface on Epi-info 2000. Statistical 
analysis were conducted using SAS version 9.2 (SAS institute inc, Cary NC) and Stata 
version 10 (Stata corps, Texas USA). Two outcomes were considered for this analysis: 1) 
Prevalent cervical lesions (defined as the presence of any cervical epithelial lesions); 2) 
Prevalent ASC-H/HSIL. Age (in years) was the independent predictor considered. Other 
covariates considered in this analysis included marital status, education level, parity, history 
of hormonal contraception, smoking history, CD4 count, and AIDS clinical stage. Univariable 
 97 
 
distributions of these characteristics were determined by computing means, median and 
ranges (for continuous variables) and proportions at different levels (for categorical 
variables).  
In bivariable analyses, the crude relationship between each outcome and age was 
assessed using locally weighted regression (LOWESS) methods with a smoothing 
parameter of 0.5 [Rothman et al, 2008].  In subsequent analyses, we used generalized 
linear models with prevalence as the outcome, an identity link and a binomial distribution, as 
we sought to estimate prevalence differences [Rothman et al, 2008]. We explored coding 
age as a continuous variable (linear or quadratic) or coding age as a categorical variable 
with cut-offs based on the LOWESS-smoothed curve. For each outcome, the coding of age 
that resulted in the best model fit (or least deviance), as assessed by a likelihood ratio test 
(for nested models) or the Akaike’s Information criterion (for non-nested models) was 
selected. Age coded as a binary variable (age 26-59 or not) had the best fit in modeling the 
association of age and any lesion, while age coded as a continuous linear variable had the 
best fit in modeling the association of age and ASC-H/HSIL.  
In multivariable analysis all covariates other than age and the outcomes were 
assessed as potential modifiers of the prevalence difference.  Each covariate was coded as 
a binary variable and a product interaction term created between age and each covariate. 
Covariates were considered modifiers if a likelihood ratio test of the product interaction term 
had a p-value less than 0.1, (a higher cut-off point set a priori to account for the low power 
associated with tests of homogeneity) or if the stratum-specific prevalence differences varied 
by 20% or more.  
Although all covariates were also considered as potential confounders, a Directed 
Acyclic Graph (DAG) analysis revealed that none of the variables should be considered  a 
confounder [Rothman et al, 2008]. We attempted to mathematically estimate the minimum 
and maximum ages at which cervical lesions are present as well as the age with the 
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maximum prevalence of lesions assuming a quadratic relationship between age and 
prevalent lesions. Only the age of maximum prevalence could however be estimated as all 
other models resulted in extrapolations beyond biologically plausible ages. Age was 
centered in these models to allow for a meaningful interpretation of all model parameters 
[Rothman et al, 2008]. 
 
5.4 RESULTS  
Altogether 282 women were enrolled in this study. Participants’ age ranged from 19 
to 68 years (with a mean of 36 years). The median CD4 count was 179 cells/microliter 
(interquartile range: 100 to 271). SIL were detected in 43.5% of the 276 women with 
satisfactory samples: 0.7% as ASCUS, 25.0% as LSIL, 14.5% as ASC-H, and 3.3% as 
HSIL. 
Prevalence of lesions by age 
The age of participants with no lesions ranged from 19 to 68 (with a mean of 36.3) 
years while that of participants with any lesion ranged from 19 to 62 (with a mean of 35.7) 
years.  The prevalence of any lesion tended to increased from age 19 to a peak at about 25 
years (Table 5.1), from which it stabilized between 40% and 50% until the age of 60, after 
which it reduced among the small number of women surveyed (Figure 5.1).   
On average women aged 26 to 59 had a slightly higher prevalence than relatively 
younger or older women (Prevalence difference PD: 6.5%; 95%CI: -11.4, 24.4%). However 
this PD was a function of CD4 count (heterogeneity test p-value =0.09).  Amongst patients 
with CD4 counts less than 200cells/uL, women aged 25-59 had a substantially higher 
prevalence (PD= 21.0%; 95% CI: -0.8%, 42.8%). In contrast, there was only a little 
difference in prevalence by age among women with CD4 counts greater than 200 cells/uL 
(PD= -9.8%; 95%CI: -37.8%, 18.3%). 
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We conducted bias analyses assessing what the true population prevalence 
difference of lesions could be considering the inaccuracies in conventional cytology. The 
misclassification of the outcome resulting from these inaccuracies was assumed to be non-
differential as the cytologist was masked from participants’ ages. Our analysis showed that a 
lower cytology sensitivity or specificity would mean that the study tended to underestimate 
the magnitude of the prevalence difference between age groups (Figure 5.2). For example 
with a sensitivity of 70% and a specificity of 90% among women with CD4 counts less than 
200, the prevalence of lesions in women aged 25-59 could be 35% higher than in younger 
or older women. A similar sensitivity and specificity among women with CD4 counts more 
than 200, could correspond to a 16.3% lower prevalence of lesions in women aged 25-59 
compared to younger or older women. 
Assuming a quadratic relationship between age and the prevalence of SIL, the age 
with maximum prevalence was estimated to be 34.9 (95% CI: 11.6, 58.1) years. 
Prevalence of ASC-H/HSIL by age 
The age of participants with ASC-H/HSIL ranged from 19 to 62 (with a mean of 36.5) 
years. In contrast to any lesion, the age-specific prevalence of ASC_H/HSIL increased 
slowly but more or less monotonically with age (Figure 5.1). On average, the prevalence of 
ASC-H/HSIL increased by 0.7% (95%CI: -3.8%, 5.1%) per decade increase in age. The 
age-specific prevalence of ASC-H/HSIL did not appear to differ by CD4 count.  
 
5.5 DISCUSSION 
Data on age-specific prevalence of SIL are needed if age-targeted screening is to be 
considered in HIV-positive women. In this paper, we show that while the prevalence of SIL 
appeared highest in the third and fourth decades of life, and the prevalence of ASC-H/HSIL 
gradually increased with age, the prevalence of lesions did not appear to be age-limited. 
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The epidemiology of SIL in the general population of (mainly HIV-negative) women 
has been at the origin of age-targeted screening in these women. Studies conducted in the 
1980s, documented the prevalence of lesions in young women [Macgregor and Teper, 
1978; Chung et al, 1982; Benmoura et al, 1986]. Subsequent studies showed that the peak 
of occurrence of precancerous lesions was in the third to fourth decade while malignant 
lesions tended to occur later in the fourth or fifth decade[Sadeghi et al, 1989; The New 
Zealand Contraception and Health Study group, 1989; Das et al, 1992; Gupta et al, 2008]. 
Lesions also appeared to be less frequent in women far past menopause [Wheat et al, 
1988].  
In this study limited to HIV-positive women, the prevalence of lesions was only 
slightly higher in all women aged 25-59 compared to other women. This suggests that, 
unlike in HIV-negative women, age only may not be a good criterion for targeted screening. 
Age differences in the prevalence of lesions, however, appeared to depend on CD4 counts. 
Amongst women with low CD4 counts, middle-aged women had a higher prevalence than 
younger or older women, suggesting that screening efforts are particularly needed in these 
women. To the best of our knowledge few studies have discussed the age-specific 
prevalence of lesions and severe lesions in HIV-positive women. Unlike our study in which 
the prevalence of ASC-H/HSIL lesions increased with age, Parham et al [2006] described an 
inverse-U trend among 691 HIV-positive women aged 23-49 years in Zambia, with a peak 
prevalence of HSIL/invasive cancer between age 35 and 40 years. It is not clear why these 
findings differ but the variations in study population age, the relatively low CD4 counts 
(median of 165) and slightly different outcomes may have contributed to this difference.  
While we document prevalent ASC-H/HSIL at all ages in HIV-positive women, it is 
not clear what the long-term outcome of these lesions would be and this may depend on 
age. It is conceivable that if lesions were less likely to progress in younger versus older 
women then targeting older women would be justified or vice versa. Prospective studies in 
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HIV-negative women have had inconsistent results: while lesions were more likely to 
progress in older women in some studies[Misra et al, 2006] the majority of studies noted 
similar progression rates irrespective of age [Konno et al, 1998; Knudsen et al, 2003; Wright 
et al, 2005; Giannopoulos et al, 2005; Winn and Jones, 2005]. Similar studies need to be 
conducted in HIV-positive women with limited access to systematic screening.  
Our findings are susceptible to bias from misclassification of outcomes as 
conventional cytology typically has a low sensitivity [Sankaranarayanan et al, 2005]. 
Nonetheless, because the cytologists were masked from participants’ age information, these 
errors are expected to be independent of age (non-differential) potentially biasing our effect 
estimates towards the null (resulting in an underestimate of the difference in prevalence by 
age groups). 
Secondly, because of the cross-sectional design of the study, the age-specific 
prevalence described here reflects the age of lesion detection and not necessarily the age of 
incidence or the age-specific prevalence in the population. Age differences in access to 
clinics may result in artificially increased prevalence in older women who are more likely to 
be in the health care system. The latter detection bias is however expected to be minimal in 
a study population of HIV-positive women in whom access to care is largely driven by 
worsening HIV disease rather than age. Four in five women in this study had advanced HIV 
diseases (WHO stage III or IV) and the small number of women aged 50 or more than 
limited the influence of these women on study estimates.  
In conclusion, cervical precancerous lesions were prevalent at all ages in this 
population of HIV-positive women, suggesting little utility of age-targeted screening. A better 
understanding of the value of age-targeted screening would require an assessment of the 
age-specific long-term evolution of untreated non-severe lesions and treated severe lesions 
using prospective studies. The potential costs and benefits associated with age-targeted 
screening will also need to be evaluated in formal cost-effectiveness analyses.
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Table 5.1: Age-specific prevalence of cervical precancerous epithelial lesion in 276 
women initiating HAART in Cameroon  
 
 
Age (Years) N Prevalence of any lesion  Prevalence of ASC-H/HSIL 
  % 95% CI  % 95% CI 
18-24 16 31.3 11.0, 58.7  6.3 01.6, 30.2 
25-34 124 45.2 36.2, 54.3  18.5 12.1, 26.5 
35-44 80 43.8 32.7, 55.3  15.0 08.0, 24.7 
45-54 42 40.5 25.6, 56.7  16.7 07.0, 31.4 
55-59 7 57.1 18.4, 90.1  42.9 09.9, 81.6 
60+ 6 33.3 04.3, 77.7  33.3 04.3, 77.7 
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Figure 5.1: Trends in age-specific prevalence of precancerous lesions and 
ASC_H/HSIL in 276 women initiating HAART in Cameroon (estimates based on locally 
weighted regression models). 
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Figure 5.2: Sensitivity analysis of outcome misclassification on the observed 
prevalence difference between age groups (26-59 versus 18-25 and 60+ years) by CD4 
count 
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CHAPTER SIX: POTENTIAL IMPACT OF ANTIRETROVIRAL THERAPY AND 
SCREENING ON CERVICAL CANCER MORTALITY IN HIV-POSITIVE WOMEN IN SUB-
SAHARAN AFRICA 
 
 
6.1 ABSTRACT 
 
Background: Despite having high cervical cancer incidence and mortality rates, screening 
for cervical precancerous lesions remains infrequent in sub-Saharan Africa. The need to 
screen HIV-positive women because of the higher prevalence and faster progression of 
cervical precancerous lesions may be heightened by the increased access to highly-active 
antiretroviral therapy (HAART). Policymakers need quantitative data on the effect of HAART 
and screening to better allocate limited resources. Our aim was to quantify the potential 
effect of these interventions on cervical cancer mortality. 
Methods:  We constructed a Markov state-transition model of a cohort of HIV-positive 
women in Cameroon. Published data on the prevalence, progression and regression of 
lesions as well as mortality rates from HIV, cervical cancer and other causes were 
incorporated into the model. We examined the potential impact of four possible scenarios: 
no HAART and no screening (NHNS), HAART and no screening (HNS), HAART and 
screening once on HAART initiation (HSHI), and HAART and screening once at age 35 
(HS35). 
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Findings: Our model projected that, compared to NHNS, lifetime cumulative cervical cancer 
mortality approximately doubled with HNS. It will require 262 women being screened on 
HAART initiation to prevent one cervical cancer death amongst women on HAART. The 
magnitudes of these effects were most sensitive to the rate of progression of precancerous 
lesions. 
Interpretation: Screening has the potential of reducing cervical cancer mortality among 
HIV-positive women in Africa. The most feasible and cost-effective screening strategy needs 
to be determined in each setting. 
 
6.2 INTRODUCTION 
Cervical cancer is one of the leading causes of cancer death among women in sub-
Saharan Africa [Ferlay et al., 2004].  More than 10 million HIV-infected women also live in 
this region [UNAIDS, 2008]. Compared to HIV-negative women, HIV-positive women have a 
higher prevalence of cervical precancerous lesions as well as a faster progression of these 
lesions to invasive cancer[Six et al, 1998; Massad et al, 2001; Schuman et al, 2003; Hawes 
et al, 2006; De Vuyst et al, 2008]. 
Mortality from cervical cancer and mortality from other HIV-associated diseases can 
be competing risks in the evolution of each other disease. Death from cervical cancer would 
prevent further progression of HIV disease and, prior to the advent of highly active 
antiretroviral therapy (HAART), the progression of cervical precancerous lesions to cancer 
was largely averted by early death from AIDS and other opportunistic infections. We 
hypothesize that the increased survival that is expected to result from increased access to 
HAART may be large enough to allow for lesions to progress to invasive cervical cancer and 
thus is likely to be followed by an increase in cervical cancer incidence and mortality. 
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 In developed countries, the potential increase in cervical cancer mortality in HIV-
positive women is curtailed by systematic and frequent screening in these women 
[Franceschi and Jaffe, 2007]. Despite having a higher HIV prevalence and cervical cancer 
incidence, screening remains very infrequent in developing countries presumably because 
of resource-limitations. Policymakers need data on the effect of screening on cervical cancer 
mortality to better allocate limited resources. 
The long term effect of cervical cancer screening in HIV-positive women in sub-
Saharan Africa, particularly in the era of HAART remains unknown. Although HAART is 
expected to increase cervical cancer mortality while screening is expected to reduce this 
mortality, the magnitude of these effects need to be estimated  to better guide policy. In this 
paper, we estimate the size the potential effect of HAART therapy with or without screening 
on the mortality due to cervical cancer in Cameroon.  
 
6.3 METHODS 
Model structure 
We developed a state-transition Markov model, using TreeAge ProTM 2008 
Healthcare Module (TreeAge Software Inc., Williamstown, MA, USA). This type of model 
allows analysts to model transitions of a cohort of patients among a number of health states 
over a long period of time subdivided into a series of short intervals [Nainmark et al, 1997]. 
Our model was designed to simulate the evolution over time of HIV infection and cervical 
precancerous and cancerous lesions in a cohort of HIV-positive women in Cameroon. The 
primary structure of the Markov model was based on a previous description of a model 
implemented by Goldie et al [1999] in HIV-positive women in the US (Figure 6.1). In brief, 
the model summarizes the progression of cervical neoplasia in HIV in five states: normal 
with no lesion, low-grade squamous intra-epithelial lesions (LSIL), high-grade squamous 
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intra-epithelial lesions (HSIL), invasive cervical cancer and death. Each of the four (non-
death) states is stratified by CD4 cell count.  The cancer stage is further stratified by stage of 
cervical cancer and whether cancer has been diagnosed (thus being treated) or not. During 
their lifetime, women’s disease state can progress from normal to LSIL to HSIL to cervical 
cancer. Women in the HSIL and LSIL states can regress to lower states. Death can occur to 
women in any of the four states and can result from cervical cancer, HIV related-causes or 
other causes of death. 
 
Model parameters  
Parameters used in the model were abstracted from the published literature and 
reflected data for Cameroon as much as possible. The values used in the baseline model 
are shown in Table 6.1. The baseline model was designed to simulate the progression over 
time of a cohort of HIV-positive women aged 25 with CD4 count >500, 30% of whom had 
precancerous lesions (one-third of which were high grade lesions). All cause age-specific 
mortality rates were estimated based on abridged life tables for women in Cameroon [WHO, 
2008]. HIV mortality rates were estimated based on WHO data [UNAIDS, 2007].The 
proportion of HIV-mortality that occurs in each CD4 category was estimated based on data 
by Goldie et al [1999]. Cervical cancer mortality rates were also abstracted from WHO 
estimates of annual cervical cancer incidence and deaths in Cameroon [Ferlay et al., 2004]. 
Age-specific mortality rates from other causes were estimated by adjusting (using another 
Markov analysis) all-cause age-specific mortality rates to deduct mortality from cervical 
cancer and mortality from HIV. 
In the absence of published data on long-term progression or regression rates of 
precancerous lesions in HIV positive women in Cameroon, we used published estimates 
from women in the pre-HAART era from Goldie et al [1999]. The effect of HAART on 
 112 
 
HIV/AIDS-related mortality was also estimated based on the published literature [Murphy et 
al, 2001; Mermin et al, 2008] 
 
Model assumptions 
Key simplifying assumptions of the model include: 1)The natural history of cervical 
cancer involves progress from normal to LSIL to HSIL to local cancer to regional/distant 
cancer to death from cancer, without skipping. 2) The regression of neoplasia can only be 
from HSIL to normal or LSIL, of from LSIL to normal. A patient cannot regress from cancer. 
Cancer stages also cannot regress. 3) HIV diseases progression is only from CD4 500+ to 
200-500 to <200. This is a historic parameter, indicating the advance in HIV disease. Once a 
patient has CD4 <200 she will always be classified in the CD4 <200 category, even if her 
actual CD4 count improved with treatment. In other words worsening HIV-disease cannot 
regress. This assumption is consistent with data that show that improvements in 
antiretroviral therapy do not appear to reduce the progression of precancerous lesions even 
amongst women with improved CD4 counts [Palefsky, 2003]. 4) The progression/regression 
rate of cervical precancerous lesions is not dependent on a previous history of precancerous 
lesions as the parameters used in the model are from heterogeneous populations (that 
include patients with and without a previous history of lesions) [Goldie and Kuntz, 2003].  
 
Scenarios and outcomes assessed 
We assessed the projected lifetime cumulative mortality due to cervical cancer in 
four plausible scenarios of HIV and cervical cancer care in Cameroon: no HAART and no 
screening (NHNS), HAART when indicated and no screening (HNS), HAART when indicated 
and screening on HAART initiation (HSHI), and HAART when indicated and a single screen 
at age 35. The age 35 was selected based on WHO recommendations for screening in 
resource-limited settings [WHO, 2006]. 
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Sensitivity analyses  
The sensitivity of cumulative cervical cancer mortality to parameter estimates was 
analyzed in one-way sensitivity analyses. We were particularly interested in the sensitivity of 
HAART effectiveness in lowering HIV-mortality and SIL progression rates since the baseline 
values used were all external to the study and these values are likely to vary substantially 
depending on the study population. 
 
6.4 RESULTS 
Baseline model 
A substantial proportion of women were expected to die from cervical cancer. The 
baseline model projected a lifetime cumulative cervical cancer mortality of 25.4 per 1000 
HIV-positive women who were infected at age 25 and neither received HAART nor were 
screened for cervical cancer (Table 6.2). Cumulative cervical cancer mortality doubled to 
46.6 per 1000 HIV-positive women who were infected at age 25, were placed on HAART 
when their CD4 went below 200cells/mm3 and had no screening for cervical cancer. If the 
latter women were screened either once at HAART initiation or once when they were aged 
35, then mortality could reduce to 42.8 and 41.7 per 1000 women respectively. Interestingly, 
cervical cancer mortality following HAART and screening once at HAART initiation was still 
higher than cervical cancer mortality associated with no HAART and no screening. 
In absolute measures, these mortality projections meant that compared to no HAART 
and no screening, an additional cervical cancer death would occur for every 47 women put 
on HAART when indicated, but not screened. Conversely, once women were put on HAART 
as indicated, then screening once at HAART initiation would prevent one case of cancer for 
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every 262 women screened. Screening once at age 35 was projected to prevent one cancer 
death per 202 women screened.   
The timing of cervical cancer deaths was also influenced by the type of intervention 
received (Figure 6.2A). With NHNS the majority of cervical cancer deaths occurred within 
the second and third decade after diagnosis. In patients on HAART the occurrence of 
deaths was further delayed beyond the third decade after infection.  
Only HAART had a substantial impact on the overall survival from all causes of death 
after infection (Figure 6.2B and Table 6.3). Compared to no HAART and no screening, all 
three scenarios with HAART (HAART with no screening, HAART with one screen at HAART 
initiation and HAART with one screen at age 35) resulted in gains in life-expectancy.  
However, there was only minimal difference in survival from all causes under the three 
scenarios with HAART, with one time screening only slightly increasing survival (Table 6.3). 
 
Sensitivity analysis 
The projected cervical cancer mortality estimates were robust to the magnitude of 
the effect of HAART in reducing HIV-related mortality (Figure 6.3A). All four mortality 
estimates were within 10% of their baseline value unless the effect of HAART was below a 
two-fold decrease in HIV mortality. Further increasing the effect of HAART only slightly 
increased cumulative cervical cancer mortality. 
Mortality estimates were most sensitive to the rate of progression of precancerous 
lesions to more severe lesions or invasive cancer (Figure 6.3B). In all four scenarios 
cumulative mortality increased with faster progression rates. Doubling the progression rate 
resulted in a near doubling of cervical cancer mortality.  Nevertheless, the relative mortality 
between each of the scenarios remained constant across progression rates. 
Compared to the sensitivity to the progression rate of lesions, the model mortality 
estimates were rather robust to other parameters such as cancer mortality rates and other 
 115 
 
baseline parameters. The cumulative cervical cancer mortality only slightly increased with 
increases in cervical cancer mortality rates (Figure 6.3B). Cumulative cervical cancer 
mortality was also robust to the baseline prevalence of lesions (Figure 6.4A) and the 
proportion of lesions that were high grade lesions (Figure 6.4B). As expected, mortality from 
cervical cancer decreased as the age of HIV infection (the initial age) of the cohort 
increased (Figure 6.4C). Screening test sensitivity had very little impact on cervical cancer 
mortality with mortality only slightly decreasing as sensitivity increased. Life expectancy also 
increased only slightly with improved sensitivity - a gain of 0.06 years as sensitivity 
increased from 50% to 100%.  Meanwhile, screening test specificity had no impact on 
cervical cancer mortality or life expectancy.  
 
6.5 DISCUSSION 
The magnitude and the impact of HAART treatment and screening, on cervical 
cancer mortality in HIV-positive women in sub-Saharan Africa remain unknown. The ethical 
and practical complexities of potentially denying care to patients and following women for 
their lifetime respectively make it unfeasible to conduct a study to quantify this impact. 
Computer-based simulation models, however, provide an alternative means of quantifying 
the potential impact of these interventions. These models are of even greater importance in 
sub-Saharan Africa, where real-life estimation is hampered by limitations in the long-term 
follow-up of patients, in cancer diagnosis and in the determination of cause of death.  
In this paper, we used a mathematical model to project that mortality due to cervical 
cancer in HIV positive women in Africa is potentially very high. While this mortality can be 
worsened by providing HAART without screening, screening can be associated with non-
neglibible reductions in mortality from cervical cancer. These data confirm and quantify the 
potential gains of cervical cancer screening in HIV-positive women in regions with high 
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cancer incidence and mortality such as Cameroon.  With an estimated 200,000 HIV-infected 
women in Cameroon [UNAIDS, 2007] our projections imply that screening these women 
once at HAART initiation would prevent close to 763 deaths due to cervical cancer, while 
screening these women once at age 35 could prevent approximately 990 deaths in these 
women.  
WHO guidelines for screening in resource-limited settings include at least a one-time 
screening in the third or fourth decade of life [WHO, 2006]. Our projected potential gains 
with one-time screening in HIV-positive women are much smaller than those in other 
settings where screening is systematic and more frequent. For example, screening in the UK 
was estimated to prevent one death for every 65 women screened systematically [Peto et al, 
2004]. The reductions in cervical cancer mortality associated with a single screen in HIV-
positive women were also less compared to the estimated 25-36% reductions in lifetime risk 
reported in models of HIV-negative women in five other developing countries [Goldie et al, 
2005]. These differences could be due to a higher incidence and faster progression of 
precancerous lesions in HIV-positive women compared to HIV-negative women [De Vuyst et 
al, 2008]. 
Although we show potential benefits of screening, our analysis did not take the cost 
of screening into account. A formal assessment of the cost-effectiveness of screening in this 
and other settings will provide additional information regarding resource needs and potential 
effects for cervical cancer screening. Our data show that even one time screening at HAART 
initiation or at age 35 would potentially be beneficial. According to guidelines from  the 
Commission on Macroeconomics and Health, a policy is generally considered  cost-effective 
if the incremental cost per life saved is less than the country’s GDP per capita [WHO, 2001]. 
Our analyses estimate that one-time screen policies would improve life expectancy by 
approximately 0.10 years. With Cameroon’s GDP per capita being estimated at USD 
1019[UNSD, 2009], we further estimated that a one-time screening strategy will need to 
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have a cost of 101 USD per screen at most for it to be considered cost-effective. More 
formal cost-effectiveness analyses including appropriate weighting for disability and 
discounting will be needed to confirm this. 
In the absence of prospective data on cervical cancer progression and regression 
rates for Cameroonian women, we used published data from the pre-HAART era in the US 
and assessed the impact of this choice in sensitivity analyses. A faster progression rate in 
developing countries could translate to even higher mortality due to cervical cancer. 
Nevertheless, the relative effects of HAART and screening were projected to remain similar, 
while the number of deaths averted with screening would increase as progression rates 
increase. On the other hand, if HAART was shown to have an effect on the progression of 
lesions, a finding that has been inconsistent [Palefsky, 2003], then the mortality due to 
cancer as well as the gains associated with screening would be reduced.  
While cervical cancer screening could substantially reduce mortality due to cervical 
cancer, it was projected to have very little effect on all cause mortality.  We did not assess 
the quality of life gains, but these data indicate that even with screening further gains in 
overall life expectancy will depend on the extent of prevention and care for other causes of 
mortality including opportunistic infections.  
In conclusion, cervical cancer could account for a high proportion of deaths among 
HIV- positive women in Africa once they have access to HAART. These deaths could be 
reduced with screening, even when done just once. Antiretroviral treatment scale-up 
activities need to be followed by strategies to systematically increase access to screening 
services as well as treatment for cervical precancerous and cancerous lesions as needed. 
While the feasibility and cost-effectiveness of more frequent screening is still to be 
assessed, women need to be provided the opportunity to get screened at least once on 
initiating HAART or at age 35. 
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TABLES 
Table 6.1: Baseline parameters used in modeling cervical cancer mortality in HIV 
positive women 
Variable CD4 
>500  
CD4  
200-500  
CD4  
<200  
Source  
 
    
Initial prevalence of lesions, % 30 NA NA Mbu et al, 2008 
Initial proportion of lesions that were 
HSIL (%) 
33 NA NA Mbu et al, 2008 
 
    
HIV infection 
    
HIV mortality rate (per 1000 per year)* 0.05 6.06 48.6 UNAIDS, 2007 
Effect of HAART in reducing HIV 
mortality 
NA NA 4-fold Murphy et al, 2001; 
Mermin et al, 2008 
HIV progression rate (per 100 per year)** 18.1 27.5 NA Goldie et al, 1999 
 
    
Cervical Cancer 
    
Cancer mortality rate (per 1000 per year)* 
   [Ferlay et al., 2004 
Local invasive cancer  41.1 41.1 41.1  
Regional invasive cancer 222.1 222.1 222.1  
Distant invasive cancer 543.5 543.5 543.5  
 
    
Progression rate (per 100 per year) 
   Goldie et al, 1999 
Normal to LSIL 0.016  0.67  0.67   
LSIL to HSIL 0.73  2.93  2.93   
HSIL to local invasive cancer 2.0  2.42 2.42  
Local to regional invasive cancer 4.03  4.03  4.03   
Regional  to distant invasive cancer 4.03  4.03  4.03   
 
    
Regression rate (per 100 per year) 
   Goldie et al, 1999 
LSIL to normal 2.99  2.99  2.99   
HSIL to normal 0.30  0.30  0.30   
 
    
Screening test 
   Goldie et al, 1999 
Sensitivity, % 70  70  70   
Specificity, % 90  90  90   
* Mortality in each CD4 category or cervical cancer stage were determined by weighting crude estimates by the proportions due to 
each category or stage from Goldie et al[1999]. ** estimated from mean duration at each stage  
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Table 6.2: Projected cumulative (lifetime) cervical cancer mortality in HIV-positive 
women in Cameroon on HAART and or screened for cervical cancer 
 
 
Intervention 
Mortality per 
1000 NNT NNS 
No HAART, No Screen 25.4 Ref. - 
HAART, No Screen 46.6 47 Ref 
HAART+ Screen once at HAART initiation  42.8 - 262 
HAART+  Screen once at age 35 41.7 - 202 
NNT - Number of women who need to receive HAART for each additional cancer death. 
NNS - Number of women who need to be screened for each cancer death prevented. 
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Table 6.3: Projected cumulative cause of mortality and gains in life expectancy in 
HIV-positive women in Cameroon on HAART and or screened for cervical cancer. 
 
Intervention 
 Cause of mortality  
(proportion) 
 Gains in life 
expectancy (years) 
 
 HIV/ 
AIDS 
Cervical 
cancer 
Other 
cause 
 Due to 
HAART 
Due to 
Screening 
No HAART, No Screen  63.3% 2.5% 34.1%  Ref. - 
HAART, No Screen  28.3% 4.7% 66.8%  10.6 Ref. 
HAART+ Screen once at HAART 
initiation  
 28.4% 4.3% 67.1%  
- 0.09 
HAART+  Screen at age 35  28.4% 4.2% 67.2%  - 0.11 
Ref: Referent 
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FIGURE LEGENDS 
Figure 6.1: Summary of states in the Markov model (Adapted from an original 
depiction by Goldie et al, 1999) 
 
Figure 6.2: Cumulative mortality from cervical cancer (A) or from all causes of 
death (B) by intervention in a cohort of HIV positive women getting infected at age 
25. (NHNS: No HAART No Screening; HNS: HAART but No Screening; HSHI: 
HAART and one screen at HAART initiation; HS35: HAART and one screen at age 
35).  
 
Figure 6.3: Sensitivity of cumulative cervical cancer mortality to the relative effect 
of HAART in reducing HIV-mortality (A); the progression rate of precancerous 
lesions (B) and cervical cancer mortality rate(C).  (NHNS: No HAART No Screening; 
HNS: HAART but No Screening; HSHI: HAART and one screen at HAART initiation; 
HS35: HAART and one screen at age 35).  
 
Figure 6.4: Sensitivity of the cumulative cervical cancer mortality to baseline 
parameters:  the prevalence of squamous intraepithelial lesions at beginning of 
cohort (A); the proportion of lesions that are high grade squamous intraepithelial 
lesions at the beginning of cohort (B); and the initial age of cohort (C).  (NHNS: No 
HAART No Screening; HNS: HAART but No Screening; HSHI: HAART and one 
screen at HAART initiation; HS35: HAART and one screen at age 35).  
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CHAPTER SEVEN: CONCLUSION 
 
 
 
 
This dissertation was premised on the hypotheses that cervical precancerous lesions 
are prevalent in HIV-positive women in Cameroon and that these were not being adequately 
managed as there was no systematic screening and thus no care. We sought to provide 
data that could assist clinicians and policy makers with better options for caring for 
precancerous lesions particularly in an era of increased access to antiretroviral therapy. 
We conducted a cross-sectional study in which we collected primary data from 
Cameroon and screened women for precancerous lesions using conventional cytology 
methods. While we successfully assured the adequacy of the vast majority of samples 
collected, the accurate reading of cytology smears turned out to be a challenge with little 
agreement between the first cytologist and a more experienced cytologist.  The resultant 
potential for misclassification bias was however explored in bias analyses of prevalence of 
SIL. 
We confirmed our initial hypothesis of a high prevalence of precancerous lesions. 
The prevalence in our study was similar to that in women in similar contexts. Unfortunately, 
the predictive value of the clinical characteristics considered either individually or as a 
group, was poor. Women’s age, a characteristic that has been used to somewhat target 
women in the general population, was not a good predictor either. 
Interestingly, despite the relatively poor diagnostic performance of the risk scores 
developed to predict the presence of lesions or the presence of lesions requiring follow-up 
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care (ASC-H/HSIL), these scores resulted in fewer numbers of diagnostic errors (assuming 
false positives and false negatives all had the same cost) when compared to universal 
screening or no screening. However, the balance was tilted towards favoring universal 
screening as the relative cost of a false negative decision to not screen increased (a 
scenario which is probably more realistic). 
Overall, we could not identify any single or group of readily available clinical factor(s) 
on which to target the decision to screen or not.  
We then proceeded to quantify the potential impact on cervical cancer mortality of 
HAART in women who are not being screened and then assess the potential impact of 
screening in women who are put on HAART when it is indicated. We projected that the 
cumulative mortality due to cervical cancer could double once HAART was made available 
to women who previously were not screened and do not have access to HAART. In the 
population we simulated this could translate into one additional cancer death for every 47 
women who are placed on HAART. This mortality could be reduced by screening. A single 
screen at age 35 would prevent one cervical cancer death per 202 women screened.  The 
number of cervical cancer deaths that could be prevented would increase with even more 
frequent screening, but frequent screening is probably not affordable in settings such as 
Cameroon. 
The public health implications of these findings are important. First, cervical cancer 
prevention (and eventual care) needs to be part of any comprehensive program seeking to 
increase access to antiretrovirals, as cervical cancer may be a long-term unintended 
secondary effect of antiretroviral therapy. Patients may need to be monitored for 
precancerous lesions in a similar way to which they are monitored for drug side-effects and 
the development of drug resistances. The challenge to policy-makers would be how to 
effectively implement such monitoring in a cost-effective manner.  Potential strategies to 
reduce screening costs include targeted screening, the use of cheaper and accessible 
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screening tests with high sensitivity and specificity, or less frequent screening. Our data 
suggest a limited utility of targeted screening. The alternatives to cervical cytology being 
considered including visual inspection techniques and or targeted HPV-DNA testing could 
be of use but these remain expensive and inaccessible. The development of a more 
accurate and cheaper screening test, that could preferably be used at the point-of-care 
could go a long way to improve the early detection (and subsequent treatment) of lesions 
that are likely progress to lesions. 
Secondly, there needs to be an overhaul of resources (including human resources) 
dedicated to cancer prevention and care in these settings. Diagnosed precancerous and 
cancerous lesions will need to be treated for screening to have any impact on cervical 
cancer mortality.  
Future studies will need to assess the long-term evolution of precancerous lesions in 
HIV-positive women in Africa, including in women who are screened and treated. Because 
cost remains a barrier and a key determinant, formal analyses of the cost-effectiveness of 
various screening strategies will be imperative to better guide policy. 
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Appendix 1: Sample Markov node from TreeAge pro 2008 
normal cx high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
normal cx mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
normal cx low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
lsil high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
lsil mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
lsil low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
hsil high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
hsil mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
hsil low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
local icc high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
local icc mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
local icc low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
regional icc high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
regional icc mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
regional icc low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
distant icc high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
distant icc mod cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
distant icc low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
 [+] 
Dead
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
Cervical (pre) Ca in HIV Markov
--- Markov Information
Term: 
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Appendix 2: Sample normal cervix high CD4 (>500/uL) subtree 
stable cx
normal cx high cd4
progress cx
lsil high cd4
stable hiv
stable cx
normal cx mod cd4
progress cx
lsil mod cd4
progress hiv
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
TN
stable cx
normal cx high cd4
progress cx
lsil high cd4
stable hiv
stable cx
normal cx mod cd4
progress cx
lsil mod cd4
progress hiv
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
FP lsil--> repeat Pap in 6months
and Rx as necesary
stable cx
normal cx high cd4
progress cx
lsil high cd4
stable hiv
stable cx
normal cx mod cd4
progress cx
lsil mod cd4
progress hiv
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
FP hsil -->col, bx
FP-->col, bx
normal cx high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
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Appendix 3: Sample HSIL moderate CD4 (200-500/uL) subtree 
complete
regress cx
normal cx high cd4
stable cx
hsil high cd4
progress cx
local icc high cd4
stable hiv
complete
regress cx
normal cx mod cd4
stable cx
hsil mod cd4
progress cx
local icc mod cd4
progress hiv
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
TP-->col, Bx, HSILRx
complete
regress cx
normal cx high cd4
partial 
regress cx
lsil high cd4
stable cx
hsil high cd4
progress cx
local icc high cd4
stable hiv
complete
regress cx
normal cx mod cd4
partial
regress cx
lsil mod cd4
stable cx
hsil mod cd4
progress cx
local icc mod cd4
progress hiv
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
FN
hsil high cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
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Appendix 4: Sample distant ICC low CD4 (<200/uL) subtree 
 
 
 
stable cx
distant icc low cd4
death from cx
Dead
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
TP--> col, Bx, CaRx
stable cx
distant icc low cd4
death from cx
Dead
survive hiv
death from hiv
Dead
survive other causes
death from other causes
Dead
FN
distant icc low cd4
--- Markov Information
Init Rwd: 0
Incr Rwd: 0
Final Rwd: 0
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Appendix 5: Study questionnaire 
Cervical Cytology at HAART Initiation in Cameroon (CCHIC) Study 
 
(Prevalence, severity and predictors of cervical epithelial lesions among women initiating HAART 
in Cameroon) 
 
Questionnaire 
 
Date: _ _/_ _/_ _ (dd/mm/yy) 
 
Part I: Identification 
File Number _ _ _ _ _ _,  Study IDNUM __ _ _ 
 
 
Part II: Medical History  
 
HIV History 
 
1. How long ago were you first diagnosed as HIV+ ? _ _ years, _ _ months 
 (If does not know, please ask date diagnosed and estimate duration) 
 
2.  Have you taken any other medication aimed at your HIV infection? (select one) 
 0 = Pills/tablets  1 = Herbs  2 = Injections     3 = other …………………… 
 
 
Gyneco-Obstetrical History 
3.  Have you ever been screened for cervical cancer (also called a “pap smear”)? (select one) 
 0= Never  1 = Yes, No lesion detected  2 = Yes, lesion detected  9 = Don’t know 
 
4. How manytimes have you been pregnant? _ _ 
 
5. How many pregnancies that lasted more than 6 months have you had? _ _ 
 
6. Have you ever had an abortion? (select one) 
  0 = No   1 = Yes,    9= Don’t  know 
 
7. Have you ever used Oral contraceptive pills? (select one) 
 0 = Never 1=Yes, Only prior to HIV diagnosis 2 = Yes, only after HIV diagnosis  
 4 = Yes, both prior to and after HIV diagnosis   9 = Don’t know 
 
8. Have you ever used Injectable Hormones (e.g., Depo-provera or Norplant)? (select one) 
 0 = Never 1=Yes, Only prior to HIV diagnosis 2 = Yes, only after HIV diagnosis  
 4 = Yes, both prior to and after HIV diagnosis   9 = Don’t know 
 
9. Have you ever used an intrauterine device? (select one) 
 0 = Never 1=Yes, Only prior to HIV diagnosis 2 = Yes, only after HIV diagnosis  
 4 = Yes, both prior to and after HIV diagnosis   9 = Don’t know 
 
10. Have you ever used a diaphragm/cervical cap? (select one) 
 0 = Never 1=Yes, Only prior to HIV diagnosis 2 = Yes, only after HIV diagnosis  
 4 = Yes, both prior to and after HIV diagnosis   9 = Don’t know 
 
11. Have you ever had Surgery for contraception (Tubal Ligation/Hysterectomy)? (select one) 
 0 = Never 1=Yes, prior to HIV diagnosis  2 = Yes, after HIV diagnosis  9 = Don’t know  
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Other medical History 
 
12. Have you been frequently exposed to cigarette smoke? (select one) 
 0 = No    
 1= Yes, I have smoked for at least a year  (estimate of packet years of smoking _ _  packets/day 
for  _  _ years) 
 2 = Yes, exposed for at least a year to someone else in household/jobsite who smoked 
 3 = Yes, other_________________________________________ 
 
Sex History 
13.  How old were you when you first had sex? _ _ years 
(Please select one in each and all of the following 14 cells) 
 a. Lifetime b. One year prior 
to HIV diagnosis 
c. Since HIV 
diagnosis  
d. In the past  6 months  with 
HIV 
14. How 
many  sex 
partners did 
you have in the 
following 
periods 
0 1 2 3 4 5 
6 = >5 
9 = Cannot 
estimate 
0 1 2 3 4 5 
6 = >5 
9 = Cannot estimate 
0 1 2 3 4 5 
6 = >5 
9 = Cannot estimate 
0 1 2 3 4 5 
6 =  >5 
8 =HIV diagnosis < 6 months  
9=Cannot estimate 
15. How often 
did you use a 
condom with 
these partners 
0 = Never  
1 = <50 %time 
2 = ≥50 % time 
3 = Always 
8 = No partner 
9 = Cannot 
estimate 
0 = Never  
1 = <50 %time 
2 = ≥50 % time 
3 = Always 
8 = No partner 
9 = Cannot estimate 
0 = Never  
1 = <50 %time  
2 = ≥50 % time  
3 = Always 
8 = No partner 
9 = Cannot estimate 
0 = Never  
1 = <50 %time  
2 = ≥50 % time  
3 = Always 
8 = No partner or HIV diagnosis < 6 
mnths  
9 = Cannot estimate 
16. How 
many  NEW 
sex partners 
did you have in 
the following 
periods 
NA 0 1 2 3 4 5 
6 = >5 
9 = Cannot estimate 
0 1 2 3 4 5 
6 = >5 
9 = Cannot estimate 
0 1 2 3 4 5 
6 =  >5 
8 =HIV diagnosis < 6 months  
9=Cannot estimate 
17. How often 
did you use a 
condom with 
these new 
partners 
NA 0 = Never  
1 = <50 %time 
2 = ≥50 % time 
3 = Always 
8 = No partner 
9 = Cannot estimate 
0 = Never  
1 = <50 %time  
2 = ≥50 % time  
3 = Always 
8 = No partner 
9 = Cannot estimate 
0 = Never  
1 = <50 %time  
2 = ≥50 % time  
3 = Always 
8 = No partner or HIV diagnosis < 6 
mnths  
9 = Cannot estimate 
 
18. On average, how often did you have sex in the 6 months preceding your HIV diagnosis: 
    _ _ per month (or _ _ per week) 
 
19. On average, how often did you have sex in the past 6 months (OR since you were diagnosed of HIV if this was 
less than 6 months ago):  
  _ _ per month (or _ _ per week) 
 
20. Have you ever been diagnosed with the following sexually transmitted (venereal) diseases? 
a. Chlamydia:   0 = No  1=Yes   9 = Don’t Know 
b. Gonorrhoea: 0 = No  1=Yes   9 = Don’t Know 
c. Herpes (genital):  0 = No  1=Yes   9 = Don’t Know 
d. Warts (genital): 0 = No  1=Yes   9 = Don’t Know 
e. Other ……………………………………………. 
 
Part III: Demographics 
 
21. What was your age at your last birthday? _ _ years 
 
22. What is your current relationship status?   (select one) 
 0 = Never married and not living with a partner         1 = married monogamous  2 = married polygamous        
 3 = Living with a partner          4 = Separated         5 = Divorced        6 = Widow 
 
23. What is the highest level of education you have ever attended? (select one) 
 0 = None   1 = Primary  2 = Secondary 3 = University 
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24. What province do you currently live in?  (select one) 
 0 = Adamawa  1 = Center  2 = East  3 = Extreme-North   4 = Littoral 
 5 = North  6 = North-West  7 = South  8 = South-West   9 = West 
 
25. Do you currently live in an urban (town) or rural (village) area?  (select one) 
  0 = Urban    1 = Rural 
 
26. What province have you lived in the longest?  (select one) 
 0 = Adamawa  1 = Center  2 = East  3 = Extreme-North   4 = Littoral 
 5 = North  6 = North-West  7 = South  8 = South-West   9 = West 
 
27. Have you lived longer in an urban (town) or a rural (village) area?  (select one) 
 0 = Urban    1 = Rural 
 
28. What is your province of origin?  (select one) 
 0 = Adamawa  1 = Center  2 = East  3 = Extreme-North   4 = Littoral 
 5 = North  6 = North-West  7 = South  8 = South-West   9 = West 
 
 
Part IV: Symptoms 
 
29. Have you ever had vaginal discharge in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
30. Have you ever had vaginal odor or smell in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
31. Have you ever had itching in or around the vagina in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
32. Have you ever had ulcer or sore in genital area in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before  2 = Yes, have it now  9 = Don’t know 
 
33. Have you ever had pain or burning during urination in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
34. Have you ever had more frequent urination in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
35. Have you ever had pain in lower abdomen in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, have it now  9 = Don’t know 
 
36. Have you ever had vaginal bleeding between periods in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before  2 = Yes, have it now  9 = Don’t know 
 
37. Have you missed any periods in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before   2 = Yes, missed my last period   
 8 = did not expect periods (pregnant, menopause…)  9 = Don’t know 
 
38. Have you ever had pain during vaginal sex in the past 6 months? (select one) 
 0 = Never 1=don’t have it now, but had it before    2 = Yes, have it now   
 8 = Have not had sex 9 = Don’t know 
 
 
Part V: Signs 
 
39. What is present on inguinal exam?  
a. Is it Normal?    0= No   1 = Yes    
b. Enlarged lymphnodes?    0= No   1 = Yes   
c. Other ……………………………………………… 
 
40. What is present on vulvo/vaginal exam?  
a. Is it Normal?   0= No   1 = Yes  
b. Warts?     0= No   1 = Yes   
c. Ulcers?     0= No   1 = Yes   
d. papules/vesicules?   0= No   1 = Yes   
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e. Abnormal vaginal  erythema?   0= No   1 = Yes   
f. Abnormal vaginal discharge?   0= No   1 = Yes   
g. Other ………………………………………………. 
 
41. What is present on cervical exam?  
a. Is it Normal?    0= No   1 = Yes  
b. Abnormal cervical erythema?   0= No   1 = Yes   
c. Abnormal cervical discharge?   0= No   1 = Yes   
d. Cervical friability?     0= No   1 = Yes   
e. Other ………………………………………………. 
 
42. What is present on bimanual pelvic exam?  
a. Is it Normal?   0= No   1 = Yes  
b. Cervical motion tenderness?   0= No   1 = Yes   
c. Adnexal tenderness?    0= No   1 = Yes   
d. Other ………………………………………………. 
 
43. What is present on abdominal exam?  
a. Is it Normal?    0= No   1 = Yes  
b. Tenderness to palpation?    0= No   1 = Yes   
c. Other ………………………………………………. 
 
Part VI: Overall assessment of HIV disease 
44. What is the patients Clinical HIV Stage (WHO Classification)? (select one) 
 1 =  Stage I  2 =  Stage II 3 =  Stage III  4 =  Stage IV  
 
45. What is the patients CD4 level count? _ _ _ _cells/mm3 
 
46. What is the patients HIV viral load? _ _ _ _logs/ml 
 
Part VII: Screening results 
 
47. Cervical smear cytology findings (select one) 
0 =  Normal   
1 =  ASC-US (Atypical squamous cell of undetermined significance) 
2 =  LSIL  (low-grade squamous intraepithelial lesion) 
3 =  HSIL     (high-grade squamous intraepithelial lesion) 
4 = Adenocarcinoma in situ 
5 = Other …………. 
9 = unsatisfactory 
 
48. Biopsy findings (select one) 
0 =  Normal  1 =  CIN 1 2 =  CIN 2  3 =  CIN 3    
4 = Adenocarcinoma in situ 5 = Invasive cancer  6 = Other …………. 
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